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ABBREVIATIONS
The abbreviations used in this thesis are those suggested 
in the Instructions To Authors of the Biochemical Journal, with the 
following additions;- 
General:
AMW Apparent Molecular Weight
BL Burkitts' Lymphoma
BLCL B-Lymphoblastoid Cell Line
B.SA Bovine Serum Albumin
CON Control
CHO Carbohydrate
EC, IC Extracellular, Intracellular
PCS Foetal Calf Serum
H-2 The Murine Major Histocompatibility Complex
HLA The Human Major Histocompatibility Complex
LPS Lipopolysaccharide, a B Cell Mitogen
MHC Major Histocompatibility Complex
MLR Mixed Lymphocyte Reaction
PAGE Polyacrylamide Gel Electrophoresis
PBS Phosphate-Buffered Saline
-f*
Poly A RNA RNA enriched for species containing poly-
adenylated 3‘-ends; that is, messenger RNA 
SDS Sodium Dodecyl Sulphate
TKM Tris-Potassium-Magnesium Buffer
TUN Tunicamycin-Treated
3D-TKM Three-Detergent Cocktail in TKM Buffer
rir
Chemicals
DMSO
DNP
DTT
NAP
PMSF
PPO
TCA
TE MED
F(ah) 2
GARIg
RAHy,RAHa,RAHs 
RAHYfRAHX,RAHic
RAHB^M
Ly
T^-Cell
T -Cell s
Dimethyl Sulphoxide 
Dinitrophenol 
Dithi othreitol 
N-(4-AzidO“2-Nitrophenyl)
Phenylmethylsulphonyl Fluoride 
2,5-Diphenyloxazole 
Trichloroacetic Acid
N , N , ISl , N  Te trame thy le thy le ne Diamine
Fragment of Immunoglobulin Molecule Generated
by Pepsin Digestion
Goat Anti-Rabbit Immunoglobulin
Rabbit Antibody to Human y, a, z, y, X ,
and K Chains
Rabbit Anti-Human g^-Microglobulin 
Membrane Marker of Murine Lymphocytes 
Helper T-Lymphocyte 
Suppressor T-Lymphocyte
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SUMMARY
Considerable attention has recently been focused on the 
mechanisms which allow B-lymphocytes to effect simultaneous bio­
synthesis and expression of receptor and effector forms of the 
immunoglobulin molecule as mandated by the Clonal Selection Hypothesis 
The genetic mechanisms responsible for the above phenomenon have 
now been established for the biosynthesis of IgM in murine lymphocytes 
Also of great interest is the possible regulatory influence exerted by 
carbohydrate moieties on the secretion and membrane deposition of 
immunoglobulin molecules.
The objectives of the work described in this thesis were to 
attempt to ascertain whether or not human B-lymphocytes expressing 
IgG, IgA and IgE adopted similar genetic strategies to allow simul­
taneous expression of structurally distinct membrane and secretory 
heavy chain polypeptides. The role of N-linked oligosaccharides in 
secretion and membrane deposition of immunoglobulin molecules was 
also studied and compared with data from similar investigations on 
the biosynthesis of human transplantation antigens in the hope of 
revealing possible carbohydrate-influenced structural signals 
necessary for transport and expression of immunoglobulins.
The antibiotic tunicamycin was used to inhibit N-glycosyl- 
ation of proteins in cells actively engaged in protein biosynthesis. 
SDS-PAGE analysis of specifically immunoprecipitated immunoglobulins 
of different classes synthesised in cells treated with tunicamycin 
revealed that four-chain immunoglobulin molecules were readily formed
XXI
in all cells. It is concluded that immunoglobulin assembly occurs 
independently of N-glycosylation of the newly-synthesised immuno­
globulin chains. HLA-A,-B,-C/microglobulin complexes were also
efficiently assembled in the presence of tunicamycin. Evidence is 
presented to support the hypothesis that 19S IgM and IIS IgA polymers 
are formed in cells treated with tunicamycin. No conclusive evidence 
was obtained with respect to incorporation of J-chain into non­
glycosylated polymeric immunoglobulins.
The presence of N-linked oligosaccharides on the immuno­
globulin heavy chain appeared to be mandatory for the efficient 
secretion of IgM and IgA from human cells synthesising these classes 
of immunoglobulin. By contrast non-N-glycosylated IgG and IgE 
molecules were efficiently secreted from IgG and IgE producing human 
B-lymphocytes.
Three experimental approaches were adopted to elucidate 
the functional role of N-linked carbohydrate side chains of immuno­
globulin molecules in the efficient membrane deposition of these 
molecules. In one case it was found that non-N-glycosylated IgM 
could be demonstrated at the cell membrane of tunicamycin-treated 
cells : this data was shown to be incorrect by more rigorous experi­
mental analyses. It is concluded that N-glycosylation of immuno­
globulins is necessary for efficient membrane deposition of IgM and 
IgA. In contrast, HLA-A,-B and -C alloantigens and also HLA-DR 
alloantigens were detected at the membrane of tunicamycin-treated 
cells and, in the case of HLA-A2 and HLA-B7, the■non-glycosylated 
molecules were alloantigenic as judged by their serological reactivity 
with alloantisera.
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Biosynthesis of membrane and. secretory forms ofy -heavy 
chain polypeptides was studied in the B-lymphoblastoid cell line 
Bec-11. Normal Bec-11 cells synthesised three intracellular forms 
of y-chain of AMWs 54k , 55K and 52K and two of these chains are 
secreted into the culture supernatant (52K and 55K). The 64K 
species was presumed to be the membrane form of y-heavy chain and 
this hypothesis was supported by the finding that IgG isolated from 
aliquots of radioiodinated Bec-11 membrane proteins contained y-heavy 
chains of AMW 64K. Tunicanycin-treated Bec-11 cells contain two
intracellular forms of y-chain, 60K and 48K, and these were shown to 
be the non-glycosylated counterparts of the 64K and of 52K and 55K 
respectively. The 48K y-chain was the sole secretory y-chain poly­
peptide synthesised by Bec-11 cells and was shown to be the non- 
glycosylated form of both the 52K and the 55K glycosylated secretory 
y-chains. Preliminary evidence that the 64K species contained hydro- 
phobic regions not found in either 52K or 55K species was obtained 
from studies using a lipophilic nitrene reagent, hexanoyl-diiodo- 
NAP-tyramine. This reagent labelled only the 64K species which 
suggested that this y-chain contained hydrophobic sequences pre­
sumably responsible for its membrane insertion.
Cell free translation of Bec-11 polyA RNA followed by 
specific immunoprécipitation of the translation products and analysis 
by SDS-PAGE revealed two y-chain bands. This data suggests that 
discrete mRNA species direct the synthesis of membrane and secretory 
y-chain polypeptides.
IgA biosynthesis was investigated in cells of the Burkitt 
lymphoma cell line Dakiki Arosros-1. Experimental investigations
XXI ir
similar to those described for Bec-11 cells illustrated that Dakiki 
Arosros-1 cells synthesised two forms of a heavy chain, one of which 
was secreted and the other which was inserted into the membrane. 
Distinct non-glycosylated counterparts were found for each of the 
above mature a-chains.
When the differences in AMW of non-glycosylated membrane 
and secretory heavy chains of each isotype were compared an interest­
ing observation was made. In the y- and a-chain systems the differ­
ence was of the order of 2000-3000 daltons suggesting a similar organ­
isation of y- and a-chain coding sequences in the genome. In Bec-11
cells, the difference was 12,000 daltons and this suggested that the 
gene has a different structure to either Cy- or Ca-gene system. 
Study of two other IgG synthesising cell lines, EB4.9 and Maija also 
revealed an AMW difference of 12,000 daltons. It is proposed that 
the cy gene has larger M-exon structures than those described for the 
human and murine Cy genes (and postulated for the Ca gene).
A serological investigation of the unique 33,000 dalton 
glycoprotein (p33) found in association with the membrane IgM of the 
Burkitt lymphoma cell line was performed. A rabbit antiserum 
(serum No,52) capable of inhibiting mixed lymphocyte reactions 
stimulated by Daudi cells was shown to specifically recognise p33.
A working hypothesis, that p33 represented an aberrant form of the 
HLA-DR antigen, was proposed, tested and shown to be incorrect.
Rabbit antisera raised against HLA-DR antigens failed to precipitate 
the IgM-p33 complex, and serum No.52 failed to recognise HLA-DR allo- 
antigens. Furthermore, peptide maps of p33 and the HLA-DR chains
XXIV
did not display any common features. Also, an antiserum to de­
natured HLA-A,-B,-C antigen heavy chain failed to precipitate the 
IgM-p33 complex. Thus, p33 was shown not to be serologically re­
lated to any of the HLA-A,-B,-C or -DR alloantigens. Carbohydrate 
was shown to be necessary for expression of the IgM-p33 complex at 
the cell membrane and also for serological reactivity of p33 with 
serum No.52. Tentative evidence to suggest that p33 represents a
mutant C fragment is discussed.
K
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INTRODUCTION
— 1 —
1. THEORIES OF ANTIBODY FORMATION
The selective nature of antibody formation was first alluded 
to by Ehrlich (1900). This early model, the 'side-chain' theory, 
proposed that certain cells of the body possessed receptors whose 
function was to recognise toxins present in foodstuffs. The toxin 
combined with its homologous anti-toxin and this event resulted in 
the excess regeneration of the anti-toxin receptor molecule. The 
manifestation of the excess regeneration of receptor was the appear­
ance, in serum, of the anti-toxin.
1.1. Instructive Theories Versus Selective Theories
Ehrlich's side chain theory represents the first selective
theory of antibody synthesis. The unifying principle of the
selective theories is that the receptor exists prior to exposure to 
antigen and that antigen contact is the specific signal for the 
production of circulating antibody.
The finding that animals were capable of responding to 
non-biological antigens presented a challenge to Ehrlich's hypo­
thesis. The observation that an animal could respond to newly 
synthesised chemical groups such as dinitrophenol, arsonate etc. 
(Landsteiner, 1946) was difficult to reconcile with the idea that 
the animal possessed "side-chains" capable of specific interaction 
with one and only one antigen. These experimental data led to the 
formulation of the instructive theories of antibody formation.
The instructive theorists reasoned that an animal could 
not possess specific receptors for each individual antigen, and
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concluded that antigen must, in some manner, 'instruct* the immune 
system. An example of the instructive theories is provided by the 
Pauling model (Pauling, 1940). In this model, all antibody molecules 
had identical amino acid sequence but possessed different three- 
dimensional structures in those regions of the molecule actively re­
sponsible for antigen binding. The information for adoption of the 
correct conformation for the antigen-binding site was determined by 
antigen contact during antibody synthesis; the antigen therefore acted 
as a "template" for its homologous antibody. Moreover, Pauling also 
proposed that the conformation of the antigen binding site of the 
antibody after 'instruction' was stable after removal of the antigen.
The theoretical basis for an experimentally testable model 
of selective antibody formation was advanced in the mid to late 1950s.
Jerne (1955) proposed, first of all, that the diverse 
population of antibodies arose during development and also that the 
generation of this antibody diversity was independent of antigen.
It was also postulated, inaccurately, that ingestion of immune complex­
es by the phagocytic cells of the system resulted in these cells 
producing large quantities of the ingested antibody. Although 
inaccurate, the Jerne proposal of a cellular involvement in antibody 
synthesis was developed by Talmage (1957) who proposed that it was a 
recognition event at the cellular level, rather than in serum, which 
was the critical step in the initiation of antibody synthesis.
The major conceptual advance was proposed by Burnet (1957) 
who fused Jerne's.hypothesis and the Talmage commentary to give birth 
to the Clonal Selection Hypothesis (Bumet, 1959) . The critical 
assumption in this model is that each immunocompetent lymphocyte
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expressed only one receptor antibody on its cell membrane and that 
antibody secretion was initiated only by stimulation of the lympho­
cyte by specific antigen. The tenets of the Clonal Selection Model 
are detailed below (section 1,3}.
1.2. Demise of the Instructive Theories
The proposals of instructive and selective theories of 
antibody formation in experimentally testable forms led to a series 
of experiments which resulted in the disproval of the theories from 
the former school of thought.
1.2.1. Negative Evidence Against Instruction
If antigen acted as a template for specific antibody form­
ation, it would be reasonable to propose that antigen would be found 
in the cytoplasm of specific antibody forming cells. Studies with 
highly radioactively labelled flagellin failed to demonstrate the 
presence of this antigen within the cytoplasm of cells actively 
synthesising antibody (Nossal ^  1965a,b) .
1.2.2. Positive Evidence Against Instruction
The instructive theories were irrevocably refuted by the 
observation that denatured antibody could be renatured to an active 
form in the absence of antigen. Antibody was denatured in urea or 
in guanidine hydrochloride, and the disulphide bridges reduced; 
antigen binding activity was lost. Upon removal of the denaturing 
agent and re-oxidation of the disulphide bridges, in the absence of 
antigen, a significant amount of antibody activity was recovered 
(Haber, 1964). This experiment convincingly demonstrated that 
antigen does not have a role as a template during formation of 
specific antibody.
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1.3. The Clonal Selection Theories
The Clonal Selection Theory (Burnet, 1959) and its 
derivatives (Mitchison, 1971) advanced the following maxims to govern 
antibody synthesis by B-Iymphocytes:
a) the lymphocyte expresses a receptor antibody 
identical to that which it will later secrete;
b) only one receptor specificity is expressed by any one 
lymphocyte ;
c) a single lymphocyte expresses only one immunoglobulin 
allotype (allelic exclusion), and only one light chain 
type ;
d) antigen plays no part in the generation of antibody 
diversity, and the lymphocyte is pre-committed to a 
given antigenic specificity;
e) combination with complementary antigen is the specific 
signal required for differentiation of a lymphocyte
to plasma cells or memory cells.
There is now overwhelming evidence to support the above 
tenets. The evidence has been obtained from experiments at the 
cellular level as well as from investigations of the molecular nature 
of antibody molecules and their genes.
2. THE B-LYMPHOCYTE AS THE CELLULAR SITE OF IMMUNOGLOBULIN
SYNTHESIS
2.1. Antibody Synthesis is Unique to B-Lymphocytes
It is now accepted that the lymphocytes comprise two
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major populations:
a) the T-iymphocytes whose development is influenced by 
the thymus and,
b) the B-lymphocytes whose functional differentiation 
depends upon processing in the avian Bursa of 
Fabricius (Click e^ al, 1956) or in its mammalian 
equivalent.
Also well established is the need for co-operation between 
the two populations of lymphocytes for an effective antibody response 
(Claman et a^, 1966; Mitchell and Miller, 1968; Mitchison 1967, 1969, 
1971a,b; Feldmann and Basten, 1972; Katz and Benacerraf, 1972),
Much evidence is available to demonstrate that B-lymphocytes are the 
antibody synthesising.cells and that T-lymphocytes play a regulatory 
role. The classical experiments which illustrate this are reviewed 
here.
A neonatally thymectomized CBA mouse (haplotype H-2 ) was 
reconstituted at age 8 weeks with the thymus of a C57BL/6 animal 
(haplotype H-2^): sheep red blood cells (SRBC) were administered as 
antigen. The spleen of the repopulated animal was removed seven 
days later and divided into three aliquots which were then treated 
with one of the following antisera plus complement:
a) anti-CBA (anti H-2 );
b) anti-C57BL/6 (anti-H-2^);
c) normal mouse serum.
Only the cells treated with the anti-CBA antiserum failed 
to make antibody suggesting:
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i) endogenous host cells (i.e. B-lymphocytes) were 
responsible for antibody synthesis and
ii) cells from the donor (i.e. T-lymphocytes) had no
effector function in the Ab formation (Mitchell and 
Miller, 1968).
Nossal and co-workers (Nossal e_t al, 1968) performed an 
elegant experiment employing the CBA/T6T6 mouse strain. This 
mutant strain of CBA mice possesses a heritable translocated chromo­
some marker which is easily identified in mitotic cells. (Ford,
1966.) CBA mice were irradiated and repopulated with CBA thymocytes 
and CBA/T6T6 bone marrow cells. In this experiment, the antibody 
forming cells possessed the T6T6 chromosome marker indicating that 
they were of bone marrow origin and not derived from the thymus.
If the irradiated CBA animal was repopulated with CBA bone marrow 
cells and CBA/T6T6 thymocytes, then the T6T6 chromosome marker could 
not be found in antibody forming cells (Nossal et al, 1968) . Those 
data suggest that the B-lymphocytes are the unique cellular site of 
antibody synthesis.
Many membrane markers are now defined which serologically 
delineate T- and B-lymphocyte populations. The most widely utilised 
markers are :
a) © or Thy-1 for T-lymphocytes (see Williams, 1976);
b) membrane immunoglobulin for B-Iymphocytes (see below).
Experiments employing antibody plus complement to elimin­
ate one or other of the lymphocyte populations serve to reinforce the 
classical data reviewed above.
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2.2. ■ Demonstration of Immunoglobulin on the Membrane of B-
Lymphocytes.
For the tenets of the Clonal Selection Hypothesis to be 
upheld, antigen receptors must be demonstrated at the B-lymphocyte 
membrane, and these must be structurally identical to serum antibody 
(i.e. immunoglobulin).
2.2.1. Detection of Membrane Immunoglobulin by Anti-Immunoglobulin
Reagents
Immunoglobulin was demonstrated at the B-lymphocyte membrane 
by use of antibody to immunoglobulin components: the antibody was
labelled with either fluorescent dye or radioiodine.
Using fluorescienated anti-immunoglobulin reagents. Raff and 
his colleagues could easily detect immunoglobulin on B-lymphocytes 
(Raff et al, 1970; Raff, 1970a). Other investigators employed 
similar reagents to demonstrate :
a) cytoplasmic and membrane immunoglobulins of different 
classes in the same cell (Pernis al, 1970) and
b) heavy and light chains were associated on the cell 
membrane (Takahashi et al, 1971).
Radioimmunoassay has revealed the presence of immunoglobulin 
on the membranes of murine (Rabellino et al, 1971) and human (Berner 
et al, 197j) lymphocytes. The binding of radioiodinated anti- 
immunogloublin to murine lymphocytes has been directly visualised by 
electron microscopy used in conjunction with autoradiography (Unanue 
et al, 1972) .
2.2.2. Antigen Binding by Lymphocytes
The technique of rosette formation has been used to illustrate 
the capacity of lymphocytes to bind particular antigens or antigens 
coupled to SRBC (McConnell et al, 1969). Radioactive antigen can 
also be used to detect cells with specific antigen receptors (Ada,
1970).
Passage of primed lymphocytes over a column of antigen-
coated glass beads led to the depletion of specific antigen-reactive,
antibody forming cells from the primed population (Wigzell and
Andersson, 1969). Elution of bound cells restored the capacity to
produce antibody. Thus, antigen binding B-lymphocytes are the
specific precursors of antibody forming cells.
Experiments employing radioactive antigen (Ada, 1970) are
useful not only for detection of antigen binding cells, but also for
enumeration of the cells binding the antigen. In experiments of this
type (reviewed by Warner, 1974), the number of cells capable of binding
-5 -6a given antigen is of the order of 10 - 10 : this figure is in
good agreement with the predictions of the Clonal Selection Hypothesis,
2.2.3. correlation of Antigen Binding Capacity and Presence of 
Membrane Immunoglobulin
Fluorescienated antibodies to immunoglobulins were again 
employed in the experiments which demonstrated that the ability to 
bind antigen co-capped with membrane immunoglobulin (Raff ad, 1973). 
This data reinforced foregoing experiments which showed that the 
ability of lymphocytes to bind antigen was abrogated by pre-treatment 
with anti-immunoglobulin reagents (McConnell et al, 1969; Greaves,
1971; Byrt and Ada, 1969; Warner et al, 1970; Warner, 1974); inhibition
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of antigen binding was not observed when lymphocytes were pre-treated 
with anti-H-2 antisera (Hammerling and McDevitt, 1974), The data 
obtained from experiments using anti-immunoglobulin as an antigen- 
binding inhibitor are open to criticism on the grounds of steric 
hindrance. The data of Raff ^  ad (1973), illustrating the co­
capping of antigen-binding sites and membrane immunoglobulin, argues 
against the steric hindrance objections and strongly suggests that 
membrane immunoglobulin is the antigen receptor.
2.2.4. Direct Correlation of Membrane immunoglobulin and Antigen 
Binding Capacity
Direct visualisation of antigen binding by membrane immuno­
globulin was achieved in the following experiment. Membrane proteins 
of murine splenocytes were radioiodinated (^^^I-iodine) by lacto-
peroxidase-catalysed iodination (Marchalonis et al, 1971). The
125
radiolabelled splenocytes were then incubated with l-radioiodinated 
DNP-haemoglobin. Complexes of receptor and antigen were then pre­
cipitated from cell lysates using either anti-haemoglobin or anti­
immunoglobulin .
The relative amounts of the two radionuclides in the pre-
131cipitate was determined (Rolley and Marchalonis, 1972). I- and
125I-radionuclides were precipitated by both anti-haemoglobuin and 
anti-immunoglobulin antisera. This implies that membrane immuno­
globulin must have been interacting directly with DNP-haemoglobin: 
this is very strong evidence in favour of the hypothesis that membrane 
immunoglobulin is the specific antigen receptor of the B-lymphocyte.
In this experiment DNP was selected as antigen because it 
had been previously demonstrated that a high percentage of unimmunised
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murine splenocytes {0.1 - 1.0%) would specifically bind this determin­
ant (Lawrence et al, 1973). This system therefore overcomes the 
limitations normally imposed by the low precursor frequency of 
specific antigen binding cells.
3. BIOSYNTHESIS OF IMMUNOGLOBULINS
3.1. General Features of Immunoglobulin Structure
The expansion in the understanding of immunoglobulin 
structure in the early 1960s posed many interesting questions re­
garding the genetics of the immunoglobulins. Many of the problems 
presented by the elucidation of the primary structure of the immuno­
globulins could be meaningfully examined by biosynthetic studies.
Before discussing such experiments it is relevant to briefly review 
the major features of the immunoglobulin molecule: the gross structure
of an immunoglobulin molecule is diagrammed in figure 1,
All immunoglobulin classes have a unit structure similar to 
that illustrated in figure I. The basic immunoglobulin molecule 
consists of a globular protein of sedimentation coefficient 7-8S 
composed of two identical heavy chains and two identical light chains. 
(Porter, 1972, 1973; Edelman, 1973.) The heavy and light chains 
have several common properties as revealed by amino acid sequencing 
studies (Hilschmann and Craig, 1965; Milstein 1966; Baglioni e^ al,
1966; Putnam e^ ad, 1966; Milstein and Pink, 1970).
a) the polypeptide chain is divisible into two regions ;
b) the N-terminal regions (residues 1 to approximately 110)
exhibit great amino acid sequence variability (the
FIGURE 1
General Features of Immunoglobulin Structure
The four-chain structure of a typical IgG molecules is shown 
(Porter, 1972; 1973; Edelman, 1973). The hypervariable regions of 
amino acid sequence are shown as shaded areas, and the hinge regions 
as stipled areas. The molecular weights given for the heavy and 
light chains are approximate. The approximate locations of inter­
chain and intra-chain disulphide bridges are also shown.
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V-region);
c) the C-terminal regions(residues 111 to the C-terminus) 
were constant in sequence and exhibited little amino 
acid sequence variability (the C-region),
All immunoglobulin sequences are in agreement with this 
generalisation, and it was clear from the earliest studies of immuno­
globulin primary structure that sequence variability could be 
correlated with antibody specificity (Wu and Kabat, 1970), The 
genetic mechanisms underlying generation and maintainance of antibody 
diversity are clearly of great interest. Biosynthetic studies and 
investigations made possible by advances in recombinant DMA technology 
have contributed greatly to the solution of problems raised by the 
primary structure of immunoglobulins.
3.2. Synthesis of Immunoglobulin Chains.
The observation that immunoglobulin chains were composed 
of two easily delineable regions of amino acid sequence led to 
investigations into the organisation and integration of V-region and 
C-region genetic elements. Three possibilities could be envisaged 
for the integration of V- and C-region elements;
a) at the DNA level;
b) at the RNA level;
c) at the protein level.
Dreyer and Bennett (1965) had controversially postulated 
that two genes were responsible for encoding a single, functional,
immunoglobulin chain. With the Dreyer-Bennett model in mind, the
problem of the molecular level at which V-C integration occurred was
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addressed by a series of experiments investigating the distribution 
of radiolabel in newly-synthesised immunoglobulin chains, based on 
the classical experiments of Naughton and Dintzis (1962).
Prior to the Dreyer-Bennett postulate experimental evidence, 
using the above approach, was obtained by Fleischmann (1963) and these 
early studies showed that Fab and Fc portions of rabbit IgG were not 
separate biosynthetic units (Fleischmann, 1963). Upon more detailed 
analysis in the same experimental system, it was demonstrated using 
cyanogen-bromide generated fragments of rabbit IgG that more radio­
activity was located in C-terminal peptides than in N-terminal pep­
tides (Fleischmann, 1967). This data is consistent with sequential 
growth of the polypeptide chain from the N-terminus to the C- 
terminus. Support for the hypothesis that immunoglobulin chains 
were synthesised from the N-terminus to the C-terminus was obtained 
from similar studies of murine IgG heavy chains synthesised in a 
murine plasmacytoma (Knopf e^ a^, 1967). That light chains were 
synthesised in the same direction was evidenced from studies in a 
mouse myeloma synthesising only light chains (Lennox a^, 1967),
The data from the above experiments suggested a uniform 
gradient of radiolabel from a heavily labelled C-terminus to a 
lightly labelled N-terminus in both heavy and light chains of the 
immunoglobulin molecule. This is consistent with the synthesis of 
V- and C- region amino acid sequences from a single template, and 
is in agreement with the two gene-one polypeptide hypothesis 
(Dreyer and Bennett, 1965). If the above hypothesis were inaccurate 
and V- and C- region polypeptides were integrated at the protein 
level, then initial incorporation of radiolabel would be observed at
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at two distinct points, each corresponding to the C-terminal region 
of the V- or C- region element. The hypothesis, upheld at the 
protein level, is further substantiated by studies of in vitro 
translation of immunoglobulin mRNA.
3.3. Sub-Cellular Site of Immunoglobulin Synthesis
There is now much evidence in the literature which 
demonstrates that membrane-bound polyribosomes are the intracellular 
site of synthesis of immunoglobulin heavy and light chains in immune 
lymphoid tissue and in cultured myeloma cells. A variety of ex­
perimental strategies have been adopted to demonstrate the role of 
polyribosomes in synthesis of immunoglobulin chains;
a) identification of nascent chains by SDS-PAGE of 
purified polyribosomes (Schubert and Cohn, 1968, 1970);
b) specific immunoprécipitation of polyribosomes and 
associated immunoglobulin chains by anti-immunoglobulin 
(Askonas and Williamson, 1966a; Williamson and 
Askonas, 1967; Schubert and Cohn, 1968; 1970; Sherr 
and Uhr, 1970; Cioli and Lennox, 1973);
c) electron microscopy coupled with autoradiography 
(Scharff and Laskov, 1970; Uhr, 1970);
d) immunoprécipitation of immunoglobulin chains synthesised 
by purified polyribosomes in a cell-free system 
(Lisowska-Ber nstein et 1970) and
e) immunoprécipitation of immunoglobulin chains 
synthesised by a cell-ftee translation system programm­
ed with mRNA purified from polyribosomes (Blobel and 
Dobberstein, 1975a,b).
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The evidence also demonstrated that heavy and light 
chains were independently synthesised on separate polyribosomes 
(Scharff and Uhr, 1965; Askonas and Williamson, 1966a; Schubert 
and Cohn, 1968, 1970). These observations were entirely consistent 
with the genetic evidence which demonstrated non-linkage between 
heavy and light genes (Herzenberg et al, 1968).
Electron microscopic analysis of the polyribosomes in­
volved in synthesis of immunoglobulin heavy and light chains in the 
murine plasmacytoma 5563 showed that the polyribosomes responsible 
for heavy chain synthesis contained 11-18 ribosomes per polyribosome, 
whereas those active in the synthesis of light chains contained 
4-5 ribosomes per polyribosome (de Pétris, 1970), These data were 
in agreement with estimates of the number of ribosomes per poly­
ribosome based on sucrose density gradient profiles of polyribosomes 
from the same tumour cell (Askonas and Williamson, 1966a; William­
son and Askonas, 1967).
3.3.1. Nature of Polyribosomes
Polyribosomes may be placed in one of two classes based 
on the nature of their attachment to membranes of the rough endo­
plasmic reticulum (Rosbash and Penman, 1971a, 1971b). Polyribosomes 
can be
a) completely membrane bound, i.e. each ribosome on the 
messenger is tightly bound to the membrane, or
b) "dangling" when some, but not all, of the ribosomes 
on the messenger are membrane bound.
Investigations in myeloma cells have provided evidence 
that polyribosomes involved in synthesis of immunoglobulin chains 
are of the dangling type (Harrison et al, 1974a, 1974b). These
■16-
observations may be interpreted in terms of polyribosome-nascent 
chain interactions and also in terms of vectorial release of de novo 
synthesised immunoglobulin chains into the cisternal compartment.
The role of 'dangling' polyribosomes and the interaction of these 
with nascent immunoglobulin chains is discussed below (section 3,4.3.) 
in terras of the Signal Hypothesis (Blobel and Sabatini, 1971;
Milstein et al, 1972; Blobel and Dobberstein, 1975a, 1975b) .
3.4. Immunoglobulin Messenger RNA and its Translation
3.4.1. Immunoglobulin mRNA Species
The Dreyer-Bennett postulate that two genes were responsible 
for encoding one immunoglobulin polypeptide allowed for V-C integrat­
ion at DNA or RNA or protein levels. The biosynthetic experiments 
(section 3.2. above) illustrated that immunoglobulins were synthesised 
from a single growing point, and this evidence ruled out the possibil­
ity that V-C integration occurred at the protein level (Lennox et al, 
1967; Knopf e_t al, 1967) .
To explore the possibility that V-C integration occurred 
at the level of mRNA, the following experiment was performed. A 
9-13S RNA fraction was isolated from a light chain producing tumour 
cell line (Stavnezer and Huang, 1971); when translated vitro in 
the rabbit reticulocyte cell-free system, the light chain poly­
peptides obtained were almost identical to those synthesised in 
vivo by the tumour itself as assessed by chromatographic and 
electrophoretic analyses of tryptic peptides. This is compelling 
evidence that the light chain was synthesised from a single mRNA 
species which itself contained information for V- and C- regions 
in a single integrated macromolecule. This data suggests that
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V-C integration occurred prior to biosynthesis of immunoglobulin 
mRNA, that is, at the DNA level.
Evidence that light chain mRNA carries the information 
for V- and C- regions as a contiguous unit comes from the data of 
Milstein and his colleagues (Milstein et a^, 1974). Light chain 
mRNA was isolated in sufficiently pure form to allow;
a) the total length of the mRNA to be estimated as 
1,250 bases (4dOO bases) ;
b) the identification of the nucleotide sequence re­
quired to specify the V , C and precursor amino acid 
sequences ;
c) investigation of two untranslated regions, one of 
ISOjdOO residues at the 5* end and another of 200+^50 
nucleotides located at the 3' end of the messenger, 
and
d) the finding of a 3'-poly-adenylated sequence of 
approximately 200 nucleotides.
These data indicated that molecular integration does not 
occur at the protein level or at the level of mRNA: indeed, the
evidence suggests that V-C integration occurs at the DNA level.
3.4,2. Translation of Immunoglobulin Messenger RNA in Vitro
Several laboratories have used mRNA purified from immuno­
globulin-synthesising cells to direct the synthesis of immunoglobulin 
light chains in cell-free translation systems. In all cases re­
ported to date, it has been observed that the product synthesised in 
vitro is larger than the homologous product synthesised in vivo 
(Milstein et al, 1972; Mach et al, 1972; Tonegawa and Baldi, 1973;
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Schmeckpeper al, 1974). The hi vitro synthesised product 
possesses an N-terminal extension of 15-20 amino acids, the "leader" 
or "signal" sequence, which serves to transfer the nascent chain 
through the rough endoplasmic reticulum membranes (Milstein et al, 
1972; and section 3,4.3. below). Similar N-terminal extensions 
have been demonstrated for a murine a-chain (Jilka and Pestka, 1977), 
murine heavy chain (Singer e^ 1980b) and human y-chain
(Singer et al, 1980a).
3.4.3. The Signal Hypothesis
The Signal Hypothesis (Blobel and Sabatini, 1971; Milstein 
et al, 1972; Blobel and Dobberstein, 1975a,b) represents an attempt 
to rationalise the observations of the hydrophobic signal sequences 
observed on many proteins and also of the attachment of polyribosomes
to membranes of the rough endoplasmic reticulum into a unified model
for biosynthesis of secretory and membrane proteins. The hypothesis 
has three basic tenets;
i) translation is initiated on free cytoplasmic mRNAs;
ii) interaction of messenger-polyribosome complexes with 
rough endoplasmic reticulum membranes is mediated via 
the signal sequence, and
iii) the signal sequence serves to effect transfer of 
nascent chains across rough endoplasmic reticulum 
membranes and into the cisternal space.
Evidence is now available to support each of the above 
maxims. Rosbach (1972) demonstrated that newly-synthesised mRNA 
could be sequestered in small cytoplasmic polyribosomes by cyclo- 
heximide: these mRNAs could be "chased" into the larger, membrane-
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bound polyribosome fraction upon removal of the cycloheximide.
The initial interaction between mRNA and the ribosome appears, 
therefore, to occur in the cytoplasm.
In immunoglobulin synthesising cells it has been demonstrated 
that those ribosomes which were tightly bound to the rough endo­
plasmic reticulum membrane were anchored via a nascent chain-membrane 
interaction (Harrison et al, 1974b). Polyribosomes, such as those 
involved in immunoglobulin synthesis, which are anchored via a 
nascent chain-membrane interaction can be removed from the rough 
endoplasmic reticulum by treatment with puromycin and KCl (Harrison 
et al, 1974a, b). Such treatment also removed all the immunoglobulin 
mRNA from the rough endoplasmic reticulum (Harrison et al, 1974b) which 
argues against direct binding of immunoglobulin mRNA to the rough 
endoplasmic reticulum membrane.
Transfer of immunoglobulin chains across membranes was 
demonstrated in experiments where an vitro protein synthesis 
system, programmed with immunoglobulin light chain message, was 
supplemented with canine pancreatic microsomes (Blobel and Dobberstein, 
1975a, b). At the end of the ^  vitro synthesis period, the newly- 
synthesised light chains were shown to be insensitive to exogenously 
added proteases which suggested that they had been transferred into 
the microsomal cisternae. This data implied that the information 
necessary for this transfer, (that is, the signal peptide), was en­
coded by the mRNA and was not part of the protein synthetic machinery.
Thus, it is clear that the N-terminal signal peptide of the 
immunoglobulin chains plays a significant role in interaction of the 
messenger-polyribosome complex with the membranes of the rough
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endoplasmic reticulum and also in efficient transfer of proteins 
across rough endoplasmic reticulum membranes.
3.5. Assembly of Immunoglobulins
3.5.1. Immediate Events after Chain Synthesis
Several important events occur during or just after immuno­
globulin chain synthesis and before assembly into four-chain structures, 
These events are
a) removal of the hydrophobic signal sequence;
b) N-glycosylation of nascent heavy chains ;
c) cyclisation of N-terminal glutamine residues.
Removal of the signal sequence is believed to occur rapidly
after transfer of the nascent chain across the rough endoplasmic 
reticulum membrane (Milstein et al, 1972; Blobel and Dobberstein,
1975a,b). The enzyme responsible for removal of the signal sequence,
signal peptidase, is believed to be localised on the cisternal face 
of the rough endoplasmic reticulum.
The topic of glycosylation of immunoglobulin chains is 
dealt with in detail below (section 3.8.); there are claims that N- 
glycosylation of immunoglobulins is a nascent chain event (Moroz and 
Uhr, 1967; Sherr and Uhr, 1969) but these data may be criticised on 
the grounds that no special precautions were taken to prevent ab­
sorption of completed immunoglobulin chains onto the ribosomes.
Cyclisation of N-terminal glutamine residues to pyrrolidone 
carboxylic acid (PGA) has been observed in several immunoglobulin 
chains; for example human X light chains subgroups I, II and V, 
some human heavy chains (see Kabat et al, 1979) and the X-light 
chain of the murine plasmacytoma MOPC 104E (Appella, 1971).
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Investigation of cyclisation of glutamine to PCA in a synthesis­
ing murine plasmacytoma, demonstrated that cyclisation was a late 
event during biosynthesis, and that PCA was virtually undetectable 
on nascent polypeptides (Stott, 1972).
3.5.2. Order of Disulphide Bond Formation
The immunoglobulin molecule possesses several inter­
chain and intrachain disulphide bridges. This discussion is con­
cerned with the formation of interchain disulphide bonds, that is 
those between two heavy chains or between heavy and light chains. 
Clearly, there are two possible orders of formation of disulphide 
bonds ;
a) heavy-heavy before heavy-light, or
b) heavy-light followed by heavy-heavy.
The order in which disulphide bridges are formed varies 
from one immunoglobulin class to another, but each immunoglobulin 
class has a characteristic pattern of disulphide bond formation
(Sevan et al, 1972; Baumal and Scharff, 1973). For example, murine
IgGl, IgG2a and IgA all form inter-heavy chain disulphide bridges 
before covalently associating with light chains (Baumal et al, 1971a; 
Parkhouse, 1971a)) the converse situation prevails in order of di­
sulphide bond formation in murine IgM (Parkhouse, 1971b). Human 
IgG molecules also form inter-heavy chain disulphide bridges first 
(Baumal et al, 1971b) but human IgM and rabbit IgG form disulphide- 
bonded heavy-light "half molecules" as their first biosynthetic 
intermediate (Buxbaum et al, 1971; Sutherland e^ al, 1970).
Several factors may influence the order in which di­
sulphide bonds are formed;
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a) non-covalent interactions ;
b) intrinsic stability of the disulphide bond formed, 
and
c) the absolute reducing conditions in the cellular 
microenvironment where assembly occurs.
As regards non-covalent interactions, these forces are 
sufficiently strong to produce a functional antibody in the absence 
of disulphide bridges (see Parkhouse, 1977). These interactions 
are probably of great significance as a primary reaction leading to 
optimal conditions for disulphide bond formation (see section 3.5.3. 
below).
The stability of a given disulphide bond correlates well 
with data pertaining to susceptibility of immunoglobulin molecules 
to mild reducing conditions (Sevan et al, 1972). For example, 
treatment of murine IgGg^, which assembles via a heavy chain dimer 
(Askonas and Williamson, 1968a) , with lOmM 2-mercaptoethanol leads 
to formation of heavy chain dimers and free light chains (William­
son and Askonas, 1968^;). The data implies that the inter-heavy 
chain disulphide bridge is more stable than that between heavy 
and light chains. Similar correlations between order of formation 
of interchain disulphide bridges and susceptibility to mild reduction 
have been demonstrated for human IgG (Williamson and Askonas, 1968a), 
human IgA (Parkhouse e_t al, 1971) , and murine IgM (Askonas and 
Parkhouse, 1971).
The absolute reducing conditions in the cellular site of 
immunoglobulin assembly may be expected to influence the order of
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disulphide bond formation. Given that there is a differential 
lability of heaVy-heavy and heavy-light interchain disulphide 
bridges, and that in each case a distinct order of disulphide bond 
formation is observed, it is reasonable to propose that the reducing 
conditions at the site of assembly would be intermediate between 
those required for reduction of the two types of disulphide bond 
(Sevan et 1972) .
3.5.3. Non-Covalent Interactions of Immunoglobulin Chains
Due to the weakness of the forces involved, evidence for
non-covalent interactions of immunoglobulin chains has been difficult
to obtain. There is some evidence to support the proposals that
such interactions do exist.
Non-covalently bound light chains could be demonstrated on
nascent heavy chains which had been dissociated from the heavy chain
synthesising polyribosomes (Shapiro e^ 1966; Schubert, 1968).
Other investigators were able to demonstrate a non-covalent inter- 
131action between l-radiolabelled light chain and polyribosomes- 
bound nascent heavy chains (Askonas et al, 1969),
However, it was not possible to immunoprecipitate heavy 
chain synthesising polyribosomes with anti-light chain antibody 
(Williamson and Askonas, 1967) . This negative data may be explained 
by proposing that the antigen-antibody interaction disrupted any 
non-covalent interactions between the heavy and light chains.
A possible route for non-covalent interaction of immuno­
globulin chains has been proposed by Sevan and his colleagues 
(Sevan et a^, 1972) . At neutral pH native heavy chains are known to 
form dimers with interactions occurring at the Fc and Fd regions 
(Bjfirk and Tanford, 1971). An equilibrium will be established
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between those heavy chains interacting at both Fc and Fd and those 
interacting only at Fc; this latter population will be capable of 
interacting with free light chains and will therefore be capable of 
forming four chain molecules.
3.5.4. Intracellular Pools and Balanced Synthesis
In biosynthetic studies of formation of intermediates an 
route to the formation of molecules, the first intermediate to
be observed was free light chain. These newly-synthesised light 
chains were rapidly released from polyribosomes to form an intra­
cellular pool of free light chains (Askonas and Williamson, 1966b). 
Given that the sole secretory product of plasma cells is fully 
assembled molecules (Williamson and Askonas, 1968b; Baumal and
Scharff, 1973a), it is most likely that the intracellular pool of 
free light chains is in precursor-product relationship with completed 
molecules. By virtue of this precursor-product relationship, 
the size of the light chain pool within any given cell is maintained 
at a constant size (Williamson and Askonas, 1968b) although the size 
of the pool varies from one cell type to another (Bevan ejt al, 1972) .
The existence of an intracellular pool of free light chains 
in immunoglobulin synthesising cells has been a general and consistent 
finding. Equally consistent has been the failure to demonstrate a 
corresponding intracellular pool of free heavy chains ; only heavy 
chain dimers were readily demonstrated (Bevan et al, 1972) . On the 
basis that immunoglobulin synthesising cells possess an intracellular 
pool of free light chains which is of constant size and that this pool 
is in precursor-product relationship with fully assembled, secreted 
molecules, it is reasonable to propose that the synthesis of heavy
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and light chains is balanced in such a manner that the amount of heavy 
chain synthesised is equal to that amount which the cell requires for 
membrane insertion or for secretion: no excess heavy chain is
synthesised. The mechanisms which control the balance of synthesis 
could operate at either or both transcriptional or translational 
levels.
3.6. Accessory Polypeptide Components of Immunoglobulins
In the polymeric immunoglobulins IgM and IgA, accessory 
protein chains are found in association with the completed IgM and 
IgA polymers. J-chain is found in both IgM and dimeric (not mon­
omeric) IgA, and secretory IgA also acquires secretory component 
during externalisation.
3.6,1. J-Chain
J-chain is a glycoprotein found in covalent association 
with the C-terminal region of 19S IgM pentamers and llS IgA dimers : 
in each case, only one J-chain molecule is found per 19S IgM or IIS 
IgA polymer (Chapius and Koshland, 1974). Human J-chain is a poly­
peptide of 129 amino acids, eight of which are cysteine (Mole et al, 
1977). It is synthesised by B-lymphocytes and is found not only in 
IgM and IgA producing cells, but also in IgG-producing cells in the 
human (Brandtzaeg, 1974) and in the mouse (Kaji and Parkhouse, 1974, 
1975; Mosmann and Baumal, 1975). The finding of J-chain in these 
cells probably reflects on earlier state of differentiation of these 
cells (i.e. as IgM producers) prior to their development into IgG- 
producing cells. This data supports the hypothesis that the genes 
encoding immunoglobulin heavy chains and J-chain are not co-ordinately 
controlled. This hypothesis is further supported by the finding of
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normal amounts of J-chain in myeloma variant cells with suppressed 
heavy chain snythesis (Kaji and Parkhouse, 1974, 1975; Mosmann euid 
Baumal, 1975) . The role of J-chain in control of accuracy of 
polymerisation of IgM and IgA is discussed below (section 3.7.).
3.6,2. Secretory Component
In addition to one molecule of J-chain, the dimeric form 
of IgA found in mucous secretions, secretory IgA, contains a further
unique glycoprotein of approximately 60,000 daltons molecular weight:
this is secretory component (Tomasi and Grey, 1972) , Secretory 
component is synthesised not by B-lymphocytes but by the epithelial 
cells in the walls of the gastrointestinal tract and airways,
(Tomasi and Bunenstock, 1968; Tourville e^ 1969.)
3.7. Formation of Polymeric Immunoglobulins
IgM and IgA are found as polymeric structures in serum and 
secretions of higher vertebrates. In both classes, J-chain is found 
in association with the 19S IgM pentamer or the IIS IgA dimer, but 
not with the monomeric forms of these immunoglobulins. This section 
reviews the current status with regard to understanding of the poly­
merisation events and the role of J-chain in such processes.
3.7.1. Observations In Vivo
In both human and murine systems, the IgM component found 
in serum is the 19S pentamer. The pentamer is not readily detected 
in the cytoplasm of cells synthesising IgM and several groups have 
demonstrated that 85 IgM monomers are the precursors of 195 IgM 
(Parkhouse, 1971b; Parkhouse and Askonas, 1969; Buxbaum et al, 1971)-. 
Although this is the general case, there are exceptions to the rule.
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For example, some human myeloma tumour cells (Buxbaum et al, 1974) 
and bone marrow cells from patients suffering from Waldenstroms 
macroglobulinaemia (Buxbaum ejt al, 1971) have readily detectable 
amounts of intracellular 19S IgM. The large weight of evidence does 
suggest that the predominant intracellular IgM is the 8S monomer.
The data are in agreement with hypotheses suggesting that the poly­
merisation event and secretion of 19S IgM from B-lymphocytes are 
closely linked if not concommitant events.
IgA is also found in the polymeric state, but does not 
polymerise to a uniform extent although the dimer is the most pre­
valent polymer. The main cytoplasmic form of IgA is the 7S monomer 
(Abel and Grey, 1968; Parkhouse, 1971a; Bevan, 1971) although there 
are certain tumours which have small amounts of oligomer in their 
cytoplasm (Halpern and Coffman, 1972).
3.7.2. Observations in Vitro
Isolated intracellular 8S IgM monomers can not be poly­
merised vitro to give 195 IgM pentamers unless they have been 
treated with a reducing agent (Askonas and Parkhouse, 1971). These 
data suggested that cysteine residues involved in inter-monomer 
disulphide bridging were reversibly blocked within the cell. Further 
evidence demonstrating the requirement of reducing conditions was 
obtained from experiments in which isolated intracellular 85 IgM was 
treated first with an alkylating agent and then with reducing agent. 
Polymerisation to 195 IgM could still be achieved from monomers treated 
in thiè fashion.
These data implicate the involvement of an enzyme mediating 
disulphide interchange (Fuchs et al, 1967) in the removal of the block
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on the penultimate C-terminal cysteine of the 8S IgM monomer. This 
enzyme may also act as a control step for the final polymerisation 
event immediately prior to, or concomitant with, the secretion event.
3.7.3. Requirements for Polymerisation
In addition to reducing conditions and the presence of a 
disulphide interchange enzyme, the polymerisation of IgM and IgA 
seems to depend on the presence of J-chain (Inman and Mestecky, 1974; 
Koshland, 1975). Both IgM and IgA can be polymerised vitro, from 
monomers prepared from the corresponding polymers by mild reduction 
(Della Corte and Parkhouse, 1973b). These experiments demonstrated:
a) total and accurate polymerisation;
b) IgM formed pentamers, IgA formed dimers, and
c) there were no residual monomers.
The process was critically dependent on the presence of J- 
chain and purified disulphide interchange enzyme. IgM, but not IgA, 
could be polymerised vitro in the absence of enzyme provided the 
concentration of 8S monomer was high (Parkhouse et al, 1971a, 1971b; 
Askonas and Parkhouse, 1971) . The important role of the disulphide 
interchange enzyme was evidenced by the finding that, in the presence 
of J-chain and enzyme, low concentrations of IgM and IgA subunits 
could be successfully polymerised in vitro (Della Corte and Parkhouse, 
1973b) .
Therefore, there appear to be three requirements for the 
accurate polymerisation of IgM and IgA;
a) reducing conditions,
b) an enzyme mediating disulphide interchange, and
c) J-chain.
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The role of J-chain is discussed in detail below (section
3.7.4.).
3.7.4. Role of J-Chain in Immunoglobulin Polymerisation
A remarkable degree of specificity is apparent when IgM 
and IgA subunits are polymerised in the presence of disulphide inter­
change enzyme and J-chain (Della Corte and Parkhouse, 1973b). The 
following observations were made:
a) IgM and IgA polymerised to pentamers or dimers 
respectively;
b) no hybrid molecules were formed, and
c) reduced albumin or 7S IgG failed to interfere with 
polymerisation.
Thus, IgM and IgA subunits could not interact despite the 
fact that the same J-chain molecule was involved in polymerisation 
of both immunoglobulin classes.
Further evidence that J-chain has a critical role in 
accurate polymerisation of IgM comes from polymerisation studies 
performed in vitro in the absence of J-chain (Kownatski, 1973; 
Eskeland, 1974). Polymerisation was shown to occur, but the poly­
mers were not 19S pentamers, but a mixture of molecular sizes of IgM,
The role of J-chain in IgM polymerisation is, however, the 
subject of great debate, while the above investigations strongly 
suggest a crucial role for J-chain in the polymerisation process, the 
findings of 19S IgM lacking J-chain in a human myeloma (Eskeland 
and Brandtzaeg, 1974) and in certain species of fish (Weinheimer 
et al, 1971), argue against J-chain being an absolute requirement for 
IgM polymerisation.
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Furthermore, the murine plasmacytoma Y5781 has been shown to 
contain a large intracellular pool of 19S IgM and a portion of the 
pentamers in this pool apparently lack J-chain (Stott, 1976) ; J- 
chain is believed to be added to these 19S IgMs just before or during 
secretion. Studies in vitro of IgM polymerisation indicated that 
monomers would polymerise in the absence of J-chain and that the 
pentamers so formed were indistinguishable from normal 19S IgM as 
judged by electron microscopy (Feinstein, 1973). Fc fragments of 
y-chain (Fey) were demonstrated to be capable of polymerisation to 
12s pentamers (5 x Fey) dm vitro in the absence of J-chain (Beale, 
1974) .
The role of J-chain in the polymerisation and secretion of 
IgM and IgA remains to be unequivocally proven. Biosynthetically, 
the evidence suggests that addition of J-chain is quite a late event. 
Structural investigations show that J-chain is disulphide bonded to 
only two of the monomeric subunits of 19S IgM (Chapius and Koshland, 
1974) and to both subunits of llS IgA (Hauptman and Tomasi, 1975) in 
the form of a disulphide "clasp".
3.8. Glycosylation of Immunoglobulin Chains
3.8.1. Biosynthesis of Lipid Linked Oligosaccharides
Many membrane associated and secretory proteins, including 
immunoglobulins, have multiple sites of addition of carbohydrate 
moieties. The carbohydrate prosthetic groups are added to the 
protein at asparagine residues (N-linked oligsaccharides) or at 
serine or threonine side chains (0-linked oligosaccharides).
The N-linked oligosaccharides may be divided into two classes:
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a) "core" or "high mannose" oligosaccharides which contain 
N-acetylglucosamine and variable amounts of mannose, 
and;
b) "complex" oligosaccharides which, in addition to N- 
acetylglucosamine and mannose, contains galactose, 
sialic acid and fucose.
In all cases where the carbohydrate is N-linked to the 
polypeptide chain the "bridge" sugar is N-acetylglucosamine. In­
deed, both "core" and "complex" carbohydrate structures are synthes­
ised via a common biosynthetic pathway (see figure 2).
The "core" oligosaccharides are assembled on a carrier lipid 
molecule, dolichol pyrophosphate, and then transferred to a specific 
site on the polypeptide chain. The amino acid sequence at the sits 
of N-glycosylation is asn-x-ser or thr (Shizimu et al, 1971). The 
first step in the synthesis of the oligosaccharide is the formation 
of dolichol diphosphoryl-N-acetylglucosamine from dolichol pyro­
phosphate and UDP-N-acetylglucosamine (Parodi and Leloir, 1979).
It is this first transfer reaction which is inhibited by the anti­
biotic tunicamycin (Takatsuki et al, 1975; Tkacz and Lampen , 1975; 
Lehle and Tanner, 1976) . The oligosaccharide is then elongated by 
addition of a further N-acetylglucosamine moiety followed by nine 
mannose residues and finally three glucose residues (Li et al, 1978; 
Hubbard and Robbins, 1979). The internal sugars are derived from 
sugar nucleotides while the peripheral moeities are added from either 
dolichol phosphoryl mannose or dolichol phosphoryl glucose (Elbein, 
1979 ; Parodi and Leloir, 1979). The highly branched oligosaccharide 
structure is then added to an asparagine residue located in the
FIGURE 2
Biosynthesis of Lipid-Linked Oligosaccharides
The biosynthesis of the lipid-linked oligosaccharide moieties 
utilised in N-glycosylation of proteins is schematically represented 
opposite.
Key;
Dol-P — Dolichol Phosphate
GlcNAc - N-acetylglucosamine
Man - Mannose
Glc Glucose
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FIGURE 2: Biosynthesis of Lipid-Linked Oligosaccharides
Dolichol Phosphate (Dol-P)
UDP-GlcNAc
UMP
Dol-P-P—GlcNAc
UDP-GlcNAc
UDP
\1/
Dol-P-P- (GlcNAc)
Dol-P ---1---> GDP-Man
GDP --------->Dol-P-Man
UDP-Glc 
Dol-P —
GDP
^  Dol-P
\K
Dol-P-P (GlcNAc ) (mn) ^
-j  Del—P—Glc
^ >UDP
Dol-P
V
Dol-P-P- (GlcNAc ) (Man) (Glc ) ^
Protein-Asn
-> Dol-P-P
\i/
Protein-Asn-(GlcNAc) (Man)(Glc)^
(Schwartz & Datema, 1980; Gibson et al, 1980; Parodi & Leloir, 1979)
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asn-x-ser/thr tripeptide sequence (see figure 2).
After the oligosaccharide has been transferred to the 
polypeptide, during or just after synthesis of the latter on membrane 
bound polyribosomes, processing of the large oligosaccharide occurs 
to yield the "high mannose" (or core) or "complex" carbohydrate side 
chains found on the mature protein. Processing begins in the rough 
endoplasmic reticulum with the removal of the three glucose units, and 
continues during transport of the protein through the Golgi membranes. 
The formation of a complex oligosaccharide requires the removal of 
six mannose units followed by the stepwise addition of N-acetylgluco­
samine galactose, sialic acid and fucose from the appropriate nucleo­
tide sugar. The addition of the latter sugars is performed by 
membrane bound glycosyl transferases. For synthesis of "high mannose" 
oligosaccharide side chains, a varying number of mannose residues are 
removed and no further sugars are added. The steps involved in 
processing of N-linked oligosaccharides are summarised in figure 3.
3.8.2. Glycosylation Events During Immunoglobulin Synthesis 
Kinetic studies of the incorporation of defined sugar 
residues into newly-synthesised immunoglobulin chains illustrated 
that different sugars were incorporated into the molecule depending 
on the intracellular location of the molecule. The order in which 
the sugars were added appeared to be similar in rabbit lymphoid cells 
(Cohen and Kern, 1969), murine myeloma cells (Melchers, 1970, 1971;
Choi et al, 1971; Parkhouse and Melchers, 1971; Della Corte and 
Parkhouse, 1973a), and in mitogen-stimulated B-lymphocytes (Melchers 
and Andersson, 1973) and was as follows:
a) glucosamine and mannose were added close to the time
FIGURE 3
Processing of N-Linked Oligosaccharides
After addition of oligosaccharide side chains to proteins, 
the carbohydrate prosthetic group is modified during intracellular 
transport of the glycoprotein. These modification events are
Key ; -
the figure.
A - N-acetyl glucosamine
F — Fucose
G - Glucose
Gal - Galactose
M — Mannose
SA Sialic acid.
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FIGURE 3: Processing of N-Linked Oligosaccharides
Protein-Asn-A-A-M^ M-M
M-M 
 >3xG
,M—M—M—G—G—G
M-M-M
Protein-Asn-A-A-M^ (M)
II M-M
Rough
Endoplasmic
Reticulum
f- > 4xM and
Protein-Asn-A-A-M M
M
UDP-A
Protein-Asn-A-A-M M
I
M
("Core") Golgi
Membranes
\|/
Protein-Asn-A-A-M
UDP-A
92xM
M-A
UDP
UDP-Gal
^ UDP
GDP-F
^  GDP
CMP-SA
Protein-Asn-A-A-M
M-A-Gal-SA
M—A —Gal — SA
( "Complex")
'■/
Membran e- 
bound
Glycosyl- 
transferases
(Schwartz & Datema, 1980; Gibson et al, 1980; Parodi & Leloix, 1979)
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of synthesis of the immunoglobulin chains (although 
there is some debate as to whether or not this is a 
nascent chain event);
b) galactose was added in the Golgi region, and
c) fucose and sialic acid were added close to, or 
concomitant with, secretion.
One exception to this trend was that during biosynthesis 
of IgM, galactose was added closer to the time of secretion.
3.8.3 Influence of Oligosaccharide Moieties on Transport of
Immunoglobulins
Much controversy has surrounded the functional significance 
of the carbohydrate moieties of glycoproteins since it was suggested 
that such prosthetic groups were necessary for efficient transport 
of glycoproteins (Eylar, 1965), In early experiments on the IgG^ 
synthesising myeloma MOPC-21, it was demonstrated that addition of 
2-deoxyglucose to the cells inhibited the migration of radiolabelled 
Y - chains from polyribosomes through the rough endoplasmic reticulum 
to the smooth endoplasmic reticulum (Melchers, 1973) . If 2-deoxy­
glucose prevented only glycosylation, then this data would have been 
consistent with the Eylar postulate. However, 2-deoxyglucose is 
known to have wide effects as a metabolic inhibitor and, therefore, 
the data obtained from the above experiments may not be due to 
interference with carbohydrate-mediated processes for the control of 
intracellular transport of immunoglobulin chains, but may reflect 
interference with the energy supply required for the transport 
processes.
Later studies of a mutant of the MPC-11 murine plasmacytoma
— 36—
which had defective glycosylation processes, revealed that IgG contain­
ing both glycosylated and non-glycosylated y-chains was efficiently 
secreted from the plasmacytoma (Weitzman and Scharff, 1976).
Data from other systems is relevant. The effects of in­
hibition of N-glycosylation on a variety of membrane associated and 
secretory proteins has been investigated (reviewed by Gibson e^ al, 
1980) and the data are summarised in table 1.
All of the experiments described in table 1 employed the 
antibiotic tunicamycin as the inhibitor of N-glycosylation. The 
antibiotic is a fermentation product of the bacterium Streptomyces 
lysosuperficius (Takatsuki ejt al, 1975) and, presumably by virtue of 
its possession of a glucosamine function, inhibits the first step in 
assembly of oligosaccharides on the dolichol carrier (Tkacz and 
Dampen, 1975; Lehle and Tanner, 1976; see figure 2). Inhibition of 
this reaction effectively inhibits synthesis of oligosaccharides which 
would normally be used in the process of N-glycosylation of proteins. 
Tunicamycin also possesses a long dolichol-like tail and a uridine 
moiety, and therefore has the capacity to inhibit metabolic processes 
other than synthesis of dolichol diphosphoryl N-acetylglucosamine, 
e.g. synthesis of dolichol itself.
In studies of immunoglobulinsecretionin the presence of 
tunicamycin, it has been demonstrated that secretion of IgM from 
MOPC 104E was inhibited by 81% by tunicamycin (Hickman and Kornfeld, 
1978) , and IgA secretion from murine plasmacytomas was inhibited by 
more than 60%. IgG secretion was inhibited by only 28% if the IgG 
synthesising cells were treated with tunicamycin (Hickman and Korn­
feld, 1978) . The secretion of igE from a rat plasmacytoma was also
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TABLE 1:- Effects of Tunicamycin on Protein Function
PROTEIN EFFECT OF TUNICAMYCIN REF.
Fibroblast Procollagen Failure of Secretion Olden et al, 1978
Sindbis Viral Proteins Failure to Insert into Schwartz et al,
Membrane 1976.
Semliki Viral Proteins Failure to Insert into Leavitt et al,
Membrane 1977.
Human Fibroblast Secreted and Active Mizrahi et al.
Interferon 1978.
Erythrocyte Glyco- Inserted Normally into Gahmberg et al.
phorin Membrane 1980.
Sindbis Viral Proteins Increased Susceptibility Schwartz et al,
to Proteolysis 1976.
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inhibited by the antibiotic (Hickman ejt al, 1977) .
With respect to membrane insertion of immunoglobulins, it 
was claimed that non-glycosylated IgA could be efficiently inserted 
into the plasma membrane of MOPC 315 cells (Hickman and Wong-Yip, 
197^). However, non-glycosylated IgM could not be detected at the 
membrane of Daudi human B-lymphoma cells cultured for prolonged 
periods in tunicamycin (Singer, 1978; this thesis). The data of 
Hickman and Wong-Yip (197^) is open to criticism, particularly on 
the grounds that no attempt was made to confirm that the presumptive 
membrane form of a-chain was different to the secretory a-chain made 
by MOPC 315 cells.
Therefore, at the outset of these studies, the situation 
remains unclear with regard to the importance of N-glycosylation of 
immunoglobulins in their secretion and membrane insertion. Since 
B-lymphocytes are known to be capable of synthesising structurally 
distinct forms of y-chain (Singer et al, 1980; Rogers ejt al, 1980; 
Alt et al, 1980a; Bergman and Haimovich, 1978; Vassalli et al, 1979; 
Sidman, 1981) y-chain (Singer and Williamson, 1980; Lifter et al, 
1980; Oi et al, 1980; this thesis) and a-chains (this thesis) it is 
of great interest to study the comparative influence of N-linked 
oligosaccharide side chains in regulation of intracellular transport 
of membrane and secretory polypeptides of immunoglobulins of various 
classes.
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4. STRUCTURE AND BIOGENESIS OF RECEPTOR AND EFFECTOR ANTIBODY
4.1. The Clonal Selection Paradox
The principal tenet of the Clonal Selection Hypothesis 
(Burnet, 1959) is that antibody forming cells express a receptor 
antibody which is identical to the antibody secreted by that cell 
upon antigen-driven clonal expansion. A paradoxical situation is 
therefore revealed, and the question arises; how can an hydrophilic 
macromolecule, such as serum immunoglobulin, exist in a functional 
state in the hydrophobic environment of the lipid bilayer? Two 
major schools of thoughtemerged to explain the paradox and the 
essential features of these theories were as follows:
a) immunoglobulin structure was such that it allowed the 
molecule to adopt different conformations and hence 
exist functionally in two different microenvironments, 
or,
b) the structures of receptor and effector (i.e. membrane 
and secretory) immunoglobulin were different.
The latter hypothesis has proved to be accurate with much 
evidence now available at protein, RNA and DNA levels which illus­
trates that membrane and secretory immunoglobulin heavy chain poly­
peptides are indeed structurally different and are discrete biosyn­
thetic entities. The pertinent data are discussed below.
4.2. Topological Considerations for Receptor Immunoglobulins
From experiments demonstrating the capacity of B-lympho­
cytes to bind antigen (McConnell e± ad, 1969; Ada, 1970; Wigzell and 
Andersson, 1969; Warner, 1974) and those illustrating that the areas
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of sequence responsible for antigen binding were located at the V 
region (at the N-terminal end) of heavy and light chains (Hilschmann 
and Craig, 1965; Milstein, 1966; Baglioni et al, 1966; Putnam et al, 
1966; Wu and Kabat, 1970), it is clear that the N-terminal portions 
of membrane immunoglobulin are exposed to the extracellular environ­
ment while the amino acids at or near the C-terminus are likely to be 
responsible for anchorage of the immunoglobulin in the cell membrane. 
Recent evidence to support this notion comes from studies with 
lipophilic nitrenes which label only the y-chain of membrane IgM; 
this is consistent with the hypothesis that the C-terminal sections 
of membrane IgM are buried in the lipid bilayer. Light chains, 
peripheral proteins, are not labelled by this reagent (Owen e^ al, 
1980).
Studies of membrane IgM radioiodinated either in situ or 
in free solution (Uhr and Vitetta, 1973) showed that the ratio of 
radioactivity in y-chains compared with light chains was almost the 
same irrespective of the iodination regime, a result which suggests 
that the membrane IgM is largely exposed on the cell membrane. 
Labelling of components buried in the lipid bilayer may have 
occurred due to diffusion of short-lived iodine radicals into the 
bilayer (B&yse and Morrison, 1971; Marchalonis and Cone, 1973).
More recent studies using a similar strategy on human IgM, illustrat­
ed that the y/L ratio for incorporation of radioiodine was signifi­
cantly lower for membrane IgM than for 8S IgM monomers derived 
from monoclonal 19S IgM myeloma proteins (Seon and Pressman, 1979). 
This data suggests that a portion of the membrane IgM is buried in 
the lipid bilayer.
— 41—
Fluorescent antibody directed against determinants located 
in the Fc portions of y-chains failed to effectively stain lympho­
cytes bearing membrane IgM (Pemis et al, 1970; Froland and Natvig, 
1972). Furthermore, it was demonstrated that the 50 amino acids 
at the C-terminus of membrane IgM were inaccessible to the antibody 
directed against Fc determinants of y-chains (Fu and Kunkel, 1974), 
These data support the notion that a portion of membrane IgM is 
inserted into the lipid bilayer.
Data pertaining to the susceptibility of membrane IgM 
to proteolysis were also in accord with the above hypothesis.
Membrane IgM of intact cells was shown to be less susceptible to 
proleolytic degradation than its secreted counterpart when treated 
with papain (Vitetta and Uhr, 1976), trypsin, a-chymotrypsin or 
pronase (Hough ejt al, 1977) .
The large weight of evidence therefore supports the notion 
that a portion of the heavy chain of membrane immunoglobulin is 
inserted into lipid bilayer.
4.3. Evidence for Structurally Distinct Membrane and Secretory
y-Chains.
Early investigations examining the possibility that the 
y-chains of membrane IgM possessed a C-terminal hydrophobic region 
compared the relative mobilités of radioiodinated membrane and 
secreted y-chains on SDS-PAGE, The initial observations suggested 
that membrane y-chain was of lower AMW than its secreted counterpart 
Melcher and Uhr, 1973). This was taken as evidence that binding of 
IgM to the cell membrane was accomplished via conformational changes, 
perhaps mediated by under-glycosylation of the y-chains destined for
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membrane insertion, which allowed extériorisation of hydrophobic 
sequences which, in turn, would form loops capable of hydrophobic 
interaction with the lipid bilayer (Vitetta and Uhr, 1975b).
However, similar studies by the same and different workers 
came to the opposite conclusion. In the later investigations the 
membrane y-chain of murine splenocytes migrated more slowly on SDS- 
PAGE than its secretory counterpart, suggesting a higher AMW for 
membrane y-chains than for secretory y-chains. The AMW difference 
between membrane and secretory y-chains was estimated to be 1700 
daltons (Lisowska-Bernstein and Vassalli, 1975; Melcher and Uhr,
1976). Similar studies in the human system also illustrated that 
membrane y-chains have a higher AMW than secretory y-chains (Singer 
and Williamson, 1980; Singer et al, 1980a; Williams and Grey, 1978). 
Human y- and a-heavy chains seem to follow this trend (this thesis) 
as do chicken (Lifter ^  al, 1980) and murine y-chains (Oi at al, 
1980),
Studies of the hydrophobic properties of membrane and 
secretory y-chains established the following;
a) removal of non-ionic detergent from cell lysates 
containing membrane and secretory IgM molecules led 
to a proportion of the molecules, the membrane IgM 
fraction, becoming insoluble; secretory IgM was 
totally soluble in the absence of the detergent 
(Melcher e_t 1976) and;
b) membrane IgM had a lighter bouyant density in the 
presence of non-ionic detergents than had secreted 
IgM as judged by isopycnic centrifugation in caesium
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chloride gradients (Melcher and Uhr, 1977).
These data, considered in conjunction with data from SDS-PAGE 
analyses, are consistent with the hypothesis that membrane y-chain 
possesses an extra hydrophobic sequence capable of interaction with 
the components of the lipid bilayer. The topological arguements 
advanced above (section 4.1.) would suggest that the hydrophobic 
peptide is located at the C-terminal region of the membrane y-chain.
The C-terminal sequences of human membrane and secretory y- 
chains in the B-cell line Daudi were analysed by carboxypeptidase 
digestion experiments (Williams et al, 1978; Singer et al, 1980a).
The kinetics of release of tritiated tyrosine were much faster for 
secretory y-chain than for membrane y-chain clearly indicating 
different C-terminal structures on the two y-chain species.
The evidence from the quoted studies are consistent with the 
hypothesis that membrane y-chain possesses a C-terminal hydrophobic 
peptide which confers the necessary structural requirements for 
efficient insertion into, and stability within, the cell membrane: 
this extra hydrophobic peptide is absent from secretory y-chains.
4.4. Biosynthesis of Membrane and Secretory y-Heavy chains
Two major hypotheses can be advanced to explain the simul­
taneous appearance within a single B-lymphocyte of structurally 
distinct membrane and secretory y-chain polypeptides. These hypo­
theses propose either;
a) synthesis of a single polypeptide, with appropriate 
post-translational modifications being invoked to 
generate membrane or secretory y-chain as required, or;
b) simultaneous synthesis of structurally distinct membrane 
and secretory heavy chain polypeptides.
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4.4.1. In Vivo Biosynthesis
Investigation of the biosynthesis of IgM in the murine B-
cell line 38C-13 and in normal spleen cells demonstrated three
species of p-chain (Bergman and Haimovich, 1978). These p-chains
were designated, in order of descending AMW, as membrane p, secretory
p and intracellular p. Digestion of isolated p-chains with carboxy-
peptidase failed to illustrate any difference at the C-termini of the
three p-chain species. The authors proposed that the polypeptides
resolved represented p-chains which were structurally differentiated
for expression either in hydrophilic serum or in the hydrophobic
environment of the lipid bilayer.
In the human system, several B-cell lines have been shown to
synthesise two distinct p-chain forms (Singer and Williamson, 1980).
In one particular cell line, BJAB, a double labelling experiment in-
35volving a pulse-chase with S-methionine followed by lactoperoxidase-
■ 131catalysed radioiodination ( I) of the cell membrane proteins of 
the same cells showed;
a) the higher AMW p-chain was doubly labelled, i.e. this 
was the membrane p-chain;
b) the lower AMW p-chain was labelled only with and was
the only p-chain found in culture supemates; i.e. this 
p-chain was structurally differentiated for expression 
in an aquaeous environment.
Two p-chain forms could also be demonstrated in both control 
and tunicamycin-treated aliquots of the B-cell lines Daudi and Raji, 
and also in products of in vitro synthesis programmed by mRNA purified
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from these cell lines (Singer, 1978; Singer et al, 1980a).
In contrast to the data of Bergman and Haimovich (1978), the 
Daudi secretory and membrane p-chains have different C-terminal amino 
acid sequences as judged by carboxypeptidase digestion of isolated 
p-chains (Williams e^ a^, 1978; Singer et al, 1980). These data are 
consistent with hypotheses favouring a C-terminal hydrophobic ex­
tension present on membrane p-chain but absent from secretory p-chain
4.4.2. In Vitro Biosynthesis
The above data strongly suggests, but does not unequivocally 
demonstrate, the simultaneous biosynthesis of distinct membrane and 
secretory p-heavy chain polypeptides in a single B-lymphocyte. The 
most compelling evidence that this is indeed the case comes from ex- 
periments where purified cellular poly A mRNA was used to direct 
synthesis of polypeptides in an ^  vitro translation system.
Translation of mRNA isolated from the murine plasmacytoma 
WEHl-321 in the rabbit reticulocyte translation system followed by 
immunoprécipitation of the vitro synthesised p-chains and analysis 
of these by SDS-PAGE showed that two p-chain bands were specifically 
immunoprecipitable from the translation products (Alt eh al, 1980). 
These p-chain bands corresponded to the distinct membrane and secret­
ory p-chains complete with signal sequences. Since there are no 
reports of post-synthetic modifications in the rabbit reticulocyte 
system it is likely that the two polypeptides are independently 
synthesised, i.e. separate mRNA species encode the distinct membrane 
and secretory p-heavy chains.
The same conclusion was reached by Singer and his colleagues
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(Singer et a2, 1980a) who performed in vitro translation of mRNA 
isolated from human B-lymphoma cell lines. Upon immunoprécipitation 
of the translation products and analysis on SDS-PAGE, two p-chain 
bands could be readily demonstrated. This is again indicative of 
independently directed synthesis of membrane and secretory p-heavy 
chain polypeptides in a single cell. Additionally, it was noted 
that the relative amounts of secretory and membrane p-chain poly­
peptides synthesised vitro were almost identical to the ^  vivo 
biosynthetic pattern. This data suggested a significant degree of 
regulation at the pre-translational level, probably at the level of 
RNA splicing (Singer, 1978; Singer et ad, 1980a) .
The data from in vivo and ih vitro biosynthetic investigations 
are consistent with the postulate that structurally distinct membrane 
and secretory p-chain polypeptides are encoded by separate mRNA 
species and can be simultaneously synthesised in a single cell. The 
next stage in the investigation is to analyse the biogenesis of the 
discrete mRNA species and to address the question of how many genes 
are required for the synthesis of membrane and secretory p-chain 
polypeptides in a single immunocompetent B-lymphocyte.
4.4.3. Existence of Discrete Messenger RNA Species Encoding Membrane
and Secretory y-Heavy Chain Polypeptides
The possibility that membrane and secretory p-chain poly­
peptides synthesised in_vitro were derived from a single precursor 
was ruled out by analysis of the number of mRNA molecules detected by 
probing separated RNAs with a highly radioactive homologous cloned 
cDNA probe.
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The first demonstration of multiple mRNA molecules encoding 
immunoglobulin heavy chains was made in the murine B-cell line 70Z/3 
(Perry and Kelley, 1978). Total cytoplasmic mRNA was separated by 
electrophoresis in agarose gels containing methyl mercury hydroxide 
as a denaturing agent, and transferred to diazophenylthioether 
paper (Alwine et al, 1977) to form an RNA "blot". The blot was 
probed using cloned sequences of the constant region of the p-chain 
gene and four mRNA species were visualised. These mRNAs were of 
length 2.Ikb, 2.4kb, 2.7kb, and 3.0kb, and it was proposed that the 
mRNA species associated with membrane-bound polyribosomes were re­
sponsible for directing the synthesis of membrane and secretory p- 
heavy chain polypeptides, whereas those mRNAs found only in the 
cytoplasm encoded the intracellular (Bergman and Haimovich, 1978) 
p-chain polypeptide.
Similar studies were performed in the cell line WEHl-231,
but in these experiments the RNA "blot" was probed with a nick- 
32translated P-labelled cloned cDNA probe containing the 770 bases 
at the 3’-end of the p-chain mRNA (Alt et a^, 1980). Two mRNA 
species were detected by this probe one of 2.7kb and another of 2.4kb 
These data illustrate that two p-chain mRNA species are present in 
WEHl-231 cells, one encoding membrane p-chain and the other encoding 
secretory p-chain, and substantiate the data obtained from iui vitro 
translation studies.
A similar finding was made in a comparable study of p-chain 
mRNA species in M0PC-104E cells (Rogers e^ al, 1980). Cloned cDNA 
probes derived from p-chain mRNA were prepared (Calame et 1980)
and two of these probes had the following properties (Calame et al,
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1980; Rogers e^ a^, 1980; Early et al, 1980);
a) pl04Epl2, contained nucleotide sequences from Cp2,
Cy3, Cp4 and the 3'-untranslated regions of germ line 
p-genes, and;
b) pl04Ep6, contained sequences derived from Cp2, Cp3,
Cp4 and from the so-called M-exon (Early eb a^, 1980).
32Probing of blots of MOPC 104E mRNA with p-nick translated 
pl04pl2 detected two RNA species of 2.4kb and 2.7kb. These ob­
servations are consistent with the data of Alt ^  (1980) and with 
in vitro translation data.
Several pieces of evidence indicate a correlation between 
the 2.7kb mRNA species and synthesis of membrane p-chain polypeptides, 
and a similar relationship between the 2.4kb mRNA and synthesis of 
secretory p-chain;
a) plasmacytomas synthesising mainly secretory p-chains 
in vivo were shown to possess more 2.4kb mRNA than
2.7kb mRNA, while in plasmacytomas synthesising more 
membrane p-chain than secretory p-chain ir^  vivo were 
shown to contain more 2.7kb mRNA than 2. 4kb mRNA.
b) the somatic cell hybrid produced by fusion of WEHl 279 
cells and MPC-11 cells synthesised only secretory p- 
chain in vivo and contained only 2.4kb mRNA (Rogers
et al, 1980).
The data therefore suggest that two distinct mRNA species 
encode membrane and secretory p-chain polypeptides and that a 2.7kb 
mRNA species encodes membrane p-chain, while a 2.4kb mRNA molecule is 
responsible for the synthesis of secretory p-chain.
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Direct evidence to support the hypothesis that the 2.7kb 
mRNA encoded the membrane p-chain was obtained from the following 
experiment. A specific restriction fragment was prepared from the 
CDNA clone pl04Ep6 which contained nucleotide sequences found only 
in regions at, and close to, the M-exon (Calame e^ al, 1980; Early 
et al, 1980). The fragment was then used to probe blots of MOPC 
104E mRNA, and it was observed that the probe hybridized only to the 
2.7kb mRNA (Rogers et al, 1980). This is positive evidence that 
the 2.7kb mRNA contains the information required for synthesis of 
membrane p-chain while the 2.4kb mRNA encodes the secretory p-chain 
polypeptide. The organisation of coding sequences responsible for 
this phenomenon are reviewed below.
5. EXPRESSION OF IMMUNOGLOBULIN GENES DURING B-LYMPHOCYTE
DIFFERENTIATION
5,1. Introduction
Many studies have demonstrated the existence in adult spleen 
and bone marrow of a cell capable of replacing the cells of the mye­
loid and lymphoid systems in lethally irradiated recipients (reviewed 
by Scher, 1981). These pluropotential stem cells are believed to 
give rise not only to all cells of the B-lymphocyte lineage, but also 
to cells of T-lymphocyte and myeloid lineages. In early B-cell de­
velopment three distinct patterns of immunoglobulin expression are 
described;
a) cytoplasmic but no membrane or secretory IgM (pre-B- 
cells;
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b) cytoplasmic and membrane IgM but no secretory IgM 
(immature B-cells), and;
c) membrane IgM with very little cytoplasmic IgM (mature 
B-cells).
In later stages of differentiation, the B-lymphocyte also 
acquires membrane IgD before switching to expression of another 
immunoglobulin isotype e.g. IgG or IgA. The ontogeny of these cell 
types and their characteristics are now discussed.
5.2. Pre-B-Lymphocytes
Pre-B-lymphocytes are defined as cells vhich contain de­
tectable cytoplasmic IgM but do not express membrane IgM. In the 
mouse, medium to large sized cells in fetal liver were shown to 
actively synthesise 8S IgM as early as 10 days gestation (Melchers 
et al, 1975; Melchers, 1977), Other workers have detected cells 
containing cytoplasmic IgM in murine fetal liver at 13 days gestation 
(Raff e^ al, 1976). Lactoperoxidase catalysed iodination of cell 
membrane proteins was employed in an attempt to detect membrane IgM 
on fetal liver pre-B-cells, and membrane IgM could be demonstrated at 
13-15 days gestation (Melchers et al, 1976). Rosette formation 
assays also detected membrane IgM positive fetal liver pre-B-cells at 
13 days gestation (Rosenberg and Parish, 1977) . However, Raff ^
(1976) could not demonstrate membrane IgM on their cytoplasmic IgM 
positive cells. The general concensus of opinion is that the cytoplasmic 
IgM positive cell is the precursor of the membrane IgM positive and 
cytoplasmic IgM positive pre-B-cell in murine fetal liver.
Evidence to support the hypothesis that the cytoplasmic IgM 
positive, membrane IgM negative cell is the precursor of cytoplasmic
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and membrane IgM positive cells was obtained from studies in the 
human using anti-idiotypic antibodies raised against monoclonal IgM 
of patients suffering from B-cell malignancies. These antibodies 
were shown to react with the membrane IgM of the malignant cells and 
also with the cytoplasmic IgM of a small percentage of the bone marrow 
pre-B-cells of these patients (Kubagawa e^ al, 1978), Pre-B-cells 
also exhibit allelic exclusion (Lawton et al, 1977).
5.2.1. Distribution of Pre-B-Cells
The earliest appearance of identifiable pre-B-cells in mice 
is in the fetal livers at 10 days gestation (Melchers et al, 1975), 
Pre-B-cells are also found in murine fetal spleen and bone marrow 
(Marchalonis et al, 1971). In adults, pre-B-cells can be demonstrated 
in the bone marrow but not in lymph nodes spleen or thymus (Raff e^ al,
1977) .
5.2.2. Heterogeneity of Pre-B-Cells
Studies of the rate of incorporation of DNA precursors into 
DNA was used to illustrate the heterogeneity of the pre-B-cell population. 
Large cytoplasmic IgM positive, membrane IgM negative cells labelled 
more rapidly than small cells of the same pattern of immunoglobulin 
expression which in turn incorporated label more rapidly than membrane 
IgM positive cells (Owen, et al, 1977). These data suggest that a 
pool of large cytoplasmic IgM positive, rapidly proliferating cells, 
give rise to smaller cytoplasmic IgM positive cells which in turn 
differentiate into membrane and cytoplasmic IgM positive B-cells.
5.2.3. Immature B-Lymphocytes
Immature B-lymphocytes are defined as cells which have 
readily demonstrable membrane IgM but have little or no cytoplasmic IgM.
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Such cells are detectable in murine fetal liver at 16 days gestation 
and in fetal spleen after 16 to 17 days. These cells are also found 
in adult bone marrow (Scher, 1981).
Morphologically, small immature B-lymphocytes are indistinguish­
able from mature B-lymphocytes. However, several features allow de­
lineation of mature and immature small B-lymphocytes. Using radio­
immunoassay methods it was illustrated that immature B-cells derived 
from adult bone marrow had a more heterogeneous distribution of membrane 
immunoglobulin (Osmond and Nossal, 1974a,b), and also that neonatal 
B-cells have more membrane immunoglobulin than adult B-cells (Sidman 
and Unanue, 1975).
A more striking difference was revealed when radioiodinated 
membrane proteins of mature and immature B-cells were subjected to 
immunoprécipitation with anti-immunoglobulin reagents and the products 
analysed by SDS-PAGE. Both populations contained species of apparent 
molecular weights 63,000 daltons (p-chain) and 22,000 daltons (light- 
chain), but the mature cells possessed a further component of AMW 
64,000 daltons not found on immature cells; this is the 6-chain 
(Vitetta et al, 1975; 1977). Thus, immature B-cells possess more 
membrane IgM than their mature derivatives, but lack IgD which is 
unique to the mature B-cell population.
5.3. Mature B-lymphocytes
The mature B-lymphocyte population consists of membrane-IgM 
positive, membrane-IgD positive and cytoplasmic-IgM negative cells.
These cells are found in the spleens of 1-2 week old mice, adult 
spleen and in adult bone marrow (reviewed by Scher, 1981). This 
population is believed to be the precursor of daughter memory cells
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expressing immunoglobulin isotypes other than y which are derived by 
antigen driven differentiation of the mature virgin B-lymphocyte.
5.4. Isotype Diversification
Much evidence is now available to substantiate the hypothesis 
that B-lymphocytes can alter their immunoglobulin isotype phenotype 
during differentiation without altering the idiotype which was origin­
ally expressed. The evidence comes from a variety of experimental 
approaches :
a) characterisation of 'double' myelomas;
b) study of idiotype expression on progeny of a single
antigen binding cell, and;
c) investigation of classes of immunoglobulin produced 
by antibody forming cells.
Several types of 'double' myeloma syndromes have been de­
scribed in which two myeloma proteins of different classes share an 
identical idiotype and, apparently, an idential V region amino acid 
sequence. 'Double' myelomas of the following types have been de­
scribed:
a) IgM and IgG2 (Wang et al, 1970a,b; Fudenberg et al,
1971) ;
b) IgM and IgGS (Penn et al, 1970);
c) IgM and IgA (Seen et al, 1973; Yagi and Pressman, 1973)
and;
d) IgG and IgA (Sledge et al, 1976).
It is generally accepted that the explanation for the occur­
ence of such rare myelomas was that transformation of a lymphocyte clone 
occured just as the lymphocyte was in the process of switching from
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expression of one gene to another while being committed to express­
ion of one particular V gene,
H
In studies of idiotype expression, it was found that the 
progeny of a single antigen binding cell had identical idiotypes to 
that found on the original cell (Press and Klinman, 1973; Eichmann 
and Rajewsky, 1975). Furthermore, it was demonstrated that IgM and 
IgD expressed on the same lynphocyte bore identical idiotypes (Salsano 
et al, 1974; Fu et al, 1975) and had identical antigenic specificities 
(Pernis e^ al, 1974).
Immunofluorescence studies revealed cells which expressed 
different classes of immunoglobulin in the cytoplasm and on the cell 
membrane (Pernis et al, 1971). Several groups of investigators have 
reported that a small percentage of antibody forming cells secrete both 
IgM and IgG (Ivanyi and Dresser, 1970; Nordin et al, 1970; Nossal et al, 
1971) .
These data are indicative of isotype diversification during 
B-lymphocyte differentiation and argue strongly that a B-lymphocyte is 
capable of altering the pattern of isotype expression whilst remaining 
committed to the original idiotype and antigen binding specificity, i.e. 
to the original gene. These findings are consistent with the pre­
dictions of the Clonal Selection Hypothesis.
5.5. Sequential Expression of Immunoglobulin Isotypes
The use of anti-Ig reagents to specifically inhibit immuno­
globulin synthesis by B-lymphocytes has established that immunoglobulin 
isotypes are sequentially expressed vivo (reviewed by Lawton and 
Cooper, 1974) .
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In the chicken it has been demonstrated that such treatment of 
embryonic lymphocytes resulted in:
a) depression of serum IgM;
b) depression of serum IgG, and;
c) depression of serum IgA levels,
all in later life (Kincade et al, 1970; Kincade and Cooper, 1973),
The same treatment at hatch depressed only serum IgM levels: IgG and
IgA levels were unaffected (Kincade ^  al, 1971). Similar obser­
vations were made in equivalent studies in germ-free mice (Lawton 
et a^, 1972).
Anti-immunoglobulin reagents were also used to inhibit
primary or secondary antibody responses ^  vitro. In the primary
response, anti-y suppressed all classes of response while anti-_,
h
anti-y^ or anti-a suppressed only the response of the isotype to which 
they were directed. However, in secondary responses, anti-y had 
progressively less effect with time after priming (Pierce et al, 1972a,
b). These data suggest that some membrane IgM-expressing cells are pre­
committed to differentiate into cells expressing one of the other iso­
types .
Two models may be invoked to explain the sequential expression 
of isotypes ;
a) the switch model for antigen-driven isotype diversifi­
cation , or ;
b) the minimal receptor model for antigen independent 
diversification of immunoglobulin isotypes.
Both models share the concept of isotype switch during an 
immune response but disagree on the underlying mechanisms. The
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'switch' model proposes that antigen drives diversification of re­
ceptor isotypes from a single precursor cell, while the 'minimal 
receptor' hypothesis suggests the existence of separate precursor 
populations for any given isotype which arise independently of 
antigenic influence. The data from in vivo anti-immunoglobulin 
treatment (Kincade et al, 1970, 1971; Lawton et al, 1972, Kincade and 
Cooper, 1973) supports the minimal receptor model while the vitro 
studies using anti-immunoglobulin as an inhibitor of antibody synthesis 
(Pierce et al, 1972a,b) supports the switch model.
5.6. Current Concepts'in Generation of Multiple Receptor Isotypes
The initial impetus for investigation of receptor isotype 
diversity came from the finding of IgD on the membranes of human (van 
Boxel et al, 1972) and murine lymphocytes (Abney and Parkhouse, 1974; 
Vitetta et al, 1975). The existence of lymphocytes in spleens of 3
day old mice expressing membrane IgG^,IgG^, igG^ and IgA isotypes 
(Parkhouse and Cooper, 1977; Kearney and Abney, 1978) has recently 
been established. These isotypes could only be demonstrated on 
cells which had previously been membrane IgM positive ; IgD was also 
danonstrated on cells at this stage of development. A significant 
conclusion drawn from these studies was that only one of the addition­
al isotypes could be expressed in any membrane IgM-positive cell 
(Kearney and Abney, 1978). Acquisition of IgD by membrane IgM 
positive cells was shown to be an antigen independent event and also 
to be independent of the switch to other receptor isotypes (Lawton and 
Cooper, 1974; Vitetta and Uhr, 1975).
5.6.1. In Vitro Stimulation of Lymphocytes with Lipopolysaccharide 
As soon as immature B-cells appeared in the livers of fetal
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mice, they could be induced to generate other receptor isotypes by 
culturing vitro in the presence of lipopolysaccharide (LPS) 
(Kearney and Lawton, 1975). The expression of such isotypes was 
independent of proliferation but required mRNA and protein synthesis 
(Kearney and Abney, 1978). Upon examination of cells positive for 
both membrane IgG^ and IgM, it was discovered that membrane IgM was 
rapidly lost from the cells at the time of maximum proliferation and, 
concomitantly, cytoplasmic IgGg became readily detectable (Kearney 
and Abney, 1978). Persistence of membrane and secretory IgM in 
cells differentiating to IgGg isotype expression could be promoted by 
inhibiting the proliferation of the differentiating cells (Kearney 
et al, 1977b). These data suggested that cellular proliferation was 
required for the loss of IgM and IgD isotypes and differentiation to 
single (e.g. IgG^) isotype daughter cells.
Much information remains to be obtained regarding the 
biological processes responsible for the control of B-lymphocyte 
differentiation and isotype diversification. Recombinant DNA 
technology has, however, provided great insights into the molecular 
mechanisms which underly many of the phenomena described during B- 
lymphocyte differentiation. The molecular genetics of the antibody 
genes are detailed in the next section (section 6).
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6. MOLECULAR BIOLOGY OF IMMUNOGLOBULIN GENES
The most striking feature of the primary structure of immuno­
globulins is the great variability of amino acid sequences at the N- 
terminal regions of both heavy and light chains. Clearly this 
variability can be correlated with the capacity of a given antibody 
to specifically bind its complementary antigen. Genetic explanations 
must therefore be found to account for:
a) the extent and maintenance of amino acid sequence 
diversity of V-regions;
b) the phenomena of allelic exclusion i.e. the expression 
of only a single V and a single V resulting in one 
antibody specificity per cell and
c) the capacity of a single B-lymphocyte to switch from 
synthesis of one immunoglobulin isotype to another 
during antigen-driven clonal expansion.
6.1. The Murine IgX Locus
Studies of the amino acid sequences of mouse myeloma 
light chains demonstrated a simple pattern of variability consistent 
with the hypothesis that V-region is encoded in the germ-line by a 
single gene (Weigert and Riblet, 1976? Gottlieb, 1980). Twelve of 
the eighteen proteins sequences had identical sequences (termed the 
Aq sequence) while the remainder differed by one or two amino acid 
substitutions restricted to the regions corresponding to the hyper- 
variable regions of kappa chains (Weigert and Riblet, 1976) .
By treatment of murine embryonic or plasmacytoma H0PC2020 
DNA with restriction endonucleases and subsequent molecular cloning
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of the DNA fragments generated, Tonegawa and his associates prepared 
cloned nucleotide sequences which contained:
a) V and C sequences in a single restriction
A l  A 1
fragment of plasmacytoma H0PC2020 DNA (Brack and 
Tonegawa, 1977) and;
b) and sequences in separate restriction
fragments of embryonic DNA (Brack e^ al, 1978).
Furthermore, the mouse DNA appeared to contain a single 
V. gene (Brack et al, 1978), and this data was consistent with the 
predictions based on amino acid sequence analysis of polypeptides 
(Wiegert and Riblet, 1976; 1978).
The data of Tonegawa*s group has several significant 
features when considered in conjunction with the known structures 
of immunoglobulin light chain mRNAs and polypeptides (Brack and 
Tonegawa, 1977; Brack et al, 1978; Bernard et al, 1978):
a) the nucleotide sequence of the gene accounts 
for only 97 residues of the 110 amino acids of 
the V-region of the A^ polypeptide;
b) the remaining V-region codons (the J-segment) are 
found in segments of DNA close to, but not 
contiguous with, the C-region;
c) the V. gene segment is separated at an unknown
A i
distance from the segments in embryonic DNA;
d) a somatic recombination event has joined V^^ and 
contiguously in the DNA of a A^ expressing plasma­
cytoma , and ;
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e) the coding sequence for the hydrophobic leader 
sequence is separated from the 5'-end of the V- 
region by a 93 base pair intervening sequence.
These data clearly illustrated that a functional gene 
is composed of multiple genetic elements, each coding sequence or 
exon being separated from the others by an intervening sequence 
(intron) of non-coding DNA. The and exons are separate
throughout the life of the B-lymphocyte but the critical event in 
formation of an active gene appears to be the recombination event 
bringing and exons together. In the plasmacytoma, integrat­
ion of all the exons needed for a functional Aj^ polypeptide appears 
to occur by splicing of the primary nuclear RNA transcript, which 
contains leader, VJ and C exons and the appropriate introns, to 
give a messenger with contiguous leader, V, J and C coding sequences. 
This process is summarised in figure 4.
The tenets of the Dreyer-Bennett postulate are supported by 
the evidence obtained, not only from the study of the structure of 
murine A^ light chain genes, but also by similar studies of the
murine Igsc and Igh loci (see below) .
6.2. The Murine igK Locus
In contrast to the limited sequence variability of the A^
polypeptides, the amino acid sequence diversity of murine K-chains
is very extensive. Multiple germ-line genes were postulated to 
account for the differences in length and amino acid sequence 
characteristic of different groups of K-myeloma proteins, and also 
because of the difficulties associated with models accounting for 
generation of individual gene groups from a single germ-line gene
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by somatic diversification (Kiihler ejt al, 1970) . Analysis of murine 
amino acid sequences suggested that a minimum of 50 groups 
were necessary to account for the framework diversity observed in 
myeloma tc-chains (Weigert and Riblet, 1976) .
Preparation of restriction fragments from embryonic and
plasmacytoma DNA followed by electrophoretic separation and probing
32of the fragments with cloned and P-cDNA probes illustrated
that and exons resided in separate fragments in embryonic DNA 
but were in the same fragment in myeloma DNA (Hozumi and Tonegawa, 
1976) . These data illustrated that Igjc genetic elements were in 
different configuration in embryonic and plasma cell DNA.
Electron microscope analysis of cloned k genes also demon­
strated that the organisation of the coding sequences was different 
in embryonic and plasmacytoma DNA (Seidman et al, 1979) . Nucleo­
tide sequencing of the cloned tc-genes revealed that, as in the 
situation, the gene possessed codons for only 95 of the 108 amino 
acids conventially assumed to represent the phenotypic -region 
(Seidman et al, 1978; Tonegawa et al, 1978). Further sequencing and 
electron microscopic analysis located the J-segments approximately 
3.7 kilobases from the 5'-end of the C^-gene (Bernard ej^  a^, 1978; 
Brack et al, 1978; sej.dman and Leder, 1978; Sakano et al, 1979).
The J-segment contained not only the remaining 13 codons of the 
region but also specified the site for somatic recombination.
Molecular hybridisation studies confirmed the data ob­
tained from analysis of the protein sequences, namely that 
multiple genes were present in the germ line (Seidman et al, 1978; 
Valbuena e^ 1978). The number of separate genes per haploid
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genome has been postulated to be of the order of 300-1000 (Seidman 
et "al, 1978; Leder et al, 1980). By integrating data obtained from 
sequence and electron microscopic investigations of the cloned genes 
a model may be proposed in which a V gene could be selected by join­
ing it to a J-segment in close proximity to the single C-gene thus 
promoting transcription of an active immunoglobulin gene. It is 
evident from the data obtained from both IgA and Igic systems that 
the J-region is of critical importance in the generation of function­
al immunoglobulin genes via somatic recombination.
6.3. Molecular Structures in Somatic Recombination
6.3.1. The J-Segment
The J segment is found in IgA, Igtc and Igh genetic loci 
(Leder et 1980). IgA, appears to contain a single J-exon and 
Igh possesses 4 J segments while Igtc has 5 J segments one of which 
J^g, is a pseudogene (Bernard et al, 1978; Sakano et al, 1979; Leder 
et al, 1980). The J-exons of J^ and probably J^ have the following 
characteristics ;
a) each has an unique nucleotide sequence;
b) each J segment is separated from its neighbours by 
approximately 300 base pairs;
c) at the 3* end of each J exon is an RNA splicing site;
d) at the 5* end of each J exon is a highly conserved DNA
recombination site, and
e) in the J^ system, the remaining codons of the V-
region are encoded by the J-exon, (This is not the
case in the J^ system where the D-segment, discussed 
below, is also responsible for encoding part of the
region of the immunoglobulin heavy chain polypeptide.)
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6.3.2. Palindromie Sequences and the 12/23 Spacer Rule
All J exons sequenced to date contain a self-complementary 
heptanucleotide palindrome at their 5'-end (Sakano et al, 1979;
Seidman e_b al, 1979) . The sequence of the palindrome is CACTGTG. 
Furthermore, a nonameric nucleotide sequence, GGTTTTTGT, is located 
12 _+ 1 or 23 4^ 1 base pairs 5' to the hep tame ric palindrome.
Similar highly conserved nonamer and palindromic heptamer nucleotide 
sequences and associated 12 or 23 base pair sequences are also found 
at the 3'-end of the V gene. Recombination occurs only between a 
V gene with a 12 base pair spacer and a J segment with a 23 base 
pair spacer or vice versa (Early et al, 1980a; Sakano et al, 1980).
The same 12/23 spacer rule also applies to V^-D^ recombination in 
the Igh system. It has been speculated that the enzymes mediating 
V-J joining in Igtc and IgA are the same and that such a recombinase 
has two functionally distinct units, one recognising the heptamer 
and nonamer separated by the 12 base pair spacer and the other 
recognising the heptamer and nonamer separated by the 23 base pair 
spacer (Sakano e;t al, 1980 ; Early e^ al, 1980a) .
The orientation of the heptameric and nonameric sequences 
associated with the V- and J-genes is such that the sequences assoc­
iated with the V gene are an inverted repeat of those associated with 
the J gene. In this orientation pairing of complementary palindromes 
within (rather than between) strands of DNA would favour formation of 
an inverted repeat stem structure (Sakano et al, 1979; Max et al, 1979) 
The formation of an inverted repeat stem structure would bring V and 
J coding sequences into close proximity and may promote activity of 
the recombinase necessary to effect V-J joining. The recombination 
event is apparently accompanied by loss of DNA between the selected
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V-gene and the chosen J-gene. Precedents for the existence of in­
verted repeat structures and of putative recombinases are provided 
by studies of bacterial transposons which demonstrate formation of 
inverted repeat stem structures and deletion of intervening material 
(Cohen, 1976); also some DNA binding proteins such as the X repressor 
are known to recognise palindromic sequences in the DNA (Ptashne et 
al, 1976). The role of inverted repeat sequences in somatic re­
combination is shown in figure 4.
6,3.3, Variability in the Frame of Somatic Recombination
Position 96 in the amino acid sequence of BALB/C < light 
chains is known to be hypervariable (Barstad et al, 1978; Max et al,
1979). The sequences of many K-chain proteins can not be accounted 
for in terms of any known nucleotide sequence unless one proposes 
that the frame of somatic recombination is variable. If such a 
mechanism were operative, cutting and splicing of the DNA at slightly 
different positions to form a contiguous VJ unit would result in 
several different amino acids being possible at position 96 in the 
amino acid sequence (Leder et al, 1980); Gottlieb, 1980).
Evidence for variability of crossing-over points in somatic 
recombination was obtained from nucleotide sequence analysis of several 
plasmacytoma recombinants and from amino acid sequences of myeloma 
proteins. The individual recombination events had the following 
consequences :
a) MOPC 41 (Seidman et al, 1979) and MOPC 321 (Sakano e_t
al, 1979) both of which preserved the germ line sequence ;
b) MOPC 173b deleted a single base giving rise to a
cryptic gene with a nonsense J (Max e^ a^, 1980) and
FIGURE 4
Somatic Recombination.Events.in Formation of Active Immunoglobulin 
Genes
The molecular events involved in processing of germ line DNA 
encoding the gene to yield functional mRNA and X^ polypeptides are 
illustrated. L, V, J and C-exons (open boxes) are separate in germ 
line DNA. Pairing of palindromic heptamers of sequence CACTGTG 
(shaded boxes) and pairing of nonameric sequences GGTTTTTGT (black 
boxes), which obey the 12/23 spacer rule, gives rise to inverted 
repeat stem structures (Early et al, 1980a; Leder et al, 1980). Re­
combination and deletion occurs to produce a contiguous VJ unit in 
myeloma DNA. A large nuclear RNA transcript is formed which contains 
L,V,J and C-exons separated by introns bounded by RNA splice sites 
(shaded triangles). RNA splicing yields an mRNA containing contiguous 
L, V, J and C-exons which is translated to yield a X^ polypeptide.
Note that the antisense strand of DNA is not shown.
Key t-
L - Leader sequence
V - Variable region exon
J - Joining exon
C - Constant region exon
— ^ —  - Hydrophobic leader polypeptide
bp - base pairs
kb - kilobases.
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c) S107B deleted 2 codons to give an in phase but 
shortened J (Leder e^ al, 1980).
The data suggest that V-J recombination can occur at various 
cross-over points and may not always occur in the proper phase.
6.3.4. The J^^ Pseudogene : A Molecular Lesion
After V -J recombination, the next major step in generation 
of K-chain mRNA is the synthesis of a primary nuclear RNA transcript 
from which introns are removed to yield an mRNA with contiguous 
coding sequences for leader, V, J and C region amino acid sequences.
The mechanism of removal of introns is not understood, but the con­
census of opinion at present is that introns begin with the sequence 
GT and end in AG (Cohen /1976) and that this is, in part, in­
volved in recognition and removal of intron sequences.
In the system, four of the five J exons are followed at 
their 3'-ends by the GT sequence (Sakano e^ a^, 1979; Max et al, 1979). 
The intron following J^^ does not begin with GT and this may be the
reason that amino acid sequences encoded by J _ are never observed in
k 3
BALB/C K - c h a i n s. If the GT sequence is required for removal of the
intron between J . and C exons then absence of the sequence may result 
k 3 K
in failure of processing of the primary nuclear RNA transcript to yield
a functional mRNA. This would be manifested as an absence of J .
k 3
sequences at the protein level, as has been observed. Thus the J^^ 
exon has the genetic information to encode a polypeptide sequence but 
is not expressed due to lack of an RNA splicing signal; it is therefore 
a pseudogene.
6.4. The Murine Igh Locus
6.4.1. The Gene : Nomenclature of Components
The generation of a functional V gene for immunoglobulin
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light chains involves a single rearrangement to bring V and J or
A  A
and coding sequences together. The generation of a gene 
requires multiple recombination events. In addition to V- and J- 
gene segments, the Igh locus also possesses a third coding region 
associated with the V-region phenotype: this is the or diversity
segment (Sakano e^ ad, 1981). Thus formation of the V-region 
phenotype depends on two somatic recombination events to give a 
contiguous V-D-J coding segment in myeloma DNA.
6.4.2, The D^-Segment
In the plasmacytoma MOPC 141, the coding sequence for the
fourteen residue peptide which comprises the third hypervariable
region of the heavy chain is found neither in the germ line V^ gene
nor in the segment (Sakano e^ al, 1980). A similar finding has
been reported for a a-heavy chain gene (Early e^ al, 1980a). It
has been proposed that the third hypervariable region of the heavy
chain is encoded in a segment of DNA that is distinct from V and JH H
coding regions and that has been termed the D^ segment (Schilling e^ 
al, 1980).
Tonegawa and his associates have recently identified several 
putative D^ segments in murine germ line DNA (Sakano e^ a^, 1981) . One 
D^ segment (Q52) was shown to consist of a 10 base pair coding region 
flanked on both sides by heptameric and nonameric nucleotide sequences 
which are believed to be recognition sequences for a recombinase.
The spacer separating the heptamer and nonamer is 12 base pairs long 
on both sides of the D coding region (Sakano et al, 1981) . Since 
the length of the spacer between the complementary heptameric and
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nonameric sequences associated with V and J DNA is 23 + 1 base pairs 
the 12/23 spacer rule (Early e^ al, 1980a; Sakano et a^, 1980) is 
upheld for recombination between and and between and J^.
The Q52 segment was located 700 base pairs 5' to the nucleo­
tide sequence in murine germ line DNA (Sakano et al, 1981).
^^combination events have been shown to occur in cytolytic
T-cell lines (Kurosawa et al, 1981) but V„-D„ joining has not been ob-
------------  H H
served. Also, it was observed that D-J recombination could occur at 
different crossing-over points, thus providing a mechanism for amplifi­
cation of diversity of the heavy chain gene repertoire (Kurosawa e^ al, 
1981).
6.4.3. Structure of Heavy Chain Constant Region Genes
Light chains contain a single constant region domain which is 
encoded by a single C-gene exon. Heavy chains have multiple constant 
region domains which exhibit a significant degree of amino acid sequence 
homology to one another (Kabat e_t al, 1979). This homology suggests 
that each domain may be encoded by a separate exon and it is possible 
that the constant region exons arose from a single ancestral gene by 
tandem duplication.
The application of recombinant DNA technology to this problem 
has resulted in the elucidation of the precise genomic structure and 
organisation of the murine Cu gene. In the earliest experiments R- 
loop mapping (Thomas e^ 1976? Kaback et al, 1979) was performed 
using three cloned Cy gene segments (Calame e^ al, 1980) and mRNA 
purified from the MOPC 104E myeloma (Rogers e^ t a^, 1980). The data 
obtained from R-loop analysis 'of each Cy clone gave similar results:
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a) two to four R-loops were observed, and this was 
consistent with the hypothesis that the Cy domains 
were encoded by separate exons (Calame et al, 1980), 
and
b) a further R-loop was detected in 10-15% of the inRNA- 
cDNA hybrids suggesting that a small exon was located 
some 2 kilobases 3* to the end of the Cy4 exon.
Several experimental observations suggested that although 
ym and ys polypeptides were encoded by distinct mRNA molecules both 
messengers were derived from a single y-chain gene?
a) restriction maps and DNA sequences of large portions 
of y.^  and y^ cDNA clones were identical (Rogers ejt al, 
1980) and
32b) hybridisation of P-labelled y  ^plasmid DNA to 
Southern blots of germline or embryo DNA treated 
with a variety of restriction endonucleases gave only 
the pattern of bands expected from the cloned germline 
Cy gene (Davis e^ al, 1980? Early e^ al, 1980).
Analysis of the genomic organisation of Cy gene sequences 
32by hybridisation of P-labelled y^ and y^ cDNA clones to Southern 
blots of restriction fragments of a germline Cy genomic clone and 
by nucleotide sequencing of the various cloned fragments revealed 
the following (Calame et al, 1980? Early et al, 1980? Rogers et al,
1980)?
a) the Cyl, Cy2, Cy3, Cy4 and M-exons are separate in 
germline DNA?
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b) the entire Cy4, C-terminal and 3'-untranslated regions 
of the y^ cDNA clone are found as a contiguous nucleo­
tide sequence in the genomic Cy clone which terminates 
187 nucleotides 3' to the end of the Cy4 exon ;
c) the sequences encoding the 3'-end of the y^-mRNA are
found in two separate M-exons located 1850 base pairs 
3* to the end of the Cy4 exon;
d) the first M-exon encodes amino acids 557-595 and is
separated by an intron of 118 base pairs from the 
second M-exon which encodes amino acids 596 and 597 
and contains the termination codon;
e) the RNA splice sites at the 5' end of the first M-exon
and those between the two M-exons obey the GT AG
rule (Breathnach et al, 1978; Catterall et al, 1978) 
and
f) both y^ and y ^ cDNA clones contain the putative poly- 
adenylation signal (AATAAA) (Proudfoot and Brownlee, 
1976) located 19 base pairs 5' to the terminal polyA 
sequence, and polyA addition to both ym and ys mRNA 
species appears to occur within the TCACT sequence 
located at the 3'-terminus of both cDNA sequences in 
the genomic clone.
Southern blot analysis of E.CoRI digested DNA from embryo 
32or MOPC 1o4e using P-labelled y^ cDNA as probe revealed only a 
single Cy band in each case. This rules out the possibility that 
y^ and y^ mRNAs are derived from two copies of the expressed Cy gene, 
and also excludes deletions of the M-exons in one of the two putative
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Cy gene copies since such an event would alter the size of the result­
ing Cy gene (Early ^  al, 1980), These data argue that y^ and y^ 
mRNA species are derived from a single nuclear RNA transcript of a 
single gene by alternate RNA splicing pathways. The role of RNA 
splicing in control of immunoglobulin gene expression is detailed 
below (section 7),
6.4.4. Assembly of Heavy Chain Genes and Messages
Two distinct molecular events are required for the formation 
of active immunoglobulin light chain genes. Firstly a somatic re­
combination event joins V DNA to J DNA and thus commits the B-lympho- 
cyte to the expression of that VJ combination. Secondly, the introns 
separating the 3'-end of the leader sequence from the 5'-end of the V 
gene and the 3'-end of the J-exon from the 5'-end of the C gene are 
spliced out from the primary nuclear RNA transcript to yield a 
contiguous light chain mRNA.
The assembly of active heavy chain genes from their component 
parts is a much more elaborate process although DNA recombination and 
RNA splicing are used to generate the functional gene. At least two 
DNA joining events are necessary to produce a gene encoding a 
region possessing antigen binding activity, A V exon must be joined 
with a D exon and that D exon must be joined to a J exon. In addition 
any one D segment may be capable of somatic recombination with any other 
D segment located 3* to itself (Sakano et al, 1981; Kurosawa et al,
1981). After V-D-J joining, the cell is then faced with the choice 
of expressing a membrane or secretory form of the heavy chain isotype 
to which it is committed. This is accomplished by RNA splicing 
mechanisms. The intron separating the leader sequence from the
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gene and that separating J from the first gene are removed as in
the light chain system, but also spliced out from the primary transcript 
are the introns separating each of the exons from each other. The 
Cy4 exon has an unique structure in that it contains an intra-exon 
splice site. This splice site allows removal of the intervening RNA 
between Cy4 and the M-exons: this "intron" also contains the coding
sequence for the C-terminal amino acids of the secretory y-chain 
(section 6.4.3. above). Alternative splicing mechanisms allows the 
transcriptional and processing machinery to utilise or ignore this 
splice site and hence give rise to mRNA molecules encoding y^ or y  ^
polypeptides respectively.
At present, only the y-gene system has been fully character­
ised. In this study it was hoped to gain some insight into possible 
similarities between the organisation of y-chain genes and the 
equivalent components of y- and a-genes in human B-lymphocytes.
6.5. The Molecular Basis of Allelic Exclusion
An unique genetic characteristic displayed by lymphocytes 
is the phenomenon of allelic exclusion. Allelic exclusion is the 
situation where a lymphocyte expresses only one heavy (or light) chain 
allotype of its two chromosomal allelic alternatives. The related 
phenomenon of isotype exclusion will also be discussed in this section.
6.5.1, Rearrangement on a Single Chromosome
The simplest mechanism which may be invoked to explain 
allelic exclusion at the DNA level is to propose that for the chromo­
some bearing the allele to be expressed, the V and J or V , D and 
elements are somatically recombined to give a rearranged V gene 
configuration while the chromosome carrying the allele to be excluded 
remains in the unrearranged, germ-line configuration. Clearly, the
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rearranged allele can be expressed while the allele remaining in the 
germ-line configuration can not. Examples of such events have been 
reported in the literature (Brack et al, 1978; Seidman and Leder,
1978; Joho and Weissman, 1980) but seem not to be the general rule, 
particularly at the Igh locus,
6.5,2. Non-Productive Rearrangement and a Stochastic Model for
Allelic Exclusion.
Three types of nonproductive gene rearrangements have been
described for V -J or V - D - J  joining;
L L H H H
a) frameshift rearrangements;
b) incomplete rearrangements, and
c) rearrangements to an abnormal DNA sequence,
DNA rearrangement requires recognition of precise nucleo­
tide sequences, but despite the highly conserved nature of these 
sequences the somatic recombination event may occur at various points 
in the recognition sequence. Several example of frameshift rearrange­
ments have been reported in several myelomas (see section 6,3,3, above), 
Frameshift rearrangements have an immunobiological significance. As 
discussed above (section 6,3.3.) a frameshift rearrangement mechanism 
can be invoked to explain the amino acid sequences of Balb/C k myeloma
proteins which can not be accounted for in terms of known and
nucleotide sequences. In the case of amino acid 96, which is known 
to be hypervariable in Balb/C k proteins (Barstad et al, 1978; Max 
et al, 1979), frameshift rearrangements increase the number of amino 
acids available at this position. Such variability increases the 
repertoire of the k gene pool and, consequently, leads to an increase
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in antibody diversity. An example of a frameshift rearrangement 
and its consequences is given in Figure 5,
In the heavy chain gene system, two distinct recombination 
events are required to generate a functional gene. In some 
instances, only one of the two DNA joining events, V^-D^ and 
will occur and this will give rise to an incomplete rearrangement.
One example of such an incomplete rearrangement is the finding of a 
normal splenic B-cell which displays a recombination but not
Vg-D^, on the unexpressed chromosome (Early and Hood, 1981), Possibly 
V^-D^ joining with no D^-J^, joining can occur also giving rise to 
another form of incomplete rearrangement.
The murine plasmacytoma MPC-11 synthesises a mutant K-light 
chain fragment (Kuehl and Scharff, 1974). Analysis of the DNA of 
MPC-11 cells revealed that a gene segment unrelated to the V-gene 
functionally expressed by the MPC-11 cells had been joined to a 
GACAGTG palindrome located between J and C (Seidman and Leder, 1980;K K
Choi et 1980). This rearrangement deletes the segments and,
because this nonproductive rearrangement yields a pseudo exon with
no J and no RNA splice site 3' to the sequences, RNA splicing
occurs between the C exon and the hydrophobic leader sequence exon
located 5' to the V sequence thus giving an mRNA containing C^ but
no V or J sequences. It is not known if this type of null re- 
K K
combinant is mediated by specific V-J joining enzymes or if it is a 
more general type of re'combination event. Many K-producing plasma­
cytomas contain non-productively arranged k-genes (Perry e^ al, 1980) 
and small k-ibRNA molecules of similar size to the mutant MPC-11 
K-mRNA have been observed in virally transformed cell lines (Alt et al.
FIGURE 5
Frameshift Mutations in Generation of Antibody Diversity
V-J joining can occur in a variety of frames. The germ 
line sequences of V 41 and J 5 DNA are shown. The V 41 sequence is
K K K
that of codon 95 (proline) and the junction site: the J^5 sequence
is of the first six nucleotides (codons for typtophan and threonine). 
Each of four possible somatic recombinations is illustrated (numbered 
1-4) and the resultant nucleotide and polypeptide sequence shown.
Note that each amino acid found at position 96 has been described at 
the protein level (Max et al, 1979),
-75-
FIGURE 5; Frameshift Mutations in Generation of Antibody Diversity
Germ Line Sequences
V 41 C C T C C C
k  M l !
1 2  3 4
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k
Recombined Nucleotide and Protein Sequences
Recombination
Event
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Nucleotide
Sequence C C T T G G  C C T C G G  C C T C C G  C C T C C
Protein
Sequence PRO TRP PRO ARG PRO PRO PRO PR
(After Max et al, 1979),
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1980a). Quantitation of Southern blots of nonproductive rearrange­
ments have illustrated that 30% of the unexpressed K-chromosomes are 
in a rearranged configuration as are between 80% and 100% of un­
expressed heavy chain chromosomes (Coleclough et al, 1981),
The observation that many, though not necessarily all, 
B-lymphocytes exhibit nonproductive rearrangements allows a probabalistic 
or stochastic model for allelic exclusion to be forwarded (Coleclough 
et al, 1981; Early and Hood, 1981) , The model makes three principal 
predictions;
a) a non-productive rearrangement on one chromosome does 
not exclude an attempt to form a productive rearrange­
ment on the second chromosome;
b) multiple rearrangements can occur on a single chromo­
some and
c) some cells with two functionally rearranged chromosomes 
should exist (though possibly at low frequency) in the 
population.
6,5.3 Evidence Against a Stochastic Model of Allelic Exclusion
Experimental evidence is available which suggests that 
allelic exclusion is not a totally random process as predicted by the 
stochastic model, Kuehl has performed experiments where a pre-B- 
cell is fused with a myeloma cell which does not produce a functional 
light chain. The hybrid cell was found to express a light chain 
presumably as a result of somatic recombination of V and J exons of 
the pre-B-cell genome. If, however, the myeloma fusion partner does 
produce a functional light chain, no new light chains were found to be 
expressed, presumably because functional V-J recombination is excluded.
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This data raises the possibility that active suppression of further 
gene rearrangement may occur once a functional gene is formed.
6o5o4. Isotype Exclusion
The evidence from studies of immunoglobulin synthesis in 
pre-B-cells suggests that y-chain is the first phenotypically 
detectable immunoglobulin component. This data indicates that V^- 
D -J recombination is the first DNA joining event to occur in the 
immunoglobulin genes. Evidence is now available which suggests 
that K genes are expressed prior to their counterparts in the IgA 
family. In a study of 10 human A-producing human B-cell lines it 
was observed that all genes were either deleted or rearranged
(Hieter e^ al, 1981), Similar analysis of K-producing human B-
cell lines showed that all of the genes were in the germ line 
configuration (Hieter ^  al, 1981). The hypothesis has been advanced 
that once a cell has successfully joined V^, D^ and J^, it then 
attempts to join V^with If this is successful then no further
gene rearrangements occur but if two nonproductive V^-J^ recombination
events occur then the cell attempts to join V. with to obtain a
A  A
functional gene. Thus, antibody gene families appear to be ex­
pressed in the order Igh, IgK, and IgA, and models of isotype ex­
clusion must attempt to explain this sequential (i.e. nonstochastic) 
mode of expression.
6.6. Molecular Basis of the Heavy Chain Switch
During maturation, a clonally expanded B-lymphocyte is 
capable of changing the heavy chain isotype which it expresses although 
it retains the original idiotype and antigenic specificity (see section 
4 above and Scher, 1981), It is now evident from the work of a
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number of laboratories that the switch in expression from one isotype 
to another involves joining of an active V-D-J gene to one of the 
possible Y, a or e C-region exons situated 3' to the end of the Cy 
and CÔ exons. The switch is accompanied by deletion of all DNA 
between 3'-end of the V-D-J gene and the 5* of the switch site 
proceeding the selected constant region exon. This hypothesis is 
based on hybridisation kinetics experiments investigating the gene 
numbers of C genes in myelomas expressing different immunoglobulin 
classes (Honjo and Kataoka, 1978), and this has been confirmed by more 
recent studies (Cory and Adams, 1980). Thus, according to the 
arrangement of C^ genes illustrated in figure 6 (after Hon jo ejb al, 
1980) a heavy chain switch, at the phenotypic level, from IgM to 
IgGg^ would result in deletion of the exons encoding Cy, C6, Cy3, and 
Cyl, but those coding for Cy2a, Ce and Ca would remain in the genome. 
Heavy chain switching and V -j joining are disimilar events. 
V-J recombination is a precise event demanding recognition of 
heptameric and nonameric nucleotide signal sequences before the 
joining process can occur (Sakano et al, 1979; Seidman et al, 1979), 
Heavy chain class switching appears to occur at a variety of switch 
recombination sites which are located in the 5' flanking sequence of 
each C^ exon (Davis et al, 1980a,b,c; Kataoka et al, 1980; Takahashi 
et al; 1980)„ The precise nature of the signals involved in the 
heavy chain switch are not yet well understood, but runs of repeated 
nucleotide sequences are thought to identify the location of switch 
recombination sites. The Ca switch site appears to be located in a 
30 nucleotide segment (Davis et al, 1980b,c) and the equivalent site 
for Cy switching is believed to be located in a 49 nucleotide repeated
FIGURE 6
Organisation of Murine C^.Genes
The order of the constant region genes for mouse immuno­
globulin heavy chains as determined by Honjo and his collaborators 
is shown (Honjo e^ al, 1980). Although shown as a continuous sequence,
it should be noted that each gene contains multiple exons coding
for separate domains and M-exons, Approximate distances between 
genes are also shown. Note that distances are not drawn to scale.
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sequence (Honjo et 1980) , Similar sequences have also been re­
ported in the human Igh system (Ravetch et al, 1980). There is 
significant nucleotide sequence homology between y and a switch sites 
but not between y and y switch sites or between y and a switch sites. 
This suggests that y-^ y and y-^ switching mechanisms are mediated by 
distinct enzyme systems, both of which are, in turn, distinct from 
the recombinase mediating V-D, D-J and V-J joining events (Davis et 
al, 1980b,c).
6,6,1. Simultaneous Expression of Cy and c6 Genes
IgM and IgD of identical idiotype are often found on the 
membrane of a single B-lymphocyte (Abney and Parkhouse, 1974; Fu e^ 
al, 1975; Coffman and Cohn, 1977) . The presence of identical idio- 
types on the expressed IgM and IgD strongly suggests that the same 
V^ gene is being expressed in conjunction with both Cy and C6 genes 
and it is therefore pertinent to explore the molecular mechanisms 
which permit the simultaneous expression of Cy and C6 genes with
the same V^  ^gene.n
Several features of the organisation of Cy and C6 exons
suggest that simultaneous expression of Cy and C6 genes may be
accomplished via RNA processing rather than via DNA rearrangement:
a) the CÔ is located some 2,5kb 3' to the M-exons of 
the Cy gene (Liu et al, 1980);
b) Cy and Cô genes are identically oriented (Liu et al,
1980) and
c) Cy and Cd can both be associated with the same V^- 
C h - J h  G x o n .
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Given that RNA processing allows the simultaneous ex­
pression of membrane and secretory y-chain polypeptides, (Rogers 
et al, 1980; Early _et al, 1980), it is reasonable to propose that
exons could be contained in a single large 
nuclear RNA transcript which could then be appropriately processed 
to yield functional y-mRNA or ô-mRNA (Liu et al, 1980), Preliminary 
evidence for the existence of such a transcript has been recently 
reported (Wall elb al, 1981) ,
6,7, Molecular Events During B-Lymphocyte Differentiation
It is now possible to understand the molecular events at 
the DNA level which are responsible for the characteristic pheno­
typic traits which are seen during B-lymphocyte differentiation.
The data also demonstrate that DNA recombination events are the 
decisive step in commitment of B-lymphocytes to make antibody of a 
given specificity.
The earliest molecular events occuring in stem cells are 
attempts to form a function V-D-J gene at the Igh locus. Each cell 
has a minimum of two attempts to form such an active gene and failure 
to do so results in cell wastage, A successful V-D-J recombination 
commits that cell to the B-lymphocyte lineage and possibly also 
actively suppresses further rearrangement at Igh (Early and Hood,
1981), This cell is phenotypically a pre-B-cell.
The next stage in development of the B-lymphocyte is the 
selection of a light chain to complement the heavy chain and so 
form an active antibody molecule. The cell appears to attempt to 
form an active V^-J^gene in preference to a V^-J^ gene (Hieter e^ al, 
1981; Coleclough et al, 1981), presumably due to the larger V^ gene
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pool which would be of selective advantage to the animal. If, 
however, no successful V^-J^ joining is achieved the cell will 
attempt to rearrange its IgA locus. Once an active light chain 
gene has been formed, the polypeptide synthesised and IgM located 
on the cell surface, the cell will be phenotypically an early B- 
lymphocyte. Transcription of Cy and C6 with a single 
gene and expression of IgM and IgD yield an antigen sensitive, 
virgin B-lymphocyte.
Upon antigen contact, the lymphocyte undergoes clonal 
expansion to yield memory cells and plasma cells. The memory cells 
may express an isotype other than IgM, but carry the sane idiotype 
as the original B-lymphocyte, and the isotype switch is accomplished 
by joining the expressed V^-D^-J^ gene to a selected C^ exon located 
3' to the Cy and Cô exons. The switch is accomplished through recom­
bination events controlled by signals encoded in stretches of repeated 
nucleotide sequence in the non-coding regions 5' to the C exons.
Switch recombination, like V - J  and V - D - J  joining, is accomplishedL L H H H
by deletion of intervening DNA.
The above summary illustrates the profound effect that the 
advent of recombinant DNA technology has had on the understanding of 
B-lymphocyte differentiation.
7, REGULATION OF IMMUNOGLOBULIN GENE'EXPRESSION
7.1. Cellular Regulation
At the cellular level, the immune response involves the
carefully controlled interplay of a variety of cell populations and
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subpopulations in a dynamic, interactive system. This discussion of 
cellular regulation of antibody synthesis will deal only with the 
influences of T-helper, T-suppressor, and macrophage populations upon 
B-lymphocytes.
7.1.1. Role of T-lymphocytes
Early experiments examining the cell population responsible 
for antibody synthesis illustrated not only that B-lymphocytes were 
the antibody forming cells, but also that T-lymphocytes exerted a 
regulatory influence upon the B-lymphocytes (Introduction, section 2; 
Claman et al, 1966; Mitchell and Miller, 1968; Nossal et al, 1968).
The influence of T-lymphocytes upon antibody synthesis by B-lymphocytes 
is of two kinds, help or suppression. The efforts of a great many 
investigators have helped to elucidate the functional and immuno- 
genetic bases of T-lymphocyte help and suppression of immunoglobulin 
gene expression (see reviews by Benacerraf and Katz, 1975; Katz, 1977).
The helper T-lymphocytes (T^-cells) have the phenotype Ly l"^ 
(Cantor and Boyse, 1975a,b). The existence of T^-cells was demonstrat­
ed in adoptive transfer experiments in which lethally-irradiated re­
cipient mice or guinea pigs received primed T- or B- lymphocyte 
populations from syngeneic animals (Mitchison, 1971a,b; Katz et al,
1970), It was illustrated that both T- and B- lymphocyte populations 
were required before an effective antibody response could be observed 
in the irradiated recipient. Furthermore, the specificity of the 
T-lymphocyte was for the carrier moiety of a hapten-carrier con­
jugate and was specific for the carrier to which the T-lymphocyte 
was educated (Mitchison, 1971a,b; Katz et al, 1970). Immuno gene tic 
analyses of the influence of H-2 genes upon the activity of T^-cells
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on antibody production showed that the T^-cells and B-lymphocytes 
required to be identical at the I-region of the H-2 complex (Katz 
and Benacerraf, 1975} and, more exactly, to the I-A subregion of 
H-2, T^-cells bind antigen only in the context of I-A and, unlike 
suppressor T-lymphocytes, cannot bind free antigen (Okumura et al, 
1977; Taniguchi and Miller, 1977).
The T-suppressor (Tg) lymphocytes have the phenotype 
Ly2 3 (Cantor and Boyse, 1975a,b): this is also the Ly phenotype
of the cytotoxic T-lymphocyte. Adoptive transfer experiments also 
illustrated the existence of the T^-lymphocyte subpopulation. It 
was found that T-cell depleted mice, when challenged with antigen, 
made antibody when repopulated with T-cells. Surprisingly, if T- 
lymphocytes were always present the B-lymphocytes made a significantly 
lower response (Gershon and Kondo, 1970). T^-cells also require to 
recognise antigen in the context of the products of the H-2 region. 
However, T^-cells are restricted to the H-2K or H-2D products (Gershon 
and Cantor, 1977), The nature of the H-2I product expressed on the 
cell membrane of Ly2 3 T-lymphocytes also delineates the T^-cells 
and cytotoxic T-lymphocytes: cytotoxic lymphocytes express I-A sub-
region products while T^-cells express products of the I-J subregion 
(Murphy et al, 1976; Tada et al, 1976).
7.1.2. Role of Macrophages
The evidence that macrophages were essential in development 
of vitro antibody responses was obtained at about the same period 
that lymphocyte interactions were shown to be important in antibody 
formation. Mosier (1967) showed that if murine non-immune spléno­
cytes were separated into adherent and non-adherent populations, an
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IgM response to sheep erythrocytes could not be mounted vitro 
by either population. Remixing of the populations led to gener­
ation of an vitro response comparable to that observed with un­
manipulated cells. The macrophages were shown not to be pre­
cursors of the antibody forming cells (Munro and Hunter, 1970), and, 
furthermore, macrophages from T-cell depleted animals were also 
capable of supporting ^  vitro primary responses (Munro and Hunter, 
1970). Macrophages are also mandatory for generation of primary 
IgG and IgA in vitro responses to sheep erythrocytes (Pierce, 1973). 
The X-irradiation studies of Gorczynski and his collaborators illus­
trated defects of macrophage function, both vivo and vitro, 
three days after irradiation which were abrogated by normal macro­
phages (Gorczynski et al, 1977), This shows good correlation between 
studies iji vitro of adherent cells and vivo studies of macrophage 
function.
Several properties of the macrophage membrane are important 
for the fulfillment of its antigen-presenting function. Cytophilic 
antibody binds to macrophage membranes via a macrophage receptor 
(Hoyden, 1964). Immune complexes also bind avidly to this receptor. 
Antigen-specific helper factors, which bind antigen, are cytophilic 
for macrophages (Feldmann, 1972). Thus, the macrophages have 
intrinsic mechanisms to promote acquisition of antigen in a passive 
manner, and to act as an 'antigen-focusing*point for efficient 
presentation of antigen to the lymphocytes.
As in the collaboration between lymphocytes, the inter­
action of macrophages with lymphocytes is subject to strict genetic 
restriction by the H-2 complex (Katz and Unanue, 1973). Genetic
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restriction was first observed in the guinea pig where it was demon­
strated that antigen-specific vitro proliferative responses occurred
only if the macrophages and T-lymphocytes were histocompatible. 
Furthermore, the response was inhibitable by antibody to the la-like 
antigens of the guinea pig lymphocyte membrane (Rosenthal and 
Shevach, 1973; shevach et al, 1972; B.D, Schwartz et al, 1976). In 
the mouse, it was shown that anti-la antibodies would inhibit the in 
vitro proliferative response, and also that the restriction mapped 
to the I-A subregion of the H-2 complex (R.H, Schwartz et al, 1976,
1978). The requirement for histocompatible macrophages was also 
shown for the ^  vitro induction of T^-cells and the restriction
mapped to the I-A subregion of H-2 (Erb and Feldmann, 1975).
7.2. Molecular Regulation
The foregoing section reviewed the influence of T-lymphocytes 
upon the antibody response. In this section the role of macro­
molecules secreted from T-lymphocytes in regulation of the antibody 
response is evaluated, and the function of RNA processing of immuno­
globulin gene transcripts as a control mechanism is also discussed.
7,2.1, T-Lymphocyte Factors
The earliest evidence of the ability of T-lymphocyte de­
rived molecules to mediate T-cell help was provided by the classical 
double-chamber experiments of Feldmann and Hasten (1972). These 
experiments illustrated that DNP-primed B-cells would make a good 
anti-DNP response when cultured in the presence of DNP-KLH and T- 
lymphocytes educated to KLH even though the two cell populations were 
separated by a cell-impermeable membrane.
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Many antigen-specific soluble 'factors' have now been 
described (reviewed by Tada and Okumura, 1979) and these may act as 
helper factors or suppressor factors. Helper factors replace live 
T^- cells in vitro or vivo T- and B-lymphocyte responses and 
suppressor factors replace T^-cells in the equivalent situations.
The question of genetic restriction of factors is a complex and un­
answered problem (see review by Berzofsky, 1980). However, although 
the role of macrophages in production of helper or suppressor factors 
appears more critical for help than for suppression (Feldmann et al,
1979) the effects of both classes of factors appears to be mediated 
via macrophages (Howie and Feldmann, 1978).
Another similarity between helper and suppressor factors is 
found in their biochemical and serological properties. The factors 
are protein in nature (Tada and Okamura, 1979) and have AMWs of the 
order of 30-50K. (Recent studies have shown that the factors are 
glycoproteins (Webb, unpublished data). Furthermore, the factors 
express la antigenic determinants; I-A encoded determinants are found 
on helper factors and I-J determinants are detected on suppressor 
factors (Tada and Okumura, 1979). Some helper and suppressor factors 
appear to share idiotypes with antibodies of corresponding speci­
ficity : C and C determinants are not found on helper or suppressor 
factors (Mozes, 1978; Germain e^ al, 1979). The la determinants and 
Vg determinants co-elute from affinity columns which is consistent 
with the hypothesis that the determinants are on the same glycopeptide 
or are within the same macromolecular complex.
Much remains to be discovered regarding the structure and 
mechanism of action of these factors. Particularly of interest is
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the relationship of factors to the T-lymphocyte receptor. Certainly, 
the finding of determinants upon factors and on T-cell 'receptors' 
(Berzofsky, 1980) arouses the suspicion that the factors may represent 
a secreted form of the receptor. The gencmic structure and pro­
cessing of T-cell receptor and factor genes then becomes of consider­
able interest. The mechanisms governing alternate expression of 
secretory and membrane forms of the immunoglobulin heavy chain poly­
peptides are relevant in this regard, and these processes are de­
scribed in the following section.
7.2.2. RNA Splicing of Immunoglobulin Gene Transcripts
The molecular processes involved in synthesis of li-heavy 
chains by B-lymphocytes is summarised in figure 7. An important 
event in these processes is the alternative splicing of the primary 
nuclear RNA transcript of the y-chain gene to yield mRNAs for either 
the membrane or secretory y-chain polypeptides. It is therefore 
pertinent to explore the possible molecular signals which underly 
this phenomenon.
The processing events which generate the immunoglobulin 
mRNA from the primary nuclear RNA transcript appear to occur in a 
specific order. The earliest post-transcriptional event appears to 
be polyadenylation (Gilmore-Herbert and Wall, 1978, 1979) which is 
followed by splicing of the transcript to remove introns (Gilmore- 
Herbert and Wall, 1978,1979; Perry et al, 1979). The fully pro­
cessed immunoglobulin mRNA molecules are then immediately transported 
to the cytoplasm (Wall, 1980).
The molecular mechanisms which permit alternative expression 
of mRNA for the secretory or membrane form of immunoglobulin heavy
FIGURE 7.
Molecular Events in Formation of Active Immunoglobulin Heavy Chains
The formation of distinct mRNA species encoding y and y
m -s
polypeptides from a single y-chain gene via splicing of a single 
nuclear RNA transcript is diagrammed.
Key
Open boxes ;- exons
Open circles:-* DNA recombination sites, which obey
the 23/12 spacer rule (Early et al, 
1980a; Sakano e^ al, 1980).
Shaded triangles:- RNA splice sites at intron
boundaries.
L - hydrophobic leader sequence exon
- V exon
D^ - diversity segment exon
J - J exon
C - constant domain exon
y
T - DNA encoding the C-teanninal secret­
ory peptide of y 
M^,M^ - membrane exons
bp - base pairs
kb - kilobases
CEO - carbohydrate
s
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chain polypeptide are not yet understood. However, an attractive 
model, based on polyadenylation of specific sites, has been proposed 
to explain this phenomenon (Rogers et al, 1980; Wall, 1981; Johnson, 
et al, 1981), Polyadenylation precedes removal of introns and 
polyadenylation of one of the two polyadenylation sites present in 
the Cy gene or other gene may determine which of the two possible 
nuclear RNA transcripts is expressed. Polyadenylation sites are 
located just 3’ to the end of the Cy4 exon and T-piece and also 3' 
to the end of the exon (see figure 7,). If polyadenylation occurs 
at the former site (i.e. 3' to the C 4 exon and T-piece) then only y^  
mRNA is synthesised as no information for the M-exons is present in 
the nuclear RNA transcript: polyadenylation of the latter site (3'
to the exon) gives rise to y^ mRNA. Thus, polyadenylation 
regulates the size of the primary nuclear RNA transcript and therefore 
the nature of the mRNA generated for export to the cytoplasm.
The alternative splicing mechanisms described above are 
clearly developmentally regulated: early B-lymphocytes synthesise
predominantly y^-mRNA while plasma cells synthesise mostly y^-mRNA. 
Current theories propose that inducible soluble factors may enforce 
polyadenylation of the site nearest the Cy4 exon thus switching off 
y^-mRNA synthesis and promoting transcription of nuclear RNA species 
containing information only for y^-mRNA (Wall, 1980). However, these 
mechanisms and the molecular mechanisms responsible for T-cell mediated 
control of B-lymphocyte differentiation are interesting questions 
which remain to be answered in the future.
MATERIALS AND METHODS
-91-
1. GENERAL MATERIALS
1.1. Cell Culture Materials
Penicillin
Streptomycin
RPMl-1540 Medium powder Gibcc Biocuit Ltd.,
Paisley, Scotland.
Foetal Calf Serum (PCS) Flow Laboratories Ltd.,
Irvine, Scotland.
Glaxo Pharmaceuticals Ltd., 
England.
Glaxo Pharmaceuticals Ltd., 
England.
Tissue culture flasks were provided by Costar Inc., 
Cambridge, Massachusetts. Accessory sterile plastics were obtained 
from Flow Laboratories Ltd,
1.2. Radiochemicals
All radiochemicals were obtained from the Radiochemical 
Centre, Amersham, England. The specific activities of the radio­
chemicals used are shown below.
Amino Acids
L-[2- h ]-glycine
L-[4,5-^h]-leucine 
35L-[ s]-methionine 
L-[2,6^h]-tyrosine
Other Compounds 
125.I-iodine
131I-iodine
Specific Activity 
30 Ci/mmol. 
100-150 Ci/mmol.
> 600 Ci/mmol.
37 Ci/mmol. 
Specific Activity 
Carrier-free 
Carrier-free
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1.3
1.4
England.
Photographic Materials 
X-Qmat-H X-ray film 
SX-80 developer 
FX-40 X-ray liquid fixer 
Lightproof vinyl bags 
Fine Chemicals
Kodak (U.K.) Ltd., London. 
Kodak (U.K.) Ltd., London. 
Kodak (U.K.) Ltd., London.
H.A. West Ltd., Edinburgh.
The following fine chemicals were supplied by Sigma Ltd.,
Cycloheximide 
Deoxycholic acid 
Dimethyl sulphoxide (DMSO)
D-L-Dithiothreitol (DTT)
Phenylmethyl sulphonyl fluoride (PMSF)
Polyoxyethylene sorbitan monopalmitate (Tween 40) 
N,N,N',N' tetramethylethylene diamine (TEMED)
Tris (hydroxymethy1) aminomethane (Trizma base)
Other fine chemicals were supplied as listed below.
2,5-diphenyloxazole (PPO) Koch-Light Laboratories,
England.
Toluene (AR grade)
2-mercaptoethanol
Heparin
Hexanoic anhydride
Koch-Light Laboratories, 
England.
Koch-Light Laboratories, 
England.
Evans Medical Ltd., 
Liverpool, England. 
Aldrich Chemical Company, 
England.
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Eastman Kodak Co., Rochester, 
New York, U.S.A.
Protein Research Foundation, 
Osaka, Japan.
New England Nuclear Ltd., 
England.
Rohm and Hass Ltd., England. 
Glaxo Pharmaceuticals Ltd, , 
England.
All other reagents were "Analar" grade and were obtained 
from BDH Chemicals Ltd., England.
N,N'-methylene bis 
acrylamide 
Pepstatin A
Protosol
Triton X-100 
Tunicamycin
1.5. Enzymes
Deoxyribonuclease I (DNAase I) Sigma Ltd., London.
Lactoperoxidase
Pepsin
Trypsin
Carboxypeptidase A
1,6. Chromatographic Reagents 
Oligo dT cellulose
Cyanogen-Bromide Activated 
Sepharose 4B 
Sephadex G200 
Sephadex G25 
QAE Sephadex
Sigma Ltd., London.
Sigma Ltd., London.
Sigma Ltd., London. 
Worthington Biochemical 
Corporation, New Jersey,
U .S .A.
Collaborative Research Inc., 
Waltham, Massachusetts, U.S.A.
Pharmacia Ltd., London. 
Pharmacia Ltd., London. 
Pharmacia Ltd., London. 
Pharmacia Ltd., London.
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TABLE 1
COMPOSITION OF RPMl-1640 MEDIUM
Amino Acids mg/litre
L-Arginine (free base) 200.0
L-Asparagine 65.0
L-Aspartic Acid 20.0
L-Cystine (2 HCl) 65.0
L-Glutamic Acid 20.0
Glycine 10.0
L-Histidine (free base) 15.0
L-Hydroxyproline 20.0
L-Isoleucine (alio free) 50.0
L-Leucine (methionine free) 50.0
L-Lysine HCl 40.0
L-Methionine 15.0
L-Phenylalanine 15.0
L-Proline (Hydroxy-L-Proline free) 20.0
L-Serine 30.0
L-Threonine (alio free) 20.0
L-Tryptophan 5.0
L-Tyrosine 28.94
L-Valine 20.0
Inorganic Salts
Ca(NO ) .4H 0 100.0
KCl 400.0
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TABLE 1 (cont’d)
Inorganic Salts (cont'd)
MgSO
NaCl
Na^HPO^ (anhydrous) 
Vitamins
Biotin
D-calcium pantothenate
Choline chloride
Folic acid
i-Inositol
Nicotinamide
Para - aminobenzoic acid
Pyrodoxine hydrochloride
Riboflavin
Thiamine hydrochloride 
Vitamin B^^
Other components 
Glucose 
Phenol red 
Reduced glutathione
mg/litre 
48.84 
6000,0 
800.0
0,2
0.25
3.0
1.0 
35.0
1.0
1.0
1.0
0.2
1.0
0.005
2000.0
5.0
1.0
2000mg/litre NaHCO^ was added separately to dissolved 
medium. The pH was adjusted to 7.0 with concentrated HCl. The
media was sterilized by filtration and stored at 4 c .
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2. STANDARD SOLUTIONS
2.1. Phosphate-Buffered Saline (PBS-A) 
170raM NaCl
3 .4mM KCl
lOmM Na_HPO,
—  2 4
1.8mM KHgPO^ pH7.2.
2.2. Toluene - PPO Liquid Scintillant
4g PPO per litre of toluene.
2.3. Triton-Toluene - PPO Scintillant
67% {by volume) Toluene
33% (by volume) Triton X-100
4g/litre PPO
2.4. Three-Detergent Lysis Buffer (3D-TKM)
1% (w/v) Triton X-100
1% (w/v) Deoxycholic acid
0.5% (w/v) SDS
O.IM Tris-HCl pH 8,2
O.IM KCl
5raM MgClg
3. TISSUE CULTURE
3.1. Tissue Culture Medium
The composition of RPMl-1640 powdered medium is detailed in 
table 1. "Complete" tissue culture medium consisted of:
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90% (v/v) RPMl-1640
10% (v/v) FCS
10^ units/litre Penicillin 
lOOmg/litre Streptomycin
2.OmM Glutamine
The FCS was heat inactivated at 56^C for 1 hour and stored 
at -20°C prior to use. Penicillin and streptomycin were mixed and 
stored at -20^C as a lOOX stock, and glutamine was also stored at -20^C 
as a lOOX stock.
I am indebted to Mrs. Irene Gall for routine preparation of 
tissue culture medium.
3.2. Routine Culture
Cells were grown in complete medium as suspension cultures 
in Costar flasks at 37^C in a 95% CO^ humid incubator and were
sub-cultured every third day.
3.3. Large Scale Culture
9
For culture of >10 cells, 2.5 litre roller bottles were 
employed. The bottles containing the cultures were gassed with CO^, 
sealed, and placed on a mechanical rolling device in a 37^c hot room.
3.4. Determination of Cell Viability
Cell viability was determined by adding an aliquot of cell 
suspension to an equal volume of trypan blue dye solution. The 
suspension was mixed and the numbers of live and dead cells estimated 
by counting in a Neubauer haemocytometer.
Trypan Blue Dye Solution 
4 parts 1% (w/v) NaCl 
1 part 1% (v/v) Trypan blue dye.
-98-
table 2
CHARACTERISTICS OF HUMAN B-CELL LINES
CELL TYPE ig MEMBRANE. SECRETION REFERENCE
BEC-11 BLCL IgGK ++ ++ Singer e^ al, 
1976.
BJAB BL IgMK ++ +■+• Menezes et 
1973.
BRI-8 BLCL IgMl ++ Crumpton and 
Suary, 1976.
Dakiki Arosros I BL IgAA ++ ++ Steinitz and 
Klein, 1980.
Daudi BL IgMK ++ Klein et al, 
1968.
Raji BL IgMK — Pulvertaft, 
1965.
U266BL Myeloma IgEA ++ Nillson e^ 
al, 1970.
a) BL - Burkitts Lymphoma
BLCL - B-Lymphoblastoid Cell Line.
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TABIiE 3
ANTIBODY PREPARATIONS 
Antibody 
Goat Anti-Rabbit IgG (GARIg) 
Rabbit Anti-Human IgM (RAHy) 
Rabbit Anti-Human IgG (RAHy) 
Rabbit Anti-Human IgA (RAHa) 
Rabbit Anti-Human IgE (RAHe) 
Rabbit Anti-Human kappa (RAHk)
Specificity 
Rabbit IgG 
Human y-chain 
Human y-chain 
Human a-chain 
Human e-chain 
Human k-chain
Source
Rabbit Anti-Human lambda (RAHA) Human A-chain
Miles Laboratories 
Miles Laboratories 
Miles Laboratories
Rabbit Anti-Human ™^cro- 
globulin (RAH
Rabbit Anti-Human MHC (No.70)
Rabbit "Anti-Daudi" (No.52)
Rabbit Anti-Human HLA-DR
Rabbit Anti-Mouse IgG 
Monoclonal Anti-Human k
Human g^M Biogenes Ltd.
HLA-A,-B,-C and Dr, C.M. Steel,
-DR Antigens 
See Results, 
Chapter 3.
Edinburgh.
Dr. C.M. Steel, 
Edinburgh.
HLA-DR Antigens Dr. M.J. Crumpton,
London.
Mouse IgG -
K-chain Dr. R. Jefferis, 
Birmingham.
Dr. R. Jefferis, 
Birmingham.
Dr. R.S. Accolla, 
Lausanne.
(a) Where no source is given, antisera were prepared in Glasgow.
Monoclonal Anti-Human A
Monoclonal Anti-HLA-DR
A-chain
HLA-DR-g-chain
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4. HUMAN LYMPHOID'CELL LINES
The characteristics of the B-lymphoma and B-lymphoblastoid 
cell lines used in this study are presented in table 2. Cells were 
maintained in culture as described above (section 3.2) or stored 
frozen in liquid nitrogen. Regular contamination checks were per­
formed to exclude cultures containing bacteria, fungi or mycoplasma,
5. SEROLOGICAL REAGENTS.
5.1. Immunization Schedule
Rabbits were immunized intramuscularly with purified antigen 
emulsified in Friends Complete Adjuvant, and received several booster 
injections prior to collection of immune serum. Antibody was pre­
pared from the immune serum and was purified by isolation of IgG 
(see below) followed by affinity chromatography using appropriate 
immobilized immunoadsorbents. A similar procedure was employed in 
raising goat anti-rabbit IgG (GARIg) antiserum, I am indebted to 
Mrs. Liz Blakeley for immunizing the animals and for collection of 
the immune serum.
5.2. Purification of IgG
The use of purified IgG, or fragments of this molecule, 
is often preferred to the use of whole antiserum. The two methods
used for purification of IgG are described below.
5.2.1. Ammonium Sulphate Precipitation
A known volume of antiserum was clarified by centrifugation 
(20,000 X g for 30 minutes) and stirred on ice. Solid ammonium
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sulphate was added slowly to 33% saturation. Stirring was continued, 
on ice, for 30 minutes and the precipitate collected by centrifugation 
(10,000 X g for 30 minutes). The pellet was resuspended in PBS-A to 
the original sample volume, and reprecipitated with ammonium sulphate. 
After a third precipitation with ammonium sulphate, the pellet was 
dissolved in PBS-A and dialysed against the same buffer to remove all 
traces of ammonium sulphate. The sample was stored frozen at -20^C 
in aliquots.
5.2,2. QAE-Sephadex Chromatography
A column of QAE-sephadex was constructed and equilibrated 
with the following buffer:
O.IM Tris-HCl pH 6.5.
After extensive dialysis against this buffer and clarifi­
cation by centrifugation, the serum sample was applied to the column 
and washed through with a large volume of buffer. Elution profiles 
were obtained by spectrophotometrie analysis at 280nm. IgG is the 
major component in the first protein peak to be eluted. The igG- 
containing fractions were pooled, concentrated, and dialysed against 
PBS-A. The samples were frozen in aliquots at -20°C.
5.3. Preparation of F(ab)2 Fragments of IgG
IgG, prepared by one of the above methods (5.2.1 or 5.2.2) 
was dialysed against several changes of digestion buffer.
0.07M Acetate buffer pH4.0
0.05M NaCl.
5 mg of IgG was then mixed with 250yg pepsin in 1ml digest­
ion buffer, and the mixture incubated at 37^C for 18 hours. After
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digestion, the pH of the mixture was adjusted to 8.0 with IN NaOH 
and then dialysed extensively against PBS-A.
FCab)^ fragments generated by pepsin digestion were isolated 
by gel filtration on a column of sephadex G200 equilibrated with 
PBS-A (Stanworth and Turner, 1978) .
5.4. Affinity Chromatography
5.4.1. Preparation of Immunoadsorbents
Antigen was covalently linked to cyanogen bromide-activated 
sepharose 4B according to Axen et ad (1967). Cyanogen bromide-acti­
vated sepharose was rinsed with ice-cold O.IM NaHCO and resuspended
— 3
in the same buffer to give a solution of approximately 20% (w/v) 
sepharose. The sample to be coupled was immediately added and the 
mixture agitated gently for 16 hours at 4*^ C. The sepharose was 
then rinsed with O.IM NaHCO^ and the absorbance ^^280^ of the eluates 
determined. The amount of protein coupled during the reaction was 
calculated from the following equation.
Coupled protein = (Total protein) - (Uncoupled Protein).
The conjugate was then rinsed overnight at 4*^ C in IM 
glycine to quench any remaining protein binding sites. The sepharose 
was washed extensively in PBS-A and stored at 4*^ C in the same buffer 
containing 0.05% sodium azide as preservative.
4.5.2. Chromatographic Procedure
The IgG fraction of immune serum was passed over a small 
column of sepharose-4B-antigen. After thorough washing of the 
column with PBS-A, bound antibody was eluted with O.IM acetic acid. 
Elution profiles were obtained by spectrophotometric analysis at 
280nm and fractions containing protein were pooled and immediately
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neutralized by addition of solid trizma base. The sample was 
dialysed extensively against PBS-A and stored in aliquots at -20^C.
5.5. Serological Precipitation
The optimum proportions, or point of maximal precipitation, 
for the GARIg-rabbit antibody system employed in these investigations 
was determined as follows. A fixed amount of GARIg was mixed with 
increasing amounts of rabbit serum (or IgG) in a constant reaction 
volume. The mixtures were incubated at 37^C for 1 hour and over­
night at 4^c. The precipitates were collected by centrifugation 
(10,000 X g for 2 minutes), washed thrice in PBS-A and dissolved in 
0.2N NaOH. The absorbance each sample was measured and
the optimum proportions point determined as the sample containing 
most protein.
5.5. Preparation of Serum No.52
A rabbit was immunized with Daudi cell membranes coated 
with antiserum to EB-1 cells. The resulting immune serum was 
absorbed twice with pooled T-cell lines (CCRF-GEM and Molt-4) and 
four times with EB-1 cells. This absorbed serum was capable of 
blocking mixed lymphocyte reaction activation by Daudi cells (Steel 
etai, 1978).
6. PREPARATION OF PLASMA MEMBRANE
Cells were grown in roller bottles and harvested by 
centrifugation (1,000 x g for 10 minutes). The cells were washed 
twice with ice-cold tris-saline prior to preparation of the plasma 
membrane fraction according to Standring and Williams (1976).
-104-
Tris-sallne
25raM Tris-HCl pH 7.4
150mM NaCl
lOmM NaN_
—  3
ImM MgSO^
2mM CaCl^
—  2
Washed cells were resuspended in ice-cold tris-saline at a 
concentration of 5 x 10^ cells/ml, and stirred on ice. An equal 
volume of ice-cold 4% (w/v) Tween-40 in tris-saline was added to the 
suspension and the mixture stirred on ice for 1 hour. The cells 
were then homogenized and nuclei and undisrupted cells removed by 
centrifugation (3,000 x g for 10 minutes). A crude membrane extract 
was obtained by centrifugation of the post-nuclear supernatant at
70,000 X g for 1 hour at 2^C in the Beckman L5-65 ultracentrifuge.
The crude membrane pellet was homogenized into a small volume of 
lOmM Tris-HCl (pH 7.4) and carefully layered onto the top of a three- 
layer discontinuous sucrose gradient composed of 11ml volumes of 
40% (w/v) 28% (w/v) and 10% (w/v) sucrose in lOra^ Tris-HCl (pH7.4). 
The gradients were centrifuged at 25,000 rpm for 15 hours at 2°C in 
the Beckman L5-65 ultracentrifuge using an SW27 rotor. Purified 
plasma membrane was harvested from the first interface and collected 
by centrifugation (100,000 x g for 2 hours).
7.' SYNTHESIS AND USE OF HEXANOYL DIIODO-NAP-TYRAMINE
7.1. Radioiodination of NAP-Tyramine
The following procedures were developed by Hebdon et al
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(unpublished). NAP-tyramine was a generous gift from Dr. M.J. Owen,
ICRF, Lincolns Inn Fields, London. All procedures were performed 
in the dark.
The following mixture was used for radioiodination of NAP-
tyramine.
lOyM KI
lOOm^ borate pH 9.2
200yM NAP-tyramine 
2mg Chloramine - T 
lOyl of this mixture (i.e. 2 nanomoles of NAP-tyramine) was 
reacted with IraCi radioiodine for 30 minutes at room temperature.
5yl of lOraM KI was then added and the mixture allowed to stand at
room temperature for 20 minutes prior to chloroform extraction. The
chloroform extracts (0 .6ml total) were washed with 1% (w/v) sodium 
metabisulphate and thrice with water. The chloroform was removed 
by a stream of N^ and the residue dried vacuo.
7.2. Acylation of Diiodo-NAP-Tyramine
The dried product from 7.1 above was dissolved in 30yl of 
the following solvent:
0.5ml Pyridine (dried over NaOH pellets)
0.01ml Hexanoic Anhydride.
The mixture was allowed to stand at room temperature for 
30 minutes, when an equal volume of water was added to destroy the 
anhydride. After standing for a further 20 minutes, the sample 
was lyophilized. The dried product was dissolved in 0.4ml water 
and extracted with 0.4ml chloroform. The aqueous phase was further 
extracted with 0 .2ml chloroform and the pooled chloroform extracts
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were washed with water. The chloroform was removed by a stream of
and the product dried vacuo. The structure of hexanoyl-diiodo-
NAP-tyramine is shown in figure 1. The product was dissolved at 
lyCi/yl in methanol immediately before use. The product was used 
within 24 hours of synthesis. A routine yield of 8-10% was achieved 
with the specific activity of the product being 20-25 Ci/mmol.
7.3. Use of Hexanoyl Diiodo-NAP-Tyramine (Owen et al, 1980).
Membranes were prepared as described above (section 6 ),
g
Purified membrane from approximately 10 cells in 250yl ICm^ Tris-
125HCl (pH 7.4) was incubated with SOyCi I-hexanoyl diiodo-NAP- 
tyramine for 15 minutes at room temperature and then placed in the 
beam of light from a standard slide projector for 30 minutes at room 
temperature. The radiolabelled membrane was collected by centrifuga­
tion and dissolved in 3D-TKM for immunoprécipitation analysis.
7
Alternatively, 10 cells were harvested from log phase
cultures, washed extensively in ice-cold TKM buffer (0.1^ Tris-HCl
(pH 8.2), O.IM KCl, 5mM MgCl ) and lysed in 90yl of ice-cold 1% (w/v)
triton X-100 in TKM buffer. The nuclei were removed by centrifuga-
125tion and the supernatant was incubated with 20yCi of l-hexanoyl- 
diiodo-NAP-tyramine for 15 minutes at room temperature prior to ex­
posure to light for 30 minutes at room temperature. After photo­
lysis, the solution was treated with lOyl of a solution of 10% (w/v) 
deoxycholic acid and 5% (w/v) SDS in TKM buffer. Insoluble debris 
was removed by centrifugation (30,000 x g for 30 minutes) and the 
supernate used for serological analysis.
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Fig JL__StruçtuT£^ fJI«çaiioyl2Diiod02N2(42azidO;;^ ^
CHg------------ CHg---------- NH ■N.
C
II
o
CHg CHg CHg------CHg— CHg
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8. RftDIOLABELLING PROCEDURES
8.1. Radioiodination of Immunoglobulins and Proteins
Proteins were iodinated by the chloramine-T method (Hunter
and Greenwood, 1962) . All reactants were prepared in PBS-I with the 
exception of the radioiodine.
PBS-I
50mM Sodium phosphate pH 7.2 
ISOmM NaCl
SOijg of protein in lOyl PBS-I was placed in a chilled
eppendorf polypropylene tube and the following reagents added in order
ImCi ^2^1
lOyl freshly prepared Img/ml chloramine-T in PBS-I.
The mixture was mixed thoroughly and allowed to stand on ice 
for 3 minutes whereupon the following were added.
20yl freshly prepared Img/ml sodium metabisulphite 
in PBS-I. 
lOyl 100 mM KI.
Radiolabelled protein and unreacted radioiodide were 
separated by repeated acetone precipitation or by gel filtration on 
a short column of sephadex G25. The sample was stored in aliquots 
at -20°C.
8.2. Radioiodination of Cell Membrane Proteins
Radioiodination of cell membrane proteins was effected by
7
lactoperoxidase-catalysed iodination (Marchalonis et al, 1971) . 10
cells from log phase cultures of greater than 95% viability were 
harvested and washed twice with 25 ml aliquots of ice-cold serum-free
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RPMl 1640 medium, and once with 25 ml of ice-cold PBS-I. The washed 
cells were transferred to an eppendorf tube, pelleted, and resuspend­
ed in 50yl of a Img/ml solution of lactoperoxidase in PBS-I. After 
incubation at 30°c for 10 minutes the following reagents were added, 
in order:
125 131l-2mCi I (or I)
10]il freshly prepared 1:1000 ,^^ 2 PBS-I
The mixture was incubated at 30^ for 3-4 minutes and 1ml
ice-cold 5mM KI was then added. The radiolabelled cells were 
pelleted and washed extensively before cell lysates were prepared 
(see section 9 below).
8.3. Biosynthetic Labelling of Cellular Proteins
2 X 10^ viable cells were harvested from log-phase cultures
and washed twice in serum-free RPMl-1640 medium lacking the amino 
acid to be used as radiolabel (labelling medium). The cells were 
resuspended in 200yl of labelling medium supplemented with 200yCi of 
the selected radioactive amino acid and incubated at 37^C for 60-90 
minutes (see individual figure legends). The radiolabelled cells 
were washed and cell lysates prepared.
8.3.1. "Pulse-Chase" Experiments
Cells were biosynthetically radiolabelled as described in 
section 8.3 above. After the labelling period, the cells were 
pelleted and resuspended in 0.25-0.5ml RPMl-1640 medium plus 10%
(v/v) FCS and reincubated at 37^C for a further 4-6 hours. Follow­
ing the reincubation period, the cells were again pelleted and the
supernatant used for analysis of secreted proteins.
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8,3,2. Use of Tunicamycin
In biosynthetic labelling experiments where tunicamycin 
was employed, an incubation period of 3 hours at 37^C was allowed 
prior to addition of radiolabel. Tunicamycin was present in all
solutions used at a concentration of 2^g/ml. Stock solutions 
of Img/ml tunicamycin were prepared in 25mM NaOH.
9. PREPARATION OF CELL LYSATES
Radiolabelled cells were washed twice in 0.5ml of ice-cold 
TKM buffer prior to solubilization in 225yl of ice-cold 1% (w/v) 
triton X-100 in TKM buffer. The suspension was mixed thoroughly and 
allowed to stand on ice for 20 minutes. Nuclei were removed by 
centrifugation (3,000 x g for 30 minutes). Deoxycholic acid and SDS 
were added to the post-nuclear supernatant to final concentrations of 
1% (w/v) and 0.5% (w/v) respectively. Insoluble debris was removed 
by high speed centrifugation (30,000 x g for 30 minutes) and the 
supernatant was used immediately for serological analysis, or was 
stored at -70°C. If stored, the high speed centrifugation step was 
repeated on the thawed lysate (Mosraann e^ al, 1979) .
10. ANALYSIS OF CELLULAR PROTEINS
10.1. Total Cellular Proteins
Total cellular proteins were precipitated from an aliquot 
of cell lysate by addition of five volumes of acetone. The protein 
precipitate was collected by centrifugation, air-dried, and solubil­
ized in SDS-PAGE loading buffer (see section 13.1 below).
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10.2. Immune Precipitation
10.2.1. Indirect Immunoprécipitation
lOyl of a 1:10 dilution of rabbit antiserum was added to 
an aliquot of cell lysate (or supernatant) and an incubation of 30 
minutes at room temperature allowed. An equivalence of GARIg was 
added and the mixture incubated overnight at 4^C. Immune precipi­
tates were harvested by centrifugation.
10.2.2. Fixed Staphyloccocal Immunoadsorbent
The Cowan I strain of Staphylococcus aureus is capable of 
binding to the F^ portions of certain immunoglobulins in immune 
complexes, for example IgGl, Ig2, Ig4 in humans (Kornvall and Williams, 
1969), IgG2a, IgG2b and IgG3 in mice (Kornvall et al, 1970 and rabbit, 
IgG (Lind at al, 1970). The binding is mediated by protein A found 
in the cell wall of aureus (Forsgren and Sjoquist, 1966) and whole 
heat-killed formalinized organisms may be used as a convenient method 
of isolating immune complexes (Kessler, 1975, 1976). For immune 
precipitation using heat-killed formalin-fixed, S_» aureus, 5yl of 
antiserum was added to an aliquot of cell lysate or supernatant and 
the mixture incubated at room temperature for 30 minutes prior to 
addition of lOOyl of a 10% (v/v) solution of aureus in 3D-TKM.
The mixture was incubated overnight at 4°C.
Specifically precipitated radiolabelled material was re­
covered by washing the bacteria three times in 1ml 3D-TKM and then 
resuspending in 0.2ml 2% (w/v) SDS. The bacteria were heated to 
lOO^C for 2-3 minutes and then pelleted. Immune complexes eluted 
into the supernatant were recovered by acetone precipitation. The
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samples were dissolved in SDS-PAGE loading buffer (see 13.1 below) or 
in lOM urea.
10.3. Purification of Serological Precipitates
Serological precipitates derived from aliquots of radio- 
iodinated cell membrane proteins were washed with three successive 
1ml aliquots of ice-cold 3D-TKM prior to analysis. This method was 
not suitable for immune precipitates derived from biosynthetically 
labelled cells. For purification of such imraunoprecipitates, the 
sample was dissolved in 50yl 3D-TKM and layered onto the top of a two- 
step discontinuous sucrose gradient. The gradient consisted of 
300yl IM sucrose in 3D-TKM and 300yl of O .5M sucrose in 3D-TKM.
After addition of the sample, the gradients were centrifuged at
3,000 X g for 30 minutes and the gradients rinsed with the following 
buffer.
50 mM Tris-HCl pH 8.8
1% (w/v) SDS
0.01% (w/v) Phenol red.
The washed immune precipitate was dissolved in SDS-PAGE 
loading buffer (see 13.1 below) or ICM urea. (Mosmann et al, 1978).
11. PREPARATION OF CELLULAR RIBONUCLEIC ACID
11.1. Isolation of Cytoplasmic RNA
Polyribosomes were prepared from large scale cultures of 
cells by the method of Mosmann et al, (1980). Ribonuclease-free 
solutions and baked glassware were used throughout.
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11.1.1. Stock Solutions
Cell Suspension Buffer 
0.88m Sucrose 
0.2M KCl
0.05M Tris-HCl (pH 7.4) 
25mM NaCl
5 mM Magnesium acetate
7mM 2-Mercaptoethanol
O.lmg/ml Cycloheximide 
O.lmg/ml Heparin. 
PBS-Cycloheximide (PBS-CH) 
PBS-A (section 2.1)
O.lmM CaCl^
O.ImM MgClg
O.lmg/ml Cycloheximide, 
Lysis Buffer 
0.88m Sucrose 
0.2M KCl
0.05M Tris-HCl (pH 7.4) 
25mM NaCl
5mM Magnesium Acetate
5mM 2-Mercaptoethanol
10% (w/v) Triton X-100. 
Sucrose Cushion
1.5M Sucrose
0.05M Tris-HCl (pH 7.4) 
25mM NaCl
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5m^ Magnésium acetate
7mM 2-Mercaptoethanol
O .Img/ml Heparin.
11.1.2. Procedure
Cells were pooled and treated with O.lmg/ml cycloheximide 
for 3 minutes at 37°C. The cells were collected by centrifugation 
and washed three times with ice-cold PBS-CH. After resuspension in 
four volumes of ice-cold cell suspension buffer, the cells were lysed 
by addition of one volume of lysis buffer. The suspension was 
centrifuged at 10,000 x g for 1 minute and the supernatant transferred 
to a fresh tube containing sufficient heparin to give a final cocen­
tra tion of O.lmg/ml. This sample was centrifuged at 10,000 x g for 
15 minutes in the Sorvail SS34 rotor and the supernatant transferred 
to 10ml sucrose cushions and centrifuged at 60,000 rpm for 2 hours at 
2°C in the 50Ti rotor on the Beckman L5-65 ultracentrifuge. The 
polyribosome pellet was resuspended in water and subjected to oligo- 
dT cellulose chromatography or stored at -70°C.
11.2. Oligo-dT Cellulose Chromatography 
11.2.1. Stock Solutions
Column Buffer
0.5M LiCl
SOmM Tris-HCl (pH 7.4)
ImM EDTA
0 .1% SDS
Elution Buffer
lOmM Tris-HCl (pH 7.4)
ImM EDTA
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0.1% SDS
11.2.2. chromatographic Procedure
Fresh or thawed polyribosomes were adjusted to SOmM Tris- 
HCl (pH 7.4), 2raM EDTA, 0.5% (w/v) SDS, 0.5M L i d  and heated to 37°c 
for 2 minutes before loading onto a small column of oligo-dT cellulose 
equilibrated with column buffer. Elution profiles were obtained by 
spectrophotometric analysis at 260nm. Poly-adenylated RNA was 
eluted from the column by addition of elution buffer. Fractions
containing RNA were pooled and adjusted to 0.3M NaCl. RNA was pre­
cipitated by addition of 2 volumes of ethanol and incubation over­
night at -20°C. The RNA pellet was dissolved in water and stored at 
-70^C in small aliquots.
12. IN VITRO TRANSLATION OF MESSENGER RNA
Rabbit reticulocyte lysate (Pelham and Jackson, 1976) was
purchased from the Radiochemical Centre, Amersham, England, as a
raicrococcal nuclease-treated, messenger-dependent lysate (MDL) .
Translations were performed as follows; lyg of mRNA (Img/ml in H^O)
3 5was added to 15yl of MDL supplemented with 20yCi L-[ s]-methionine. 
The mixtures were incubated at 30°C for 90 minutes in sealed eppendorf 
tubes. The reaction was terminated by addition of 5 volumes of ice- 
cold 3D-TKM. Translation products were analysed by immunoprécipi­
tation or acetone precipitation as described above (section 10.2.1,
10.2.2.).
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13. POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)
SDS-PAGE was carried cut using a discontinuous tris-glycine 
buffering system (Laemlli, 1970). Electrophoresis was performed on
slab gels and in cylindrical disc gels.
13.1 Stock Solutions
Solution A
45% (w/v) Acrylamide
1.2% (w/v) N,N'-methylene bis acrylamide 
Deionized, filtered and stored at 4°C.
Solution B
1.5M Tris-HCl (pH 8 .8)
0.13% (v/v) TEMED 
Filtered and stored at 4°C.
Solution C 
12% (w/v) SDS
Filtered and stored at 4^C.
Complete Sample Buffer (lOX) 
0.65M Tris-HCl (pH 6 .8)
Filtered and stored at 4°c.
Non-Reducing Loading Buffer 
65m^ Tris-HCl (pH 6,8) 
2% (w/v) SDS 
10% (w/v) Glycerol 
O.Olmg/ral Bromophenol blue
Stored at -20^0
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Reducing Loading Buffer
As for non-reducing buffer with the addition of: 
lOOmM DTT 
Stored at -20°C 
Reservoir Buffer 
25mM Trizma base 
192m^ Glycine 
0.1% (w/v) SDS
13.2 Separating Gel Preparation
Separating gels of the required percentages were prepared 
from stock solution according to the following table:
Percentage Acrylamide
*3,5% 5% 10% 12.5% 15%
Solution A(ml) 9.3 13.3 26.6 33.3 40
Solution B(ml) 30 30 30 30 30
Solution C(ml) 1 1 1 1 1
* Agarose was incorporated to 0.5% (w/v) by heating in water to 80^C
and adding to the other components.
Deionized water was added to 120ml. The solution was 
degassed, 120rag of ammonium persulphate added, and the solution 
poured immediately into the casting apparatus and allowed to polymerise
13.3 Stacking Gel Preparation
Stacking gels were prepared from stock solutions as follows: 
2.64ml Solution A
2.40ml Complete Sample Buffer (XIO)
0.2ml Solution C
18.67ml Deionized Water
24yl TEMED
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The solution was degassed and 24ing of ammonium persulphate 
added. The solution was pipetted onto the top of the separating gel 
and allowed to polymerize around a 26-well teflon template.
13.4 Sample Preparation and Electrophoresis Conditions
Pellets from acetone or immune precipitation were air-dried 
and dissolved in 20-’25yl of reducing or non-reducing loading buffer 
as desired (see individual figure legends). Samples were heated to 
100°C for 2 minutes and immediately loaded into individual wells in 
the stacking gel or to individual cylindrical gels. Electrophoresis 
was performed for 16-18 hours at 4*^ C at a constant current of 14mA 
per slab gel or 3mA per cylindrical gel. After electrophoresis, 
slab gels were processed for autoradiography or fluorography (see 
section 18,6 below) and cylindrical gels were sliced and the radio­
activity in each slice determined (see section 18.4 below).
13.5. Molecular Weight Standards
The following proteins were used as molecular weight 
standards. The apparent molecular weight (AMW) of each protein is 
given in parentheses.
Carbonic Anhydrase (30K) A gift from Dr. H.G. Nimmo
Lactate dehydrogenase (3 5K) A gift from Dr. J.R. Coggins
Aldolase (40K) A gift from Dr, J.R. Coggins
Pyruvate Kinase (57K) A gift from Dr. J.R. Coggins
Creative Kinase (46K) A gift from Dr.E.J. Milner-White
Ovalbumin (43.5K)
Bovine Serum Albumin (67K).
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13.6 Recovery of Proteins from Acrylamide Gels
After electrophoresis, gels were processed for fluorography 
(see 18.6 below). The radioactive components were located in the 
gel and the area of gel excised and scraped off the backing paper. 
Protein was eluted by incubating gel slices in 200yl of extraction 
buffer at 60°c for 16 hours (Singer, 1978).
Extraction Buffer 
250mM Tris-HCl pH 8.2 
2% (w/v) SDS 
20mM DTT
The gel slice was pelleted and the supernatant removed and 
carrier protein (50yg BSA) added. The supernatant was treated with 
five volumes of acetone and the precipitate collected by centrifu­
gation. The pellet was dissolved in lOM urea.
14. PEPTIDE MAPPING PROCEDURES
Peptide mapping was carried out according to Barber and 
Crumpton (1976). Immune precipitates were reduced and components 
separated by SDS-PAGE. The proteins of interest were eluted from 
the gel as described above (section 13.6) and subjected to repeated 
acetone precipitation prior to lyophilization.
14.1. Digestion
The dried sample was resuspended in lOOyl of O.IM NH^HCO^.
20 yg of diphenyl carbomyl chloride-treated trypsin was added and 
the mixture incubated at 37°C for 2-3 hours. The sample was then 
lyophilised.
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14.2. Ele c trophore sis
The digest was dissolved in 2o yl of water and samples to be 
compared were loaded on either side of the mid-line of a 20 x 20 cm 
thin layer cellulose plate pre-wetted with electrophoresis solvent.
Electrophoresis Solvent
Pyridine-Acetic Acid-Water (111 : 2.7 : 1,000 by volume)
pH 6.5
Electrophoresis was carried out at 3,000 V for 4-5 hours at 
room temperature. After completion of the electrophoresis, the 
plate was air-dried and subjected to chromatography.
14.3, Chromatography
Chromatography was performed perpendicular to the direction 
of electrophoresis in the following solvent.
Chromatography Solvent
Water - Acetic Acid - Pyridine - Butanol (143 : 50 : 143:
204 by volume).
After chromatography, the plates were dried and autoradio­
graphs prepared.
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15. TRYPTIC REMOVAL OF CELL MEMBRANE PROTEINS
Cell membrane proteins were enzymically digested according 
to Hickman and Wong-Yip (1979).
7
5 X 10 cells were harvested from culture, washed twice 
with serum-free RPMl-1640 medium and resuspended in the same medium 
at a concentration of 5 x 10^ cells/ml. DNAase I was added to a 
concentration of 25yg/ml to prevent irreversible clumping of cells 
during digestion. Trypsin was added to a final concentration of 
Img/ml and the suspensions incubated at 37°C for 30 minutes with 
occasional mixing. At the end of the digestion period, FCS was 
added to 20% (v/v) and the cells washed twice in RPMl-1640 medium 
containing 10% (v/v) FCS. Washed cells were resuspended in RPMl- 
1640 medium containing 10% (v/v) FCS to a final concentration of 
10^ cells/ml: an aliquot of cells was removed for immediate analysis
to assess the efficiency of the trypsin digestion. The suspensions 
were incubated overnight at 37°C and analysed by radioimmunoassay 
the following day. In experiments where tunicamycin was employed, 
a three-hour pre-incubation period at 37^c was allowed before 
trypsin-treatment; tunicamycin was present in all solutions used at 
2yg/ml,
16. RADIOIMMUNOASSAY
16.1. Preparation of Microtitre Trays
Radioimmunoassay was performed in flexible polyvinyl 96- 
well microtitre trays. Before addition of cells or antisera, the
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trays were soaked in Img/ml BSA for 1 hour at room temperature.
The trays were rinsed twice with PBS-A and used immediately,
16.2 Preparation of Cells and Assay Procedure
Cells were harvested from culture and washed twice in serum-
free RPMl-1640 medium and then once in serum-free RPMl-1640 medium
containing 0.25% (w/v) gelatin (RPMl-gelatin). The cells were 
7
resuspended at 10 cells/ml in RPMl-gelatin and lOOyl aliquots
dispensed into wells of a BSA-pretreated microtitre tray; each well
contained 25yl of monoclonal antibody. After incubation at room
temperature for 1 hour, the cells were washed three times with RPMl-
125gelatin prior to addition of 30,000 cpm of I-labelled rabbit anti­
mouse Ig (FXab)^ fragments). This mixture was incubated for a further 
hour at room temperature and then the cells were washed four times 
with RPMl-gelatin. The plate was air-dried, individual wells excised 
and the radioactivity in each determined.
17. DETERMINATION OF RADIOACTIVITY
17.1. Counting of Aqueous Samples
Aqueous samples were counted as 1% or 10% (v/v) solutions 
in triton-toluene-PPO scintillant (section 2.3) in a Beckman L5 335 
liquid scintillation spectrometer.
17.2. Counting of Non-Aqueous Samples
An aliquot of sample (5-10%) was spotted onto a glass fibre 
disc and air-dried. The disc was immersed in. two successive baths 
of ice-cold 10% (w/v) TCA for 15 minutes and then rinsed with' 
absolute alcohol. The disc was air-dried and placed in a scintill­
ation vial containing 5ml toluene-PPO scintillant. The sample was
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counted in a Beckman LS liquid scintillation spectrometer. The 
counting efficiences were:
H :— 58%
^^S:- 97%
17.3. Counting of Gamma Radiation
125 131Radioactivity in samples radiolabelled with I or I 
was determined by counting in a Beckman "Biogamma" gamma counter.
17.4. Counting of Polyacrylamide Gel Slices
After electrophoresis, cylindrical gels containing samples 
35 3labelled with S or H were sliced into 1mm slices and the individual 
slices treated with 0.5ml protosol at 60°C for 2 hours in tightly 
capped scintillation vials. 5mls of toluene-PPO scintillation fluid 
was then added to each vial and the samples mixed vigorously. The 
samples were counted in the LS-335 scintillation spectrometer,
17.5. Autoradiography of Slab Gels
After electrophoresis, gels were soaked in two successive 
baths of 20% (v/v) ethanol for 30 minutes and then dried under vacuum 
onto Whatman 3mm filter paper. The dried gel was held in contact 
with X-ray film between two glass plates and was kept in a light­
proof bag for the appropriate exposure time. Exposure was at room 
temperature.
17.6. Fluorography of Slab Gels
Fluorography was performed according to Bonner and Laskey 
(1974). Gels were immersed in three successive baths of dimethyl 
sulphoxide (DMSO) for 30 minutes each. The gel was then immersed in 
a 20% (w/w) solution of PPO in DMSO for 40 minutes, PPO impregnating 
the gel was precipitated by rinsing the gel in running tap water for
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1 hour. The gel was then dried onto paper under vacuum and exposed 
to film at -70C,
17.7. Development of Films
After exposure, autoradiographic and fluorographic images 
were visualized by immersing the film in DX-80 developer for 5 minutes, 
rinsing with water and then immersing in FX-40 fixer for 5 minutes.
The film was rinsed with water for 10 minutes and allowed to air-dry 
prior to inspection.
RESULTS AND DISCUSSION
CHAPTER 1
THE ROLE OF N-LINKED ' OLIGOSACCHARIDES IN ASSEMBLY
AND TRANSPORT OF ETUMAN IMMUNOGLOBULINS AND MAJOR
HISTOCOMPATIBILITY GENE COMPLEX PRODUCTS
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1.1. OBJECTIVES OF INVESTIGATION
The function of N-linked oligosaccharides in control of 
biosynthesis, intracellular transport and functional integrity of 
glycoproteins is the subject of great controversy (reviewed by 
Gibson et al, 1980; see Introduction section 3.8.3) . The study of 
immunoglobulin biosynthesis in human B-lymphoid cell lines is an attract­
ive model system for investigation of the functional role of such 
prosthetic groups for several reasons:
a) antisera of high avidity and known specificity are 
readily prepared to component chains of immunoglobulins 
thus facilitating the isolation of radiochemical 
quantities of proteins from cells actively synthsising 
immunoglobulins ;
b) cell lines are available which synthesise different 
classes of immunoglobulin and which also possess 
secretory and membrane forms of a given heavy chain 
polypeptide; this feature allows one to probe the 
different carbohydrate-mediated control mechanisms 
which may influence the expression of immunoglobulin 
in a particular cellular compartment; and
c) the immunoglobulin synthesised by such cell lines is 
homogeneous in nature, thus permitting a degree of 
electrophoretic resolution of component chains not 
possible when studying immunoglobulin isolated from 
peripheral blood lymphocytes.
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The products of the human major histocompatibility complex 
(MHC), the HLA locus, are also of interest since they represent a 
population of molecules expressed exclusively on the cell membrane.
Again, the influence of the N-linked oligosaccharides of these macro­
molecules on expression of these antigens may be explored, and comparisons 
of the role of carbohydrate side chains in expression of membrane immuno­
globulin and MHC gene products are possible.
The objectives of the experiments described below were to 
assess the role of N-linked oligosaccharides in:
a) intracellular assembly of immunoglobulins and MHC gene 
products ;
b) polymerisation of immunoglobulins and acquisition of 
J-chain;
c) secretion of immunoglobulins, and;
d) membrane localisation of immunoglobulins and MHC gene 
products.
The experimental approach was to treat cells with tunicamycin, 
an inhibitor of N-glycosylation of proteins (Tkacz and Dampen, 1975;
Lehle and Tanner, 1976), and to specifically isolate radiolabelled 
proteins from various cellular compartments using a variety of anti­
sera. Proteins isolated from control or tunicamycin-treated cell 
lysates and supernates were analysed by high resolution SDS-PAGE.
1.2. ASSEMBLY OF IMMUNOGLOBULINS
1.2.1. IgM and IgG
The B-lyraphoblastoid lines Bri-8 and Bee-11 synthesise IgM
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and IgG respectively (Singer, 1978; Singer and Williamson, 1980;
Methods, Table 2). Aliquots of log-phase cultures of Bri-8 and
35Bec-11 cells were treated with tunicamycin, radiolabelled with S- 
methionine, and cell lysates prepared. Aliquots of lysates derived 
from tunicamycin-treated or control cells were treated with rabbit 
antibody to human À-light chain (Bri-8) or human K-light chain (Bec-11) 
and GARIg. The immunoprecipitates were collected, washed, and re­
duced: material derived from control and tunicamycin-treated cells
were compared on adjacent tracks of a 10% (w/v) SDS-PAGE slab gel.
Figure 1,1, illustrates the profiles of radioactive components 
resolved by SDS-PAGE. Glycosylated y-chains were precipitated from 
control Bri-8 lysates using RAHX, and non-glycosylated y-chains were 
specifically inmunoprecipitated from lysates of tunicamycin-treated 
Bri-8 cells by the same antibody. A similar result was obtained in 
Bec-11 cells. Multiple forms of glycosylated y-chains were isolated 
from lysates of control Bec-11 cells using RAHk, and the same antibody 
specifically immunoprecipitated non-glycosylated y-chains from lysates 
of tunicamycin-treated cells. (The complex SDS-PAGE profiles ob­
tained, for Bec-11 IgG are discussed in detail in chapter 2.) Since 
anti-light chain antibodies were employed as the precipitating reagent 
in these experiments, heavy chains could be immunoprecipitated, and 
hence visualised by fluorographic analysis, if and only if they were 
associated with light chain. The data of figure 1.1. strongly suggest 
that the interaction of immunoglobulin y- and y-heavy chains with 
light chains during biosynthesis is not impaired by the absence of N- 
linked oligosaccharides. This is preliminary evidence to suggest 
that assembly of IgM and IgG is independent of N-glycosylation processes
FIGURE 1.1.
Assembly of IgM and IgG
Aliquots of 2.5 K 10 Bri—8 and Bee—11 cells were harvested 
from log-phase cultures and incubated at 37°C for 90 minutes in the 
presence or absence of 2 yg/ml tunicamycin in complete medium. The 
cells were then washed twice in labelling medium and resuspended in 
0.1 ml of the same medium supplemented with 200 vCi ^^S-methionine 
(Methods, 8.3.). After incubation at 37°C for 90 minutes, the 
labelled cells were washed twice with 1 ml aliquots of ice-cold TKM 
buffer and lysates prepared in 250 yl 3D-TKM (Methods, 9.).
Immunoprécipitation was carried out by treating 40 y1 
aliquots of lysate with 1 yl rabbit antiserum to human k - or X-light 
chain and an equivalence of GARIg (Methods, 10.2.1.). Immuno­
precipitates were harvested by centrifugation and washed by pelleting 
through a two-step discontinuous sucrose gradient in 3D-TKM (Methods,
10.3.). Samples were dissolved in 25 yl of reducing SDS-PAGE loading 
buffer (Methods, 13.1,), boiled for 2 minutes and electrophoresed on 
a 10% (w/v) acrylamide slab gel (Methods, 13. ). After electro­
phoresis the gel was processed for fluorography (Methods, 17.6.).
Key
Con - Immunoglobulin isolated from lysates of 
control cells 
Tun - Immunoglobulin isolated from lysates of 
tunicamycin-treated cells.
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The data of figure 1.1. do not, however, formally exclude 
the possibility that only 'half molecules' (HL) are formed or that 
the interaction between heavy chains may be critically dependent on 
the presence of N-linked carbohydrate side chains. Thus, this data 
does not allow any conclusions to be drawn regarding the assembly of 
completed 7S IgG or 8S IgM molecules. The molecular size of assembled 
immunoglobulins is investigated below (section 1.3.).
1.2.2. IgA and IgE
Biosynthetic assembly of IgA and IgE cultured in the presence 
and absence of tunicamycin was investigated using identical protocols 
to those employed for analysis of assembly of IgM and IgG (section 1.2.1.) 
The B-lymphoblastoid line Dakiki Arosros I (Steinitz and Klein, 1980) 
was used for the study of IgA biosynthesis, and the myeloma B-cell line 
U266BL (Nillson ^  al, 1970) was employed for analysis of IgE bio­
synthesis.
Figure 1.2. demonstrates that the RAHX antiserum was capable 
of specifically immunoprecipitating glycosylated a-heavy chains from 
lysates of control Dakiki Arosros I cells and non-glycosylated a-chains 
from the lysates of tunicamycin-treated cells. Since RAHX was used 
to precipitate the radiolabelled IgA, a-chains should be isolated only 
if associated with X-light chains. As a-chains are indeed present in 
the SDS-PAGE profiles of reduced immunoprecipitates, this data implies 
that association of a-chains and light chains occurs in the absence of 
N-linked carbohydrate side chains.
The corresponding experiment in U266BL cells is also pre­
sented in figure 1.2. RAHX was employed as the precipitating anti­
body and was capable of precipitating IgE from lysates of control and
FIGURE 1.2.
Assembly of IgA and IgE
Aliquots of 2,5 x 10^ Dakiki Arosros 1 or U266BL cells were 
harvested from log-phase cultures and incubated at 37^C for 90 
minutes in the presence or absence of 2 ug/ml tunicamycin in complete 
medium. The cells were then washed twice in labelling medium and 
resuspended in 0.1 ml of the same medium supplemented with 200 viCi of 
^^S-methionine (Methods, 8,3.), After incubation at 37°C for 90 
minutes, the labelled cells were washed twice with 1 ml aliquots of 
ice-cold TKM buffer and lysates prepared in 250 pi 3D-TKM (Methods, 
9.) .
Immunoprecipitates were prepared by treating 30 pi aliquots 
of lysate with RAHX and an equivalence of GARIg (Methods, 10.2.1.). 
After harvesting and purification on two-step discontinuous sucrose 
gradients (Methods, 10.3.) the samples were dissolved in 25 pi of 
SDS-PAGE loading buffer and boiled. Analysis was performed on a 
10% (w/v) acrylamide slab gel (Methods, 13. ). The gel was pro­
cessed for fluorography (Methods 17,6.).
Key: -
Con - Immunoglobulin isolated from lysates of
control cells 
Tun - Immunoglobulin isolated from lysates of
tunicamycin-treated cells.
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tunicamycin-treated U266BL cells. Glycosylated e-chains were evident 
in the profiles obtained for material immunoprecipitated from control 
cell lysates and multiple forms of non-glycosylated e-chains were 
demonstrable in the corresponding profiles of tunicamycin-treated 
cell lysates of U266BL cells. The multiplicity of non-glycosylated 
e-chains in lysates of tunicamycin-treated U266BL cells is believed 
to be due to use of tunicamycin at non-limiting concentrations, and 
that the species resolved represent intermediate forms between totally 
glycosylated and completely oligosaccharide free e-chains. Once more 
the data infers that assembly of immunoglobulin heavy and light chains 
is occuring independently of N-glycosylation of the component chains.
1.2.3. Limitations
Although the above data (sections 1.2.1. and 1.2.2.) strongly 
suggest that immunoglobulin assembly occurs in the absence of N- 
glycosylation of the immunoglobulin heavy chain, direct evidence for 
formation of macromolecules is lacking. The data illustrate
that HL molecules have been formed but do not conclusively demonstrate 
the presence of H^L^ structures. In the case of IgG and IgE, the 
detection of 7S structures is possible by analysis of radioactive immuno­
globulins on low percentage acrylamide gels under non-reducing conditions. 
The detection of IIS IgA and 19S IgM polymeric immunoglobulins is more 
difficult.
The principal intracellular forms of IgM and IgA are the 8S 
and 7S monomers respectively (see Introduction, section 3.7.).
Formation of polymers is believed to occur immediately before secretion 
and therefore it is reasonable to expect 19S IgM and 11s IgA to be 
minority species in the cytoplasm of cells actively synthesising immuno­
globulin, A second approach to the problem is to assay for the
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presence of J-chain in IgM or IgA isolated from cells synthesising 
these immunoglobulins. However, this approach is subject to the 
same problems as that of assaying for 19S IgM itself; that is, J- 
chain addition is believed to be a late event during the intracellular 
processing of IgM or IgA.
1.2.4. Assembly of HLA-A,-B and -C Alloantigens
Aliquots of log phase cultures of Bjab and Bri-8 cells were 
treated with tunicamycin, biosynthetically radiolabelled, and cell 
lysates prepared: control cell lysates were also prepared. Aliquots
of lysate were then treated with RAHg^M and S.aureus imraunoadsorbent. 
Bound complexes were eluted from washed bacteria and analysed by SDS- 
PAGE.
Figure 1.3. illustrates the profiles obtained. Material 
specifically immunoprecipitated from lysates of control cells contained 
a single polypeptide of AMW 44,000 daltons; this represents the poly­
morphic HLA-A,-B, or -C chain. This component was also present in 
immunoprecipitates derived from lysates of tunicamycin-treated cells, 
but an additional component of AMW 42,000 daltons was also resolved in 
the SDS-PAGE profiles of thes immunoprecipitates. HLA-A and -B 
antigens contain a single N-linked oligosaccharide moiety at asparagine 
86 (Parham et al, 1977). The finding of a 42,000 dalton species in 
association with microglobulin in tunicamycin-treated cells is 
consistent with the 42,000 chain being the non-glycosylated counter­
part of the 44,000 dalton chain found in control cells.
The data of figure 1.3. strongly suggest that the interaction 
of HLA-A,-B or -C chain with g^ microglobulin does not depend upon the 
N-glycosylation of asparagine 86 of the HLA-A, -B or -C chain. These
FIGURE 1.3.
Assembly of HLA-A,-B,-C - gg.Microglobulin Complexes
2.5 X 10^ Bri-8 or Bjab cells were harvested from culture, 
treated with tunicamycin, biosynthetically radiolabelled, and lysed 
as described in the legend to figure 1.2. (Methods, 8,*9).
Immunoprecipitates were prepared by adding 5 lil of RAHg^M 
to SO ]il aliquots of lysate and then adding 100 yl of a 10% (v/v) 
suspension of the S.aureus immunoadsorbent (Methods, 10.2.2.).
After overnight incubation at 4^0, the bacteria were washed three 
times with 1 ml of ice-cold 3D-TKM, and bound immune complexes eluted 
by boiling the organisms for 2 minutes in 100 yl 2% (w/v) SDS.
The bacteria were pelleted, the supernate removed and treated with 
500 yl acetone to precipitate protein. The precipitate was dissolved 
in 25 yl of reducing SDS-PAGE loading buffer, boiled, and analysed on 
a 10% (w/v) acrylamide slab gel (Methods, 13.). After electrophoresis 
the gel was processed for fluorography (Methods, 17.6.).
Key: -
Con - Material derived from lysates of control
cells
Tun - Material derived from lysates of tunicamycin-
treated cells.
-133-
Assem bly of HLA-j32 M icroglobulin Complexes 
B R I-8  B R I-8
G LA N IM R  
Con Tun Con Tun Con Tun
Actin —I
H L A + C H O -^
HLA -  CHO
©
crq
F
©
-134-
conclusions are based on the same arguement made above for immuno­
globulin assembly; that is, since is the precipitating anti­
body, HLA-A,-B or -C chains should be immunoprecipitated if, and only 
if, they are associated with microglobulin. Since HLA-A,-B and 
-C chains are present in immunoprecipitates derived from either control 
or tunicamycin-treated cells, it is reasonable to suggest that the 
interaction of the 44,000 dalton chain with g^ microglobulin does not 
depend on N-glycosylation of the former.
1.3. MOLECULAR SIZE OF ASSEMBLED'IMMUNOGLOBULINS
1.3.1. IgG and IgE
Radiolabelled IgG was isolated, by specific immunoprécipitation, 
from lysates and supernates of control and tunicamycin-treated Bee-11 
cells. Radiolabelled IgE was isolated from lysates of control and 
tunicamycin-treated U266BL cells. After washing, the immunoprecipitates 
were analysed on a 6% (w/v) acrylamide gel under non-reducing conditions. 
The data obtained are shown in figure 1.4.
Bec-11 cells are known to secrete IS IgG (Singer and William­
son, 1979; Singer, 1978). Using biosynthetically radiolabelled IgG 
secreted from control Bec-11 cells as an internal marker and BSA as an 
independent marker, it is clear from the mobilities of material isolated 
from lysates of control and tunicamycin-treated Bec-11 cells that IS 
IgG is the predominant species isolated. The molecular size of IgG 
secreted from tunicamycin-treated Bec-11 cells also appears to be 7S.
The data are therefore consistent with the hypothesis that N-lihked 
oligosaccharide moieties do not exert any influence on the assembly
-135-
of IgG macromolecules.
Two major species were detected in the SDS-PAGE profiles 
of IgE isolated from control and tunicamycin-treated U266BL cells.
The major component in both immunoprecipitates migrated with a 
slightly slower electrophoretic mobility than the BSA marker : its
AMW was therefore of the order of 70-80K which would be consistent 
with the hypothesis that this species might represent an HL inter­
mediate .
The other species present on the profiles had an electro­
phoretic mobility comparable to that of 7S IgG; this is believed to 
represent 7S IgE. Significantly, the material isolated from lysates 
of control U266BL cells had a higher AMW than the corresponding 
material in tunicamycin-treated cells. This observation supports the 
hypothesis that these bands represent 7S IgE since the IgE isolated 
from lysates of tunicamycin-treated U266BL cells would contain non­
glycosylated e-chains, of lower AMW than their glycosylated counter­
parts, and hence the assembled complex would be of lower AMW than 7S 
IgE isolated from lysates of control U266BL cells.
The data are therefore consistent with the hypothesis that 
N-glycosylation of immunoglobulin heavy chains is not required for 
efficient assembly of molecules. The analysis is now extended
to encompass assembly of IgM and IgA molecules to the and polymer
states.
1.3.2. IgM and IgA
In accord with the above hypothesis, SDS-PAGE analysis of 
immunoprecipitated IgM and IgA from lysates and supernates of control 
and tunicamycin-treated Bri-8 and Dakiki Arosros-1 cells demonstrated
FIGURE 1.4.
Molecular Size of Assembled IgG and'IgE
Aliquots of 2.5 x 10^ Bec-11 or U266BL cells were harvested
from log phase cultures and treated for 3 hours at 37^C in the presence
or absence of 2 yg/ml tunicamycin in complete medium. The cells were
washed twice in labelling medium resuspended in 0.1 ml of the same
35
medium supplemented with 250 uCi of S-methionine and incubated at 
37°C for 90 minutes. After labelling the Bec-11 cultures were di­
vided into two equal aliquots. A pulse-chase was performed on one 
aliquot and a lysate prepared from the other; the final volume of 
both samples was 250 tl. Lysates were prepared from the U266BL 
sample (Methods, 8,3;9).
Immunoprécipitation was effected by treating 50 \il aliquots 
of lysate or supernate with 1 yl rabbit anti-light chain antibody, 
plus an equivalence of GARIg (Methods, 10.2.1.). Washed precipitates 
were dissolved in 25 Ul non-reducing SDS-PAGE loading buffer, boiled, 
and loaded onto a 6% (w/v) acrylamide slab gel (Methods, 13). After 
electrophoresis, the gel was processed for fluorography (Methods, 17.5.) 
Key:-
IC - Intracellular
EC - Extracellular
Con - Immunoglobulin isolated from lysates or
supernates of control cultures.
Tun - Immunoglobulin isolated from lysates or
supernates of tunicamycin-treated cultures.
-136-
HKC-11 
1Ç. KÇ 
BSA CON TUN TUN CON
0  Or i R i r\
BSA ---- * -
' ...
CHOj
©
FIGURE 1.5.
Molecular Size of Assembled IgM and IgA
Aliquots of 2.5 X 10^ Bri-8 or Dakiki Arosros-1 cells were 
harvested from culture and treated in the presence or absence of 
2yg/ml tunicamycin for 3 hours at 37^C in complete medium prior to 
biosynthetic radiolabelling (Methods, 8.3.). 500 yCi of ^H-leucine
was used as label for Bri-8 cultures and 500 yci ^^S-methionine was 
employed with Dakiki Arosros-1 cultures. Pulse-chase experiments 
were performed (Methods, 8.3.) and immunoprécipitation performed on 
aliquots of chase supernate or lysate.
Washed immune precipitates, generated using RAHy or RAHct, 
were dissolved in non-reducing SDS-PAGE loading buffer, boiled, and 
analysed on a 6% (w/v) acrylamide gel (Methods, 13). The gel was 
processed for fluorography (Methods 17,6.). Samples derived from 
Bec-11 lysates (see legend to figure 1.4.) were also electrophoresed 
as marker proteins.
Key; -
IC - Intracellular
EC - Extracellular
Con - Immunoglobulin isolated from lysates and
supernates of control cultures.
Tun - Immunoglobulin isolated from lysates and
supernates of tunicamycin-treated cultures.
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that 8S IgM and 7S IgA structures were formed in the absence of N- 
glycosylation (figure 1.5.),
Material of slower electrophoretic mobility than the marker 
7S IgG proteins derived from lysates of control and tunicamycin-treated 
Bec-11 cells was specifically immunoprecipitated from lysates and 
supernatants of Bri-8 cells using RAHy and GARIg. The mobility of 
the isolated components is consistent with the notion that they 
represent 8S IgM. The 8S IgM species was present in lysates of 
control and tunicamycin-treated Bri-8 cells and in the supernates of 
control cultures. Also present in each of these profiles was material 
located at the origin of each track which had failed to enter the gel.
This is believed to be 19S IgM. These data illustrate that lack of 
N-glycosylation in IgM-producing cells does not interfere with the 
assembly of 8s IgM monomers and tentatively indicates that 19S IgM 
pentamer formation also occurs independently of N-glycosylation.
Analysis of IgA assembly in Dakiki Arosros-1 cells demon­
strated that material of comparable AMW to Bec-11 7S IgG could be 
immunoprecipitated from control and tunicamycin-treated cells. Once 
again these data are consistent with the hypothesis that N-glycosyl­
ation is not important in the control of assembly of complete immuno­
globulin molecules. No high molecular weight material was observed in 
IgA-containing immunoprecipitates derived from Dakiki Arosros-1 cells 
and this is consistent with the interpretation that these cells are secreting 
monomeric IgA,»
1.3.3. Assembly of J-Chain into Polymeric Immunoglobulins
In an attempt to provide more substantial data pertaining to 
the intracellular assembly of the 19S IgM pentamer, radiolabelled IgM 
was isolated from lysates and supernatants of control and tunicamycin-
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treated cultures of Bri-8 cells. After reduction, the immuno­
precipitates were analysed by SDS-PAGE, and the fluographic pattern 
of radioactive components resolved is shown in figure 1.6.
The data fail to show the presence of J-chain in either
glycosylated or non-glycosylated IgM isolated from lysates of Bri-8
cells. However, the apparent absence of J-chain from glycosylated
IgM isolated from Bri-8 culture supernatants suggests that conditions
for the detection of J-chain itself are not optimal under these
experimental conditions. In experiments studying the biosynthesis
35and fate of murine J-chain (Mosmann et al, 1979) S-cystine was 
employed as radioactive tracer. This is a more appropriate radio- 
label in experiments studying J-chain due to the large number of 
cysteine residues in the molecule: in the above experiments, tritiated
leucine was the radioactive amino acid used.
Experiments addressing the question of integration of J- 
chain into polymeric immunoglobulins have been performed in the mouse. 
In studies of IgM polymerisation, it was found that pentamer formation 
and addition of J-chain to 19S IgM was not inhibited by addition of 
tunicamycin to a murine plasmacytoma synthesising IgM (Tartakoff 
and Vassalli, 1979), In the IgA-producing murine plasmacytoma MOPC 
315, it was demonstrated that J-chain was covalently bound to IgA in 
cells treated with tunicamycin; covalently bound J-chain could also 
be demonstrated in IgM isolated from tunicamycin treated cells 
(Mosmann and Williamson, unpublished observations).
The murine data suggest that J-chain is successfully added 
to non-glycosylated polymeric immunoglobulins. This would indicate 
that the failure to find J-chain in IgM synthesised and secreted by
FIGURE 1.6.
Apparent Absence of J^hain from Non-Glycosylated 19S IgM
Aliquots of 2.5 X 10^ Bri-8 cells were treated with tuni­
camycin as described in the legend to figure 1.5, and biosynthetically
3
labelled with 500 yCi H-leucine: control cultures were also pre­
pared. After a 2 hour labelling the cultures were divided into 
equal aliquots and a pulse-chase performed on one aliquot and a 
lysate prepared in 3D-TKM from the other. The final volume of each 
sample was 250 yl (Methods, 8,9.).
IgM was specifically immunoprecipitated from 50 y1 aliquots 
of lysate or supernate by addition of 1 yl RAHy plus an equivalence 
of GARIg (Methods 10.2.1.). The immunoprecipitates were collected 
by centrifugation, and washed by centrifugation through a two step 
discontinuous sucrose gradient in 3D-TKM (Methods, 10.3.). Samples 
were dissolved in 25 yl reducing SDS-PAGE loading buffer, boiled for 
2 minutes, and analysed on a 15% (w/v) acrylamide slab gel. The 
gel was processed for fluorography (Methods, 17.6.).
The region of the gel where J-chain would be expected to 
migrate is indicated on the figure. microglobulin was visualised
in an adjacent track on the same gel (not shown).
IC - Intracellular
EC - Extracellular
Con - IgM immunoprecipitated from lysates or
supernates of control cultures.
Tun - IgM isolated from lysates of tunicamycin-
treated cells.
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Bri-8 cells could be due to insensitivity of fluorographic detection 
in the experimental system rather than absence of J-chain from the 
IgM pentamer, although alternative explanations are possible, (for 
example, lack of J-chain in Bri-8 cells or a more rigorous requirement 
for N-glycosylation of y- or a-chains in human cells than in murine 
cells prior to J-chain addition) .
1.4. SECRETION OF IMMUNOGLOBULINS
1.4.1. IgM and IgA
The efficiency of secretion of immunoglobulins from normal 
and tunicamycin-treated cells was investigated by isolating radio­
labelled immunoglobulin from lysates and culture supernates of control 
and tunicamycin-treated cells by immunoprécipitation. Isolated 
immunoglobulins were analysed by SDS-PAGE.
The cell line Bri-8 was employed for analysis of IgM 
secretion in control and tunicamycin-treated cells. IgM was isolated
from cell lysates prepared after a 90 minute pulse labelling and
secreted IgM was immunoprecipitated from culture supernatants after 
a 5 hour pulse-chase. Figure 1.7. illustrates that glycosylated 
y-chains were present in culture supernatants of control Bri-8 cells. 
The secretion of IgM from tunicamycin-treated Bri-8 cells was greatly 
inhibited as indicated by the almost total absence of non-glycosylated 
y-chains in the supernatants of such cultures. The trace amount of 
non-glycosylated y-chain found in such cell supernates was always 
accompanied by the presence of glycosylated y-chains. This suggests 
that the presence of a small amount of carbohydrate may be sufficient
FIGURE 1.7.
Inhibition of Secretion of Non-glycosylated IgM
2,5 X 10^ Bri-8 cells were harvested from log-phase 
cultures and incubated in the presence or absence of 2 yg/ml tuni­
camycin for 3 hours at 37°C in complete medium. The cells were washed
twice in labelling medium and then biosynthetically labelled with 
35200 yCi of S-methionine, Incorporation was allowed to proceed for 
90 minutes whereupon the culture was divided into equal aliquots and 
a 5 hour pulse-chase performed on one aliquot and a lysate prepared 
frcm the other (Methods, 8,9.).
IgM was isolated from aliquots of lysate and supernate by 
specific immunoprécipitation using 1 yl RAHy plus an equivalence of 
GARIg (Methods 10.2.1.). Washed immune precipitates were dissolved 
in 25 yl reducing SDS-PAGE loading buffer and analysed on 12.5%
(w/v) acrylamide gel (Methods, 13). After electrophoresis, the gel 
was processed for fluorography (Methods 17.6.).
Keyi-
IC - Intracellular
EC - Extracellular
Con - IgM isolated from lysates and supernates
of control cultures.
Tun - IgM isolated from lysates and supernates of
tunicamycin-treated cells.
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to enable the cell to secrete IgM, However, the secretion of IgM 
containing totally non-glycosylated y-chains was never observed.
This data strongly suggests that the N-linked oligosaccharide prosthetic 
groups of y-chains are important in control of secretion of IgM, and 
may represent a mandatory structural requirement for this biosynthetic 
event. Similar data have been obtained for other IgM-secreting cells 
(e.g. Bjab and Namalva) ,
Figure 1.8. also shows the results obtained from a similar 
experiment performed on the IgA secreting B-lymphoma cell line Dakiki 
Arosros 1. IgA was efficiently secreted from control Dakiki Arosros 
1 cells but IgA containing non-glycosylated a-chains was never isolated 
from culture supernates-of tunicamycin-treated Dakiki Arosros 1 cells. 
Thus, IgA secretion seems to depend on the presence of N-linked oli­
gosaccharide moieties on the a-chain, in the same way that N-glycosylation 
of a-chains appears to be mandatory for secretion of IgM.
1.4.2. IgG and IgE
Radiolabelled IgG was isolated, by specific immunoprécipitation, 
from lysates and supernates of control and tunicamycin-treated cultures 
of Bec-11 cells. The washed immune precipitates were reduced and 
analysed by SDS-PAGE.
Figure 1.9. demonstrates that two y-chain polypeptides were 
isolated from supernates of control Bec-11 cultures but that only one 
y-chain species could be immunoprecipitated from supernates of tunicamy­
cin-treated cultures.
This data suggests that;
a) non-glycosylated IgG is efficiently secreted from 
tunicamycin-treated Bec-11 cells, and;
FIGURE 1.8.
Inhibition of Secretion of Non-KSlycosylated IgA
Tunicamycin-treatment, biosynthetic labelling and pulse- 
chase treatments of Dakiki Arosros-1 cells were as described for 
Bri-8 cells in the legend to figure 1.7,
Aliquots of lysate and supernate were treated with 1 \il 
RAHa and an equivalence of GARIg (Methods 10.2,1.) to specifically 
immunoprecipitate IgA. Washed immunoprecipitates were dissolved 
in 25 nl of reducing SDS-PAGE loading buffer, boiled, and electro­
phoresed on a 10% (w/v) acrylamide slab gel (Methods, 13), The gel
was processed for fluorography (Methods 17.6.),
Key : -
Con - IgA derived from lysates and supernates
of control cultures 
TM - IgA derived from lysates and supernates
of tunicamycin-treated cultures.
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FIGURE 1.9.
Secretion of Non-Glycosylated IgG
The protocols used for tunicamycin-treatment, labelling 
and pulse-chase of Bec-11 cells were identical to those described 
for Bri-8 cells in the legend to figure 1.7. (Methods, 8,9).
Immunoprécipitation was carried out on aliquots of lysate 
and supernate by addition of 1 yl of RAHk plus an equivalence of 
GARIg (Methods 10.2.1.). Washed immunoprecipitates were dissolved 
in reducing SDS-PAGE loading buffer and analysed on a 10% (w/v) 
acrylamide slab gel (Methods, 13) and the pattern of radioactive 
components visualised by fluorography (Methods, 17.6.).
Key :-
IC - Intracellular
EC - Extracellular
Con - IgG immunoprecipitated from lysates and
supernates of control cultures.
Tun - IgG imiriunoprecipitated from lysates and
supernates of tunicamycin-treated cultures.
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b) only one secretory y-chain polypeptide is synthesised 
by Bec-11 cells.
An identical experiment performed on U266BL myeloma cells 
suggested that IgE could be secreted from tunicamycin-treated cells 
(figure 1.10, panel A). However, the e-chains specifically immuno­
precipitated from culture supernates of tunicamycin-treated U266BL cells 
had identical electrophoretic mobilities to those isolated from super­
nates of control cultures. Based on the assumption that this effect 
was due to residual N-glycosylation of e-chains after a 3 hour tuni­
camycin- treatment , the experiment was repeated but with an extended 
(12 hour) pre-treatment with tunicamycin prior to pulse-chase. An 
identical result was obtained: e-chains isolated from supernates of 
control and tunicamycin-treated cultures of U266BL cells had identical 
electrophoretic mobilities as judged by high resolution SDS-PAGE 
(figure 1.10, panel B). However, in both instances the AMW of the 
secreted e-chains is greater than that of the glycosylated intra­
cellular e-chains. This is indicative of extensive post-synthetic 
modification of e-chains. One possible explanation is that the post­
synthetic modification events are 0-glycosylation events. Such 
processes would occur independently of N-glycosylation and would not 
be inhibited by tunicamycin. The objection to such an hypothesis is 
that the e-chain secreted from tunicamycin-treated cells would still 
be expected to have a lower AMW than its counterpart secreted from 
control cells since tunicamycin-treatment would have prevented addition 
of N-linked oligosaccharides to the former. Therefore, equal 
modification of e-chains in control and tunicamycin-treated U266BL 
cells would result in an AMW difference consistent with absence of
FIGURE 1.10.
Secretion of Non-Glycosylated IgE
Protocols for generation of lysates and supernates from 
control and tunicamycin-treated cultures of U266BL cells were 
identical to those described in the legend to figure 1,7. (Methods, 
8,9) .
IgE was isolated from aliquots of lysate or supernate by 
addition of 1 yl RAHe plus an equivalence of GARIg (Methods, 10,2.1,), 
Washed immunoprecipitates were dissolved in 25 yl of reducing SDS- 
PAGE loading buffer, boiled, and electrophoresed on a 10% (w/v) 
acrylamide gel (Methods, 13), The gel was processed for flurography 
(Methods 17.6,).
Panel A 3 hour pretreatment with tunicamycin.
Panel B - 12 hour pretreatment with tunicamycin,
Key:-
IC - Intracellular
EC - Extracellular
Con - IgE derived from lysates and supernates
of control cultures,
Tun - IgE derived from lysates and supernates
of tunicamycin-treated cultures,
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N-linked oligosaccharides from the e-chain secreted from the latter 
cells. This is clearly not the case (figure 1.10, panel B), Hence, 
one must propose two alternative explanations :
a) U256BL cells contain an extremely large intracellular 
pool of dolichol phosphates which is not depleted even 
after 12 hours treatment with tunicamycin, or;
b) the post-synthetic machinery, postulated to be 0- 
glycosylation in this instance, compensates for the 
absence of N-linked oligosaccharides by adding 
carbohydrate side chains to the N-glycosylation sites 
themselves, or to alternative sites, to render the
e-chain "fully glycosylated".
The extent of glycosylation of e-chains secreted from 
tunicamycin-treated U266BL cells is currently being investigated.
The nature of the data shown in figure 1.10. renders meaningful 
interpretation of the data difficult. The least controversial con­
clusion is one which proposes that the N-linked oligosaccharide 
moieties of e-chains are not critical for secretion of IgE but that 
other glycosylation mechanisms may operate which provide oligo­
saccharide side chains capable of delivering the correct signal for 
secretion of IgE from U266BL cells.
1.4.3. Trends in Immunoglobulin Secretion and Possible
Explanations
The data presented in this section demonstrates an 
apparently differential function of the N-linked oligosaccharides 
of human immunoglobulin heavy chains in the control of active 
secretion of assembled immunoglobulin molecules. The presence of
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N-linked oligosaccharides was apparently mandatory for the efficient 
secretion of IgM and IgA but non-N-glycosylated IgG and, perhaps,
IgE were efficiently secreted from cells synthesising these classes 
of immunoglobulin.
The data are in good agreement with the results of similar 
studies in other species. The requirement for glycosylation of 
y-chains for efficient secretion of IgM appears to be universal : 
treatment of murine (Hickman and Kornfeld, 1978}, human (this thesis) 
and rabbit lymphocytes (Williamson et al, unpublished) with tuni­
camycin results in almost total abrogation of IgM secretion. The 
data presented herein has not been rigorously quantitated, but it 
strongly argues in favour of the notion that IgM containing only 
non-glycosylated y-chains can not be secreted from B-lymphocytes. 
Residual secretion of IgM from tunicamycin treated murine plasma­
cytoma cells (Hickman and Kornfeld, 1978) may be accounted for in 
terms of 'mixed' molecules which contain not only non-glycosylated 
y- chains, but also one (or, in the case of pentamers, several) 
glycosylated y-chain(s) which serves to deliver the necessary 
biochemical signal for secretion of the 'mixed' molecule: high
resolution SDS-PAGE analysis of the secreted product would reveal 
apparently efficient secretion of IgM containing non-glycosylated 
y-chains. The apparent exception to the stringency of requirement 
for N-glycosylation of y-chains for efficient secretion is the cell 
line WEHl-279 (Sibley and Wagner, 1981). However, high resolution 
analysis of the secreted product was not performed and the argue- 
ments regarding secretion of 'mixed' molecules may be advanced to 
explain this data.
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The finding that non-glycosylated IgM is not efficiently 
secreted from B-lymphocytes is almost unanimous. Equally ubiquitous 
is the observation that non-glycosylated IgG is efficiently secreted 
from tunicamycin-treated cells synthesising this immunoglobulin 
isotype. These findings are made not only in the human system, but 
also in the rabbit (Williamson e^ al, unpublished) and in the mouse 
(Hickman and Kornfeld, 1978). However, the most elegant demonstration 
of the differential role of N-linked oligosaccharides in secretion of 
IgM and IgG came from studies of a cloned hybridoma, X63/38C-13, which 
synthesises and secretes both IgM and IgG, Upon tunicamycin-treatment 
of the hybridoma, it was found that IgG was efficiently secreted in the 
non-glycosylated form whereas IgM was not (Blatt and Haimovich, 1981).
Ccmparatively little data is currently available on the role 
of N-lihked carbohydrate moieties on the efficiency of secretion of 
IgA and IgE. However, with respect to secretion of IgA, the data 
presented above is in agreement with findings in the murine.plasma­
cytoma MOPC 315; that is, non-glycosylated IgA is not efficiently 
secreted from tunicamycin-treated cells (Hickman and Wong-Yip, 1978).
In the case of IgE, however, the data herein and that published for the 
rat plasmacytoma are in disagreement. Treatment of the rat plasma­
cytoma with tunicamycin resulted in inhibition of secretion of IgE 
from that cell line (Hickman et al, 1977). However, the human myeloma 
cell line studied here, Ü256BL, continues to secrete IgE even after 
prolonged culture in tunicamycin (see figure 1.10). The paradoxical 
finding of e-chains of apparently identical AMW in supernates of 
control and tunicamycin-treated U266BL cells has been discussed 
(section 1.4,2.). It may be that U266BL cells possess alternative
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glycosylation mechanisms which allow for addition of carbohydrate 
in the absence of normal N-glycosylation mechanisms : this may be a
reflection of the state of differentiation of this cell. In the 
absence of such alternative glycosylation pathways, secretion of 
non-glycosylated IgE may be inhibited as has been demonstrated in 
the rat (Hickman et al, 1977), This would imply that oligo­
saccharide moieties, irrespective of the nature of their chemical 
linkage to the polypeptide chain, are a prerequisite for the 
efficient secretion of IgE,
Examination of carboxy-terminal sequences of human immuno­
globulin heavy chains reveals that y- and a- heavy chains possess an 
extension of 19 amino acids at their C-termini: such extensions are 
absent in e and in all y-subclasses. The amino acid sequences of the 
y- and a-heavy chain C- teminal extensions are greater than 58% 
homologous. The penultimate C-terminal residue is a cysteine which 
is involved in inter-chain disulphide bonding between the subunits of 
polymeric immunoglobulins and J-chain. The asparagine residue 14 
residues proximal to the C-terminus is part of the asn-x-ser/thr 
sequence necessary for N-glycosylation and is, indeed, glycosylated 
(Shimizu et al, 1971). However, it is interesting to speculate that 
this glycosylation site is critical in efficient transport and 
secretion of IgM and IgA, IgG and IgE lack such a site and are 
efficiently secreted without N-linked carbohydrate moieties at other 
sites on the molecule. Several possible functions could be en­
visaged for N-linked oligosaccharides located at the asparagine 
residue noted above:
a) enhanced solubility of the IgM molecule;
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b) adoption of the correct configuration for polymer­
isation;
c) promotion of J-chain integration via glycosylation 
of J-chain or y-chain, and;
d) a signal for transport of IgM through the membranous 
elements of the cell.
The data of Tartakoff and Vassalli (1979) would argue 
against alternatives b) and c) since their data indicates that the 
polymerisation of murine IgM and integration of J-chain occur in 
tunicamycin-treated cells, which does not favour a model based on 
carbohydrate-mediated control of conformation(s) necessary for poly­
merisation.
There are reports in the literature of carbohydrate having 
a role in the hydrophobicity of certain glycoproteins. In the case 
of human fibroblast interferon, inhibit of N-glycosylation by tuni­
camycin treatment of the fibroblasts inhibited neither secretion of 
interferon nor the biological activity of the molecule. However, 
there was an increase in hydrophobicity of the molecule (Mizrahi 
et al, 1978), In the case of a large molecule, such as IgM, the 
presence of carbohydrate moieties may critically influence the 
stability of the molecule in an aquaeous environment. This argue- 
ment would be applicable in more general terms, that is, the level 
of glycosylation of the entire immunoglobulin molecule may be 
important in determining its solubility.
In early studies of the mechanisms responsible for 
simultaneous expression of membrane and secretory forms of IgM a 
model was proposed in which the carbohydrate moieties of IgM played
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a critical role in controlling the expression of such molecules 
(Vitetta and Uhr, 1975b), Although this model has now been shown 
to be inaccurate, the role of carbohydrate, particularly that moiety 
closest to the C-terminus of the y-chain, in control of transport 
and secretion of polymeric immunoglobulins may still prove to be 
important.
The y-chain is synthesised on membrane-bound polyribosomes, 
and the nascent chain is directed through the rough endoplasmic 
reticulum membranes by the signal sequence (see Introduction, section 
3), Glycosylation then occurs either at the level of the nascent 
chain (Moroz and Uhr, 1967) or during transport. A fully glycosyl­
ated secretory human y-chain contains five N-linked carbohydrate 
side-chains, the two closest to the C-terminus being simple units 
and the remainder being complex oligosaccharides (Shimizu et al,
1971): membrane y-chain has only four N-glycosidically linked
prosthetic groups. Both y-chain forms will be synthesised on 
polyribosomes and transferred through the rough endoplasmic reticu­
lum: N-glycosylation of asparagine 563 of the secretory y-chain
may be the biochemical signal required for release of the secretory 
y-chain into the cisternal space or into a secretory vesicle. This 
event requires a single chemical reaction: the addition of a pre­
formed 'core' oligosaccharide to asparagine 563 from the dolichol 
carrier, A similar arguement, involving the N-glycosylation of 
asparagine 483, may be invoked as a signal for release of secretory 
a-chains from the polyribosomes. Formation of "non-cyclic" pentamers 
of IgM could still occur via the interchain disulphide bonds between 
adjacent Cp3 domains (Putnamet al, 1973). The binding of J-chain 
is, however, more difficult to account for if a carbohydrate-mediated
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signal is necessary to release the IgM from the polyribosome, since 
the relevant cysteine residue may be subject to steric hinder- 
ance due to its proximity to the rough endoplasmic reticulum mem­
brane or membranes of other sub-cellular compartments.
The above hypothesis pertains only to IgM and possibly 
IgA secretion. Equivalent sites are absent from human IgG (the 
closest N-glycosylation site is 55 residues from the C-terminus) 
and also from IgE (no glycosylation sites in C^4). A different 
explanation must therefore be found to account for the apparent 
failure to secrete IgE from tunicamycin-treated rat plasmacytoma 
cells (Hickman e^ al, 1977),
One possible explanation is that the amount of carbohydrate 
present on the rat e-chain is related to its solubility; absence 
of N-linked oligosaccharides may render the molecule unstable in 
aquaeous solution (Hickman and Kornfeld, 1978). Such a model is 
also relevant to the data described in the above experiments. The 
human secretory immunoglobulin heavy chains have varying amounts of 
carbohydrate :
Number of 
N-linked Carbohydrate 
Heavy Chain Side Chains
y 5 (Shimuzi et al, 1971)
a 3 (Turner, 1977)
e 6 (Turner, 1977)
Y 1 (Turner, 1977)
According to the Hickman and Kornfeld model, which proposes 
that heavily-glycosylated glycoproteins are less soluble in the non­
glycosylated state, human IgG would be efficiently secreted in the 
non-glycosylated state whereas non-glycosylated IgM, IgA or IgE
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would not be efficiently secreted. The data of this section is in 
agreement with such a model, with the exception of the observation 
of the apparent secretion of non-glycosylated IgE. This anomaly 
may be due to large intracellular pools of dolichol phosphates in 
U266BL cells or 0-glycosylation of the e-chain (see section 1.4,2, 
above) .
1.5 . MEMBRANE DEPOSITION OF IMMUNOGLOBULINS AND mJOR
HISTOCOMPATABILITY COMPLEX GENE PRODUCTS
1.5.1. Experimental Approaches
Three major experimental regimes were employed to investi­
gate the influence of N-linked carbohydrate moieties in localisation 
of immunoglobulins and HLA-A,-B,-C and -DR alloantigens into the cell 
membrane:
a) cell membrane proteins were removed by tryptic 
digestion and the cell allowed to synthesise antigens 
de novo in the presence or absence of tunicamycin. 
Expression of newly synthesised proteins at the cell 
membrane was determined by radioimmunoassay using 
monoclonal antibodies or human alloantisera;
b) cells were cultured for prolonged periods in tuni­
camycin prior to radioiodination of cell membrane 
proteins. Membrane proteins were isolated by 
immunoprécipitation and analysed by SDS-PAGE, and;
c), cells were exposed to a large amount of radioactivity 
for a short period and the fate of immunoglobulins
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labelled during this short pulse was determined 
by analysis of membrane proteins by immunoprécipi­
tation at various times during a pulse-chase in 
the presence of cycloheximide,
1.5.2. Rad io immunoa s s ay
As a preliminary attempt to assess the functional role 
of N-linked oligosaccharides in the efficient expression of immuno­
globulins and MHC gene products at the cell membrane large cultures 
of cells were subjected to treatment with trypsin and allowed to 
resynthesise and, if possible, re-express immunoglobulins and MHC 
gene products at the cell membrane. The experimental strategy is 
open to criticism on' several grounds (for example, loss of cell 
viability, and incomplete removal of endogenous membrane proteins) 
but the data obtained from this approach provided tentative evidence 
that immunoglobulin and MHC products were expressed at the cell 
menbrane of tunicamycin-treated cells.
The cell line Daudi was selected as the model system for 
the study of expression of HLA-DR alloantigens and IgM because of 
the lack of HLA-A,-B,-C alloantigens at the Daudi cell membrane 
(Jones e^ al, 1975) and because of the high level of membrane IgM 
expression on Daudi cells (Klein e^ al, 1968).
Analysis of the level of re-expression of HLA-DR allo­
antigens on the membranes of control or tunicamycin-treated cultures
of Daudi cells was performed using a monoclonal antibody directed
125against the 6-subunit of the HLA-DR alloantigen molecule and I- 
rabbit anti-mouse immunoglobulin (F(ab)^ fraction). The data 
shown in figure l.llA, illustrate that HLA-DR alloantigens could be
FIGURE 1.11.
Membrane Deposition of Non-Glycosylated Proteins 
7
5 X 10 cells from log phase cultures were treated with
2 yg/ml tunicamycin for 3 hours prior to treatment with trypsin in 
the presence of DNAse 1 (Methods, 15). Cells were washed extensive­
ly and cultured at 37^C for 16 hours at a concentration of 10  ^cells/ 
ml of RPMl-1640 supplemented with 20% (v/v) PCS and 2 yg/ml tuni­
camycin. Parallel control cultures were also prepared.
For radioimmunoassay, 10^ cells in 100 y.1 RP Ml-gela tin were 
added to individual wells of a BSA-treated 96-well microtitre plate, 
each well containing 25 yl of the desired antiserum (Methods, 16). 
After a 1 hour incubation at room temperature, the cells were washed 
three times with RPMl-gelatin prior to addition of approximately
3 X lo'^  cpm of ^^^I-rabbit anti-mouse IgG (F (ab) ^  fraction). After
a 1 hour incubation at room temperature, the cells were washed four
times with RPMl-gelatin and the plate dried. Individual wells of
125the plate were assayed for I in the gamma counter (Methods 17.3.). 
Key
A - Daudi cells, assayed with monoclonal anti-
HLA-DR 3-chain.
B - Daudi cells, assayed with monoclonal anti-K.
C - Bri-8 cells, assayed with anti-HLA-B7 allo-
antiserum.
D - Mich cells, assayed with anti-HLA-A2 allo-
antiserum.
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detected at the cell membranes of control and tunicamycin-treated 
cultures. The level of detectable HLA-DR alloantigens was, in each 
case, statistically significantly different from the level of 
detectable HLA-DR on cells assayed immediately after trypsin treat­
ment (p<0.05) and significantly different from the normal mouse serum 
control (p<0.05), It can be inferred from these data that HLA-DR 
alloantigens may be expressed at the cell membrane even if they lack 
N-linked oligosaccharide side chains. However, the level of ex­
pression of HLA-DR on both control and tunicamycin-treated Daudi cells 
after trypsin treatment and re-expression was significantly differ­
ent (p<0.05) from the amount of HLA-DR detectable on Daudi cells 
assayed immediately after harvesting from normal culture, This may 
reflect the harshness of the procedures used in this experimental 
regime and indicates that the cells, although viable, may be severely 
debilitated after exposure to trypsin and tunicamycin.
In an equivalent experiment to examine membrane IgM ex­
pression in the presence or absence of tunicamycin, a monoclonal 
antibody to human kappa chain was used as probe. The data from this 
experiment were not as conclusive as those obtained for expression of 
glycosylated and non-glycosylated HLA-DR antigens. A degree of re­
expression on both control and tunicamycin-treated cells was evident 
(figure l.llB.) and was significantly different from the normal mouse 
serum control (p<0.05) in both cases. However, the level of detect­
able IgM on control cells after re-expression was not significantly 
different from the level of IgM detectable on control cells immediate­
ly after trypsin treatment. The corresponding difference in the 
tunicamycin-treated culture was, however, statistically significant
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(p<0.05). In both cultures, the level of re-expressed IgM is
lower than that detected on freshly harvested cells and the differ­
ence is statistically significant (p<0,05). Thus, the data are 
consistent with the suggestion that non-glycosylated IgM may be ex­
pressed at the cell membrane. However, the degree of confidence 
which one can have in the data is not great and the need for a more
rigorous experimental strategy is clear.
The expression of non-glycosylated HLA-A,-B, and -C
antigens was also investigated by this approach. Human alloantisera
125in combination with I- rabbit anti-human immunoglobulins (Fabg fraction) 
were used to detect the re-expressed alloantigens. The data are 
summarised in figures l.llC. and l.ll.D. Briefly, the data suggest 
that in tunicamycin-treated Bri-8 cells and Mich cells the HLA-B7 and 
HLA-A2 molecules re-expressed by these cells were alloantigenic. In 
each case, the levels of detectable re-expressed HLA-B7 or HLA-A2 was 
statistically significantly different (p<0.05) from the amounts de­
tected on cells assayed immediately after trypsin digestion or the 
normal human serum control. These data are subject to the same 
faults described above in the case of IgM re-expression and must be 
regarded with some scepticism. However, the data are exciting from 
the point of view that, if correct, they suggest that the N-linked 
olligosaccharide moiety linked to asparagine 86 of the HLA heavy 
chain not only plays no role in membrane deposition of the HLA-A,-B,
-C antigens, but also has no influence on the alloantigenicity of 
HAL-A2 or HLA-B7 molecules, at least in a serological context.
These findings are in agreement with recently published data (Ploegh 
et al, 1981) which elegantly demonstrate the assembly, membrane
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deposition and alloantigenicity of non-glycosylated HLA-A2 and HLA- 
B7 molecules. An interesting question does remain to be answered 
regarding the functional integrity of a non-glycosylated HLA-A,-B,
-C alloantigen as a target molecule for a cytotoxic T-lymphocyte.
In summary, the data from this experimental approach suggest 
that N-linked oligosaccharides have no role in the membrane deposition 
of IgM, HLA-DR and alloantigenic HLA-A2 and HLA-B7 molecules. The 
protocols used are extremely harsh and the experiments are consequent­
ly subject to a variety of errors. In an attempt to support the above 
observations, two new approaches were devised and these are described 
below.
1.5.3. Analysis of Membrane Proteins of Cells Cultured for
Prolonged Periods in the Presence of Tunicamycin
The data presented in the previous section (1.5.2.) lead 
to the suggestion that non-glycosylated IgM could be expressed at 
the cell membrane. However, the methods employed led to extensive 
cell damage and tended to give rise to irreproducible results. It 
was necessary to adopt a new approach to test the hypothesis, arising 
from the above data, that N-linked oligosaccharides play no function­
al role in efficient transport of glycoproteins to the cell membrane.
Daudi and Dakiki Arosros-1 cells were cultured for 96 hours 
in the presence of lyg/ml tunicamycin. At the end of the culture 
period the membrane proteins were radioiodinated by lactoperoxidase- 
catalysed iodination and aliquots of the radiolabelled proteins sub­
jected to immunoprécipitation with anti-K or anti-A antisera plus 
GARlg. The immune precipitates were washed, reduced and analysed 
by SDS-PAGE, The data are presented in figure 1.12.
FIGURE 1.12.
Absence of Non-Glycosylated IgM and IgA from Membranes of Cells
Cultured for Prolonged Period In Tunicamycin
Daudi and Dakiki Arosros-1 cells were cultured in complete
medium supplemented with 1 yg/ml tunicamycin for 96 hours, with a
7
single change of medium. After culture 10 viable cells of each
line were harvested from culture, washed twice with 25 ml aliquots
of ice-cold serum-free medium and once with 25 ml ice-cold PBS-I.
The membrane proteins of these cells were radioiodinated by lactoperox-
131idase-catalysed iodination using ImCi of I (Methods, 8.2.).
Lysates were prepared in 250 pi 3D-TKM (Methods, 9.).
IgM and IgA were isolated by specific immunoprécipitation
using 1 pi of either RAHp or RAHa plus an equivalence of GARIg (Methods,
10.2.1.). Washed immune precipitates were dissolved in 25 PI re­
ducing SDS-PAGE loading buffer and electrophoresed on a 10% (w/v) 
acrylamide slab gel (Methods, 13.). The gel was processed for 
fluorography (Methods, 17.6.).
Key: -
Con - Membrane immunoglobulin of control cells.
Tun - Membrane immunoglobulin of tunicamycin-
treated cells.
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The SDS-PAGE profile obtained for Daudi membrane IgM was
identical for material derived from either control, freshly harvested
cells or from cells cultured for four days in tunicamycin; that is
glycosylated y, p33 and K-chains were demonstrable in both profiles
and non-glycosylated chains were not observed. In these experiments 
131I was used in a deliberate attempt to identify minor membrane 
components and, therefore, small quantities of non-glycosylated 
y-chain, but non-glycosylated y-chains were never observed. An 
identical result was obtained with the IgM producing B-lymphoma Bjab 
(data not illustrated).
An identical experiment was performed using the IgA produc­
ing cell line Dakiki Arosros-1. In these experiments, no non- 
glycosylated a-chains were observed in the SDS-PAGE fluorographic 
patterns of IgA immunoprecipitated from either control or tunicamycin- 
treated cells.
In both cell lines the only immunoglobulin components de­
tectable on the membranes of tunicamycin-treated cells' were glycosylated 
]i- or a-heavy chains and light chains. The amount of these compon­
ents which were specifically immunoprecipitated from tunicamycin- 
treated cells was very low compared to the amount isolated from the 
freshly harvested cells. This was not unexpected as, in the design 
of the experiment a half life of 24 hours (Vitetta and Uhr, 1975b) 
was assumed for membrane immunoglobulin, so that after 96 hours only 
6.25% of the original immunoglobulin would remain and any newly-syn- 
thesised material would be the predominant molecular species on the 
cell membrane. The finding of low amounts of glycosylated immuno­
globulin components on the cell membranes of cells exposed to
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tunicainycin for prolonged periods is consistent with the above 
assumption. The data from these experiments are inconsistent with 
the hypothesis that the N-linked carbohydrate moieties of immuno­
globulins are not important in the membrane localisation of these 
proteins. The data suggest that the N-linked oligosaccharides of 
immunoglobulins are necessary for efficient membrane deposition of 
IgM and IgA. However, the possibility that the failure of the 
cells to insert immunoglobulins onto the cell membrane reflects a 
toxic effect of the tunicamycin rather than absence of N-linked 
carbohydrate on the immunoglobulins can not be excluded. Therefore, 
it is again necessary to attempt to find a less ambiguous experimental 
regimen to explore the role of N-glycosylation of immunoglobulins in 
efficient membrane insertion of these macromolecules.
1.5.4. Immune Precipitation of Biosynthetically Labelled 
Immunoglobulin Inserted into the Cell Membrane 
The experimental protocols hitherto employed to attempt to 
demonstrate non-glycosylated immunoglobulin on the cell membrane 
have yielded conflicting results. Furthermore, these strategies 
necessitated harsh treatment of the cells either by trypsin digestion 
and/or by prolonged exposure to tunicamycin, both procedures leading to 
loss of large quantities of cells. In a final attempt to unequivocally 
answer the question "Are non-N-glycosylated immunoglobulins efficiently 
localised into the cell membrane?", the following protocol was adopted. 
Cells were exposed to tunicamycin for a short period of time prior to 
labelling with a large amount of radioactive amino acid for 30 minutes. 
Cycloheximide was then added and aliquots removed at various intervals. 
The cells were treated with antibody, washed extensively, and cell
FIGURE 1.13.
Inhibition of Membrane Insertion of Non-glycosylated IgM 
710 Bjab cells were treated with 2 yg/ml tunicamycin in
complete medium for 3 hours at 37^0. Cells were then washed twice
with labelling medium prior to resuspension in O.1 ml of the same
35medium supplemented with 0,5 mCi S-methionine, Incorporation was 
allowed to proceed at 37°C for 30 minutes whereupon 1 ml of complete 
medium containing 20 yg/ml cycloheximide was added to the culture 
(time 0). The culture was reincubated at 37°C, and 0.1 ml aliquots 
removed at time O, 30, 60, 120, 180 and 240 minutes. Control cultures 
were prepared simultaneously.
The cells were washed twice in PBS containing 0.01%
(w/v) azide (PBS-azide) and then treated with 25 yl of a 1:10 
dilution of RAHy in PBS-azide for 30 minutes at room temperature.
The cells were washed three times with PBS-azide, and lysates prepared 
in 100 yl 3D-TKM (Methods, 9.). 50 yl of 10% (v/v) S,aureus in
3D-TKM was added to each lysate and the mixtures incubated overnight 
at 4^C. The bacteria were washed three times in 3D-TKM and bound
immune complexes eluted by boiling in 2% (w/v) SDS. The bacteria
were pelleted, and the supernates treated with 5 volumes of acetone 
to precipitate protein. The precipitates were dissolved in SDS-PAGE 
loading buffer, boiled, and analysed on a 10% (w/v) acrylamide slab 
gel (Methods, 13.). The pattern of radioactive components was 
visualised by fluorography (Methods, 17.6.).
Kgy.:
Con - Membrane IgM of control Bjab cells.
Tun - Membrane IgM of tunicamycin-treated Bjab cells,
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lysates prepared. ' S.aureus was added to immunoprecipitate the 
immune complexes. This approach has several attractive features:
a) the cells are not subjected to excessive handling 
or enzymatic treatment prior to analysis;
b) the exposure to tunicamycin is relatively short, and;
c) kinetic effects, if any, due to absence of N-linked 
oligosaccharides may be revealed.
Such an experiment was performed on Bjab cells, and the 
data is illustrated in figure 1,13, In control cells, IgM could be 
precipitated from the cell membrane immediately after the end of 
the labelling period, and was easily isolated from aliquots of cells 
removed throughout a 4-hour chase in the presence of cycloheximide. 
By contrast, no radiolabelled immunoglobulin could be immunoprecipi- 
tated from the cell membranes of tunicamycin-treated Bjab cells at 
any time during the chase period. This is good evidence that IgM 
containing non-glycosylated y-chains is not as efficiently inserted 
into the cell membrane as its glycosylated counterpart. A longer 
chase period would be needed to confirm or refute the hypothesis 
that IgM containing non-glycosylated y-chains is never localised 
on the cell membrane,
Non-glycosylated a-chains could, however, be precipitated 
from the membranes of tunicamycin-treated Dakiki Arosros-1 cells 
(figure 1.14.). In control cells, radiolabelled glycosylated 
a-chains were specifically immunoprecipitable from Dakiki Arosros-1 
cell membranes throughout the chase period. In tunicamycin-treated 
Dakiki Arosros-1 cells, radiolabelled glycosylated and non-glycosyl­
ated a-chains were immunoprecipitable from cell membranes. In this
FIGURE 1.14.
Inhibition of Membrane Insertion of Non-Glycosylated IgA 
710 Dakiki Arosros-1 cells were treated for 3 hours at 
37*^ C with 2 yg/ml tunicamycin in complete medium prior to washing 
in labelling medium and labelling with 500 yCi ^^S-methionine for 
30 minutes at 37^0. 1 ml complete medium containing 20 yg/ml
cycloheximide was then added to the culture (time 0) which was re­
incubated at 37°C. 0.1 ml aliquots were removed at times 0,30,60,
120,180 and 240 minutes. Control cultures were prepared simul­
taneous ly.
Cells were washed twice in PBS-azide and treated with
_25 yl of a 1:10 dilution of RAHa for 30 minutes at room temperature.
The cells were washed thrice with PBS-azide and lysates prepared in
100 yl 3D-TKM (Methods, 9.). 50 yl of 10% (v/v) S.aureus in 3d -
TKM was added to each lysate and the mixtures incubated overnight 
at 4°C. The bacteria were washed three times in 3D-TKM and bound 
immune complexes eluted by boiling the washed bacteria for 2 minutes 
in 2% (w/v) SDS. The bacteria were pelleted and the supernate re­
moved and treated with five volumes of acetone. The resulting pre­
cipitate was dissolved in 25 yl reducing SDS-PAGE sample buffer, 
boiled, and analysed on a 10% (w/v) acrylamide slab gel (Methods, 13.) 
The gel was processed for fluorography (Methods, 17.6.).
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case it is believed that the non-glycosylated a-chain appeared on the 
cell membrane only by virtue of its association with a glycosylated 
a-chain. Therefore, by an arguement similar to that advanced for 
"secretion" of non-glycosylated y-chains (section 1.4.1.), the 
presence of a minimal number of N-linked oligosaccharide chains on 
a given molecule may be sufficient to allow a 'mixed' molecule to be 
transported through the cell to its final destination. The notion 
that totally non-glycosylated IgA would not be inserted into the 
cell membrane could be easily tested by exposing cells to tunicamycin 
for a slightly longer time prior to labelling. Based on the above 
arguement and upon the data of figure 1.12. it is reasonable to 
propose that the above hypothesis is correct.
1.5.5. Comparative Role of N-Linked Oligosaccharides in Membrane 
Deposition of Immunoglobulins and MHC Gene Products 
The N-linked oligosaccharide moieties of membrane immuno­
globulins and of MHC gene products appear to have different functional 
significances in transport of these macromolecules to the cell mem­
brane. The data presented here suggests that N-glycosylation of the 
immunoglobulin heavy chain is necessary for the efficient membrane 
deposition of the completed immunoglobulin, while the carbohydrate 
side chains appear to be unnecessary for membrane localisation of 
HLA-A,-B,-C and HLA-DR antigens.
As regards membrane deposition of immunoglobulins, the 
present findings made by radioimmunoassay of cells which had been 
treated with trypsin and allowed to resynthesise and re-express 
antigens in the presence of tunicamycin agree with those of other 
workers; that is, N—linked oligosaccharides of immunoglobulin heavy
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chains do not influence membrane deposition of these macromolecules. 
However, more rigorous analysis by SDS-PAGE of specifically immuno­
pr ecipita ted material derived from;
a) cells subjected to prolonged culture in tunicamycin, 
or;
b) immunoglobulins 'chased' onto the cell membrane of 
actively synthesising cells,
were at variance with published data. The data derived from the 
'pulse-chase' experimental strategy is probably the most reliable 
of the three methods used, although the data for HLA-A,-B,-C antigen 
expression has been vindicated by the work of other investigators 
(Ploegh et al, 1981),
In the case of expression of non-glycosylated IgM, it was 
found that the presence of N-linked oligosaccharides on the y-chain 
was required for efficient membrane insertion. The method of 
culturing cells for prolonged periods followed by SDS-PAGE analysis 
of specifically immunoprecipitated, radioiodinated membrane protein 
has been employed previously and yielded the same result (singer,
1973). The length of culture period was extended in the experiments 
described herein from 8 hours (Singer, 191&) to 96 hours (figure 1.12) 
The finding of only small quantities of glycosylated IgM, and no 
non-glycosylated IgM, supports the findings and conclusions of 
Singer (19TS); that is, non-glycosylated IgM is not inserted into the 
plasma manbrane of B-lymphocytes.
One group of workers has recently claimed that non- 
glycosylated IgM can be demonstrated at the cell membrane of tuni­
camycin-treated murine plasmacytoma cells (Sibley and Wagner, 1981).
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However, two major criticisms of their data are possible;
a) no pre-incubation period in tunicamycin was employed 
prior to allowing cells to replace antigens removed 
by trypsin , and;
b) no analysis, other than binding of fluorescent anti­
body, was performed on the immunoglobulins which were 
claimed to be on the membrane of the cell.
The data are, of course, also subject to the same criticisms 
which apply to the radioimmunoassay data reported in this thesis.
The pre-incubation of cells with tunicamycin is a critical step in 
any experiment of the kind quoted above. Sibley and Wagner (1981) 
may have succeeded in removing all IgM from the membranes of the 
cells, but failure to exhaust endogenous dolichol phosphate pools 
would result in continuation of glycosylation for some time with the 
resultant appearance of IgM (glycosylated) at the membrane of 
tunicamycin-treated cells.
The pulse-chase data presented herein demonstrate that cells 
pre-incubated with the antibiotic, pulsed, and allowed to express 
immunoglobulins fail to deposit IgM on their cell surfaces. These 
cells have not been subjected to trypsinisation or prolonged exposure 
to tunicamycin, but are viable, actively-synthesising cells. The 
conclusion from this experiment is that non-glycosylated y-chains 
are incapable of being transported onto the cell membrane.
With respect to IgA expression, prolonged culture in tuni­
camycin followed by high resolution SDS-PAGE analysis of membrane 
proteins, and pulse-chase experiments demonstrated that non-glycosyl­
ated IgA could not be found on the cell membrane of tunicamycin-treated
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cells. In pulse-chase experiments, glycosylated and non-glycosyl­
ated a-chains were detected on the membrane, but this is believed to 
be due to incomplete exhaustion of dolichol phosphate pools within 
the cell and bears directly on the criticisms of the claims of other 
groups to be able to detect non-glycosylated IgM (Sibley and Wagner, 
1981) and IgA (Hickman and Wong-Yip, 1979) on the cell membrane of 
tunicamycin-treated cells. It is proposed that IgA containing 
solely non-glycosylated a-chains would not be expressed at the cell 
membrane.
The data obtained herein by pulse-chase experiments may be 
questioned on the grounds of the length of chase period, four hours. 
This may be thought to be too short, giving rise to a false negative 
if lack of carbohydrate caused only a kinetic effect rather than a 
total inhibition of expression. The data from the experiments 
analysing the membrane proteins of cells cultured for 96 hours in 
tunicamycin tend to argue against these criticisms since no non- 
glycosylated y- or a-chains were found in SDS-PAGE profiles of 
radioiodinated immunoglobulins specifically immunoprecipitated from 
such cells. The data is entirely consistent with the hypothesis 
that N-linked oligosaccharide prosthetic groups are a mandatory 
requirement for efficient membrane localisation of human IgM and 
IgA: it is proposed that this requirement will also apply to
membrane expression of IgG, IgD and IgE, Experiments are in 
progress to test this proposal.
While the data for immunoglobulins suggests a crucial role 
for carbohydrate in transport of proteins to the cell membrane, the 
radioimmunoassay data (however controversial) suggests that the
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opposite is true for gene products of the HIA complex. The data 
suggested that non-glycosylated HLA-A,-B and -C antigens could be 
efficiently expressed on the membrane of tunicamycin-treated cells 
and, moreover, that the HLA-A2 and HLA-B7 alloantigens were sero­
logically alloreactive, Similar findings have been made by a 
more rigorous pulse-chase approach by several workers (Ploegh e^ al, 
1981; Owen, 1981) and immunoprécipitation data supports the finding 
that non-glycosylated HLA-A,-B and -C antigens are serologically allo­
reactive (Ploegh e^ al, 1981). Similar experiments on murine class 
1 MHC antigens (H-2K, H-2D, H-2L and H-2R) suggest that these 
molecules are efficiently inserted into the plasma membrane in the 
non-glycosylated state (M.J. Owen, personal communication; Black 
et al, 1981). Indeed, it appears that microglobulin is of 
greater importance in the efficient membrane localisation and sero­
logical activity of class 1 molecules than carbohydrate (Ploegh 
et al, 1979; Ploegh et al, 1981a),
The appearance of non-glycosylated HLA-A,-B,-C and H-2K 
molecules at the cell membrane raises interesting questions regarding 
the immunobiological functional capacity of these molecules, H-2K 
and other H-2 class 1 molecules are known to serve as target molecules 
for H-2-restricted cytotoxic T-lymphocytes (Doherty et al, 1976), and 
HLA-A,-B and -C antigens perform the corresponding function in humans 
(McMichael et al, 1977), The data presented herein and that of 
other groups (Ploegh et al, 1981) suggest that the non-glycosylated 
HLA-A, -B and -C antigens are serologically alloantigenically active. 
However, it is not clear if these molecules will be functionally active 
as target molecules for cytotoxic T-lymphocytes. Experiments to
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test the functional integrity of non-glycosylated H-2 class 1 mole­
cules as target molecules for killer T-cells have recently been 
reported. The data suggest that the efficiency of killing of 
virally-infected target cells by virus-specific, H-2 restricted 
cytotoxic T-lymphocytes was inhibited by up to 50% if the target 
cell expressed non-glycosylated H-2 antigens (Black at al, 1981).
These data suggest that the genetic determinants recognised by B- 
cells (antibody) and by T-cells (killer cells) are different; 
the serologically defined alloantigenic determinant does not depend 
upon N-glycosylation whereas the expression of the determinant re­
cognised by cytotoxic cells seems to depend on the presence of 
oligosaccharide side chains upon the class 1 molecule. In a 
different system, it was demonstrated that carbohydrate was needed 
on target molecules for efficient killing of targets by H-2 restrict­
ed cytotoxic T-lymphocytes specific for the sex-linked transplant­
ation antigen H-Y (Shapiro and Erickson, 1981).
The radioimmunoassay data also suggested that non-glycosyl­
ated HLA-DR antigens were expressed at the cell membrane. This data 
has yet to be corroborated by pulse-chase experiments but if accurate, 
several interesting biological questions may be asked. Firstly, are 
non-glycosylated HLA-DR molecules capable of stimulating the mixed 
lymphocyte reaction? A similar question could be asked of murine 
la antigens if these antigens are expressed at the cell membrane in 
the non-glycosylated state. Secondly, one may also investigate 
the possibility that the serologically defined HLA-DR aliospecificities 
are distinct from the determinants defined by cellular reactions, as 
has been suggested by analysis of class 1 molecules.
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Available data illustrates that the N-linked oligo­
saccharides of glycoproteins are of different degrees of importance 
in intracellular transport and in expression of glycoproteins. In 
many cases the requirement for glycosylation of a given protein for 
efficient expression appears to be mandatory. N-linked oligo­
saccharides may serve to protect proteins from proteolytic degrad­
ation thus ensuring the efficient transport and expression of the 
mature molecules (Schwartz et al, 1976). An interesting question 
remains to be answered. That is, does the cellular machinery 
involved in transport and ultimate expression of glycoproteins re­
cognise the oligosaccharide moieties themselves, or is the recog­
nition unit a complex three-dimensional structure, controlled by 
the presence of the oligosaccharides, but dependent more on higher 
protein structure than on carbohydrate?
CHAPTER 2
BIOSYNTHESIS OF STRUCTURALLY DISTINCT MEMBRANE AND 
SECRETORY FORMS OF IMMUNOGLOBULIN HEAVY CHAINS 
IN IgG AND XgA PRODUCING HUMAN B-LYMPH0CYTE5
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2.1. RATIONALE FOR INVESTIGATION
The existence of structurally distinct membrane and secret­
ory forms of u-heavy chain in a single B-lymphocyte is now well es­
tablished in murine (Melcher and Uhr, 1976; Bergman and Haimovich,
1978) and human (Singer et al, 1980(a.); Singer and Williamson, 1980) 
lymphocytes. Studies at the RNA (Singer et al, 1980a; Rogers et al, 
1980; Alt e^ al, 1980) and the DNA levels (Early e^ al, 1980) have 
demonstrated that the membrane and secretory y-heavy chain polypeptides 
are encoded by separate mRNA species, and that the two mRNA species 
are generated by RNA splicing of a primary nuclear RNA transcript of 
a single gene.
IgM-producing cells are representative of primary or early 
B-cells. The Clonal Selection Hypothesis predicts that during antigen- 
driven B-lymphocyte differentiation, daughter cells will arise which 
will have altered the heavy chain isotype which they synthesise, but 
that the idiotype expressed will be identical to the original IgM- 
producing cell. Bearing in mind the precedents of the IgM system 
it is of interest to ask the question "do memory B-lymphocytes 
synthesise structurally distinct receptor and effector forms of the 
heavy chain isotype (y,a or e) to which they are committed?". Some 
preliminary data is available showing that membrane y-chains have a 
higher AMW than their secretory counterparts in human (Singer and 
Williamson, 1980) mouse (Oi ^  al, 1980 and chicken lymphocytes 
(Lifter at al, 1980). In the following studies, biosynthesis of 
IgG and IgA were studied in established human B-cell lines.
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2.2. MODEL SYSTEMS
2.2.1. IgG Biosynthesis; Bec-11 Cells
Bee-11 cells are B-lymphoblasto id cells established by 
in vitro transformation of human tonsillar lymphocytes by Epstein- 
Barr virus. The line was established by Searle Laboratories,
High Wycombe, England. The cells express HLA-A,-B,-C antigens 
(Dick ^  al, 1975) and HLA-DR antigens. Although originally be­
lieved to express IgD on the cell membrane (Singer at al, 1976) , 
Bec-11 cells are now known to express IgG on the cell membrane and 
to secrete IgG into the culture supernate; two gamma chains are 
found in such supernatants as judged by SDS-PAGE under reducing 
conditions (Singer and Williamson, 1980). The cells express a 
kappa light chain.
2.2.2, IgA Biosynthesis; Dakiki Arosros-1 Cells
Dakiki Arosros-1 cells were established in continuous 
culture by ^  vitro transformation with Epstein-Barr virus of 
peripheral blood or cervical lymph node lymphocytes from an African 
patient suffering from nasophoryngeal carcinoma (Steinitz and 
Klein, 1980). Dakiki Arosros-1 cells were shown to express IgA on 
their cell membrane with a lambda light chain. Two other clones 
derived at the same time, Dakiki Arosros-2 and 3 were shown to 
express IgM (k) and IgA (X) respectively on their cell membranes 
(Steinitz and Klein, 1980). Dakiki Arosros-1 cells were shown to 
secrete IgA (Results chapter 1, figure 1.8,).
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2.3 . IgG BIOSYNTHESIS IN BEC-11 CELLS
2.3.1. Synthesis of Multiple Gamma Chain Forms
IgG synthesised by Bec-11 cells in the presence or absence 
of tunicamycin was isolated from cell lysates by immunoprécipitation 
with RAHk , and GARIg, reduced and analysed by SDS-PAGE; figure 2.1. 
shows the pattern of radioactive components detected by fluorography.
Tracks A and B show the component chains of IgG synthesised
by Bec-11 cells in absence or presence of tunicamycin respectively.
Three y-chain bands predominate in track A and these correspond to 
glycosylated y-chains. Track B shows one major band not present 
in track A together with three other minor components. A photo­
graphic enlargement of the relevant area of the fluorogram permits 
closer examination of the resolved components and illustrates that 
of the four y-chain bands immunoprecipitable from tunicamycin­
treated Bec-11 cell lysates, two are of identical electrophoretic 
mobility to those found in immunoprecipitates derived from lysates 
of control Bec-11 cells, and the remaining two y-chain bands are 
unique to tunicamycin-treated Bec-11 cells. These latter two bands 
are postulated to be non-glycosylated forms of the y-chain bands re­
solved in track A.
The data suggest that there may be two structurally distinct 
forms of y-chain in Bec-11 cells. Previous data from this laboratory 
have demonstrated that IgG isolated from aliquots of radioiodinated 
cell membrane proteins of Bec-11 cells contains y-chains of higher 
AMW than the y-chains isolated from secreted IgG from Bec-11 cells 
(Singer and Williamson, 1980), Therefore, the slowest mobility (64K)
FIGURE 2.1.
Multiple Gamma Chain Forms in Bec-11 Cells
2.5 X 10^ Bec-11 cells were harvested from log phase
cultures and incubated at 37^C for 90 minutes in complete medium
containing 2 yg/ml tunicamycin. The cells were then washed twice
in labelling medium and resuspended in 0,1 ml of the same medium
35supplemented with 200 yci S-methionine (Methods, 8.3.). After 
incubation at 37^C for 90 mintues the cells were harvested, washed 
twice in ice-cold TKM buffer and cell lysates prepared in 250 pi 
3D-TKM (Methods, 9). Control cultures were prepared in parallel.
Immunoprécipitation was carried out on 40 pi aliquots of 
lysate by addition of 1 pi RAHk plus an equivalence of GARIg (Methods,
10,2.1.), Immunoprecipitates were collected by centrifugation and 
washed by pelleting through a two-step discontinuous sucrose gradient 
in 3D-TKM (Methods 10.3.), The washed precipitates were dissolved 
in 25 pi of reducing SDS-PAGE loading buffer, boiled, and electro- 
phoresed on a 10% (w/v) acry1amide slab gel (Methods, 13.). The 
pattern of radioactive components in the gel was detected by 
fluorography (Methods, 17,6.). A photographic enlargement of the 
area of the fluorogram containing the y-chains is also shown.
A - IgG immunoprecipitated from lysates of
control Bec-11 cells.
B - IgG immunoprecipitated from lysates of
tunicamycin-treated Bec-11 cells.
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band resolved in figure 2,1. track A is proposed to represent the
mature, glycosylated menbrane form of y-chain (y ); the slowest
m
mobility band (60K) in track B is postulated to be the non-glycosyl­
ated form of y^. The two faster mobility bands (55K and 52K) in 
track A are the secretory y-chains (y^), and the fastest mobility 
(48K) band in track B is postulated to be the single non-glycosylated 
y-chain from which both secretory forms of y^  arise.
2,3.2. Molecular Weight Estimations
The AMW of each y-chain form was determined relative to a 
set of molecular weight standards (Methods, 13.5,). These cali­
brations are important for two reasons :
a) the number of N-linked oligosaccharide side-chains 
possessed by each y-chain form can be estimated, and;
b) the length of the C-terminal extension, postulated to 
effect membrane insertion of stability properties on 
y^ ., may also be estimated.
10% (w/v) aery1amide SDS-PAGE gels were found to give 
optimal resolution of y-chain bands and, therefore, AMW values ob­
tained from experiments on such gels are used throughout. The 
AMWs of each y -chain form are given in table 2.1.
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TAHLE 2.1.
AMWs of Bec-11 y-chain Polypeptides
Polypeptide AMW
y + CHO 64K
m
Y - CHO 60Ks
yg (minor) + CHO 55K
yg (major) + CHO 52K
yg - CHO 48K
The AMW estimates given are representative values and are 
useful only in a comparative context: they are not intended as
absolute values.
AMW estiamtions were also performed on 11% (w/v) and 12.5% 
(w/v) acrylamide gels but resolution of the y-chain components was 
inferior to that obtained with 10% gels. The data given in table
2.1. may be tentatively interpreted in terms of the number of N- 
linked oligosaccharide moieties added to a non-glycosylated y-chain. 
The data obtained from AMW estimations on 11% (w/v) and 12.5% (w/v) 
acrylamide gels (not shown) were in good agreement with the inter­
pretations drawn from the data shown in table 2.1 , and discussed 
below.
N-linked oligosaccharides are added,to glycoproteins as 
large pre-formed units from a lipid carrier (see Introduction, 
section 3.8.). Each N-linked oligosaccharide added to the poly­
peptide contributes 2500-3000 daltons to the AMW and subsequent 
processing reduces this contribution by a very small amount. Indeed,
- 1 8 0 -
the anomalous behavour of glycoproteins on SDS-PAGE is well docu­
mented (Melcher and Uhr, 1976) and thus it is possible to predict 
only the approximate number of N-linked oligosaccharide moieties 
present on any one peptide.
Therefore, if one N-linked oligosaccharide is assumed to 
contribute 3000 daltons to the AMW of a polypeptide, then the data 
of table 2.1. may be interpreted as follows. The AMW difference
between glycosylated and non-glycosylated forms of y is 4000 daltons;
m
given the intrinsic inaccuracies in AMW calibrations and also the 
anomalous behaviour of glycoproteins on SDS-PAGE, this data suggests 
that one N-linked oligosaccharide is added to the 60K y^-chain to 
yield the fully glycosylated, mature 64Ky^^giycoprotein. By a 
similar arguement, the 52K glycosylated species could be generated 
frcm the 48K non-glycosylated chain by addition of a single N-linked 
oligosaccharide side chain, and the 55K y-chain species could then 
be generated by addition of another carbohydrate side-chain to the 
52K molecule. The finding of 52K and 55K secretory y-chains in the 
cell cytoplasm and supernatant raises intriguing questions regarding 
the mechanisms of intracellular processing and transport of secretory 
IgG in Bec-11 cells, and these problems are explored below (section
2.3.5.) .
The most interesting feature of this comparative study is
the AMW difference between the non-glycosylated forms of y - and Y -m s
polypeptides. The difference, 12,000 daltons, is equivalent to an 
entire immunoglobulin domain and is approximately four-fold larger 
than the equivalent difference between y^- and y^- polypeptides.
This finding has consequences for the structure and organisation of
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human Y-chain genes and notably the M-exon components of these
genes. The AMW difference between y and y of Bec-11 cellsm s
suggests a larger C-terminal extension, perhaps promoting binding 
to the cytoskeleton via a long cytoplasmic tail. The data herein 
is in agreement with observations made in the chicken and mouse IgG 
systems (Lifter et al, 1980; Oi et al, 1980) but represents an 
extension to the above work in that the comparisons were made on 
non-glycosylated molecules where the errors introduced by the 
anomalous behaviour of glycoproteins on SDS-PAGE is minimised.
Clearly, it is essential to discover if a putatively larger C- 
terminal extension on the membrane heavy chain is a characteristic 
feature of ’memory' immunoglobulin isotypes and therefore related to 
memory B-cell activation, or if it is peculiar to IgG synthesising 
memory cells. Accordingly, biosynthesis and structure of IgA molecules 
has been investigated, and the data of this section may be discussed 
more meaningfully in the light of data pertaining to a-chain structure 
(see section 2,8 . below).
The biosynthetic features of the putative Y^ "^ a-ud Yg~ 
polypeptides are now presented below.
2,3.3. Comparison of Radioiodinated Membrane IgG and Biosynthetic-
ally Labelled IgG
The hypothesis that the 64K Y-chain band precipitated from 
control Bec-11 cells is the membrane Y-chain form was tested by 
comparing, under reducing conditions, IgG isolated from aliquots of 
radioiodinated Bec-11 cell membrane proteins or from aliquots of 
lysate of biosynthetically labelled Bec-11 cells.
FIGURE 2.2.
Comparison of Radioiodinated Membrane IgG with Biosynthetically 
Labelled IgG
2.5 X 10^ Bec-11 cells were harvested from log phase
cultures, washed twice in labelling medium and resuspended in 0.1 ml
35of the same medium supplemented with 200 yCi S-methionine (Methods, 
8.3.). After incubation at 37^C for 90 minutes, the cells were 
harvested and washed twice in ice-cold TKM buffer prior to prepar­
ation of cell lysates in 250 yl 3D-TKM (Methods, 9.).
7lO Bec-11 cells were harvested from log phase cultures
of >95% viability and washed twice with 25 ml aliquots of ice-cold
serum-free medium and once with 25 ml ice-cold PBS-I prior to lacto-.
peroxidase catalysed radioiodination of membrane proteins using 2 mCi 
125of I (Methods, 8.2.). The labelled cells were washed extensively 
prior to preparation of cell lysates in 250 yl 3D-TKM (Methods, 9.).
IgG was isolated from 50 yl aliquots of lysate by immuno­
précipitation with 1 yl RAH and an equivalence of GARIg (Methods,
10.2.). The washed immunoprecipitates were reduced and analysed by 
SDS-PAGE on a 10% (w/v) acrylamide slab gel (Methods, 13.). The 
gel was processed for fluorography (Methods, 17.6.).
Key_^ -
A - Radioiodinated Bec-11 membrane IgG.
B - Biosynthetically labelled Bec-11
intracellular IgG.
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A single band was resolved when reduced immunoprecipitates 
derived from aliquots of radioiodinated Bec-11 cell membrane proteins 
were analysed (figure 2,2.). This band co-migrated with the 64K 
band resolved from identical immunoprecipitates derived from lysates 
of biosynthetically labelled Bec-11 cells. This observation is 
consistent with the hypothesis that the 64K y-chain species is the 
membrane form of y-chain.
Although only y-chain is visible in the SDS-PAGE profile 
of radioiodinated Bec-11 IgG, two pieces of evidence may be cited to 
support the proposal that Bec-11 membrane IgG is 7S (i.e. y^L^). 
Firstly, the precipitating reagent was an anti-K reagent and so the 
y-chain could only be immunoprecipitated if it was associated with 
the K-chain. Secondly, previous experiments have shown Bec-11 
membrane IgG to have an AMW of 150,000 under non-reducing conditions 
(Singer and Williamson, 1979).
The data of figure 2.2. strongly suggest that the membrane 
form of Bec-11 y-chain is the 64K species, consistent with the 
assignment made in section 2.3.1.
2.3.4. Both Glycosylated Secretory Gamma Chains Arise from a
Single Non-Glycosylated y-Chain
Two electrophoretically distinct y-chain forms can be 
demonstrated in IgG secreted from Bec-11 cells (Singer and William­
son, 1980). The data of figure 2.1. suggest that both of these 
forms of y-chain arise from a single non-glycosylated form. This 
postulate was tested experimentally by isolating IgG from culture 
supernatants of control and tunicamycin-treated cultures of Bec-11 
cells by immunoprécipitation, and comparing the SDS-PAGE profiles
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of the reduced immunoprecipitates with those of identically-prepared 
samples derived from lysates of control and tunicamycin-treated 
cells. The observation that IgG containing only non-glycosylated 
y-chains is efficiently secreted from Bec-11 cells (see Results, 
chapter 1, figure 1.9.), allows direct comparison of the y-chains 
secreted from tunicamycin-treated cells with y-chains isolated from 
lysates of tunicamycin-treated cells (figure 2.3.).
Analysis of the SDS-PAGE profile of the component chains of 
IgG secreted from tunicamycin-treated cells (see figure 2,3.) re­
vealed that only one non-glycosylated y-chain is secreted. Com­
parison of the electrophoretic mobility of this secreted non- 
glycosylated y-chain with y-chains immunoprecipitated from cell 
lysates of tunicamycin-treated Bec-11 cells showed that the secreted 
chain is of identical electrophoretic mobility to that of the fast­
est mobility (48K) intracellular non-glycosylated y-chain. The 
following conclusions may be drawn from this data:
a) the 48k y-chain species detected in cell lysates 
of tunicamycin-treated cells is the single non- 
glycosylated form of the two secretory y-chains;
b) only one potentially secretory y-chain is synthesised 
in Bec-11 cells, and;
c) both y-chains found in the supernate of Bec-11 cells 
are derived from this single non-glycosylated y-chain 
form, and differ only in the amount of carbohydrate 
they possess.
These data, when considered in conjunction with the data 
of figure 2.2., are-in agreement with the assignments made in
FIGURE 2.3.
Bec-11 Cells Synthesise a 'Single•Secretory Gamma Chain Polypeptide
2.5 X 10^ Bec-11 cells were harvested from log-phase 
cultures and treated for 3 hours at 37^C in the presence or absence of 
2 yg/ml tunicamycin in complete medium. The cells were then washed 
twice in labelling medium, resuspended in 0.1 ml of the same medium
containing 250 yCi ^^S-methionine, and incubated at 37^0 for 90
minutes (Methods, 8.3.). After incubation, the culture was divided
into two equal aliquots. A lysate was prepared in 250 yl 3D-TKM
from one aliquot (Methods, 9.) and a 5-hour chase performed on the 
second aliquot: the final volume of the chase supernate was 250 yl
(Methods, 8.3.).
IgG was isolated from aliquots of lysate and supernate by 
specific immunoprécipitation using 1 yl RAH plus an equivalence of 
GARIg (Methods, 10.2.). The washed immunoprecipitates (Methods,
10.3.) were dissolved in 25 yl of reducing SDS-PAGE loading buffer, 
boiled and electrophoresed on a 10% (w/v) acrylamide slab gel (Methods, 
13,). The gel was processed for fluorography after electrophoresis 
(Methods, 17.6.).
Key; -
IC - Intracellular
EC - Extracellular
Con - IgG isolated from lysates or supernates
of control cultures.
Tun - IgG isolated from lysates or supernates of
t tunicamycin-treated cultures.
N.B. This figure is identical to figure 1.9.
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figure 2.1. and table 2.1. That is, the mature membrane form .of 
y-chain (64K) is apparently derived from a non-glycosylated y-chain 
of 60,000 daltons, while both mature secretory forms (55K and 52K) 
arise from a single non-glycosylated y-heavy chain polypeptide (48K).
The finding of two non-glycosylated y-chains of markedly 
different AMWs in Bec-11 cells leads to the conclusion that Bec-11 
cells are capable of simultaneous biosynthesis of structurally 
distinct membrane and secretory y-heavy chain polypeptides.
2.3.5. Pattern of Glycosylation of Bec-11 Secretory y-Chain
Two possible mechanisms may be invoked to account for the 
finding of secretory y-chain polypeptides containing different amounts 
of carbohydrate in the assembled IgG molecules secreted from Bec-11 
cells ;
a) Bec-11 cells secrete two distinct 7S IgG*species 
containing identical polypeptide chains but with 
each individual 7S molecule differing in the extent 
of glycosylation of its constituent y-chains;
b) Bec-11 cells secrete a single 7S IgG molecule which 
has been assymetically glycosylated during intra­
cellular transport: that is, after initial glycosyl­
ation (conversion from 48K to 52K) one y-chain 
undergoes a further glycosylation step (conversion
to 55K) while the other y-chain does not: such a
precedent exists in rabbit IgG (Hinrichs and Smyth, 
1970), or;
c) Bec-11 cells secrete multiple 7S forms which may be 
accounted for in terms of a mixture of a) and b) above.
-187-
Two experimental observations favour the first of these 
interpretations. As previously demonstrated (figure 2.3.), two 
y-chains are observed in culture supernates of control Bec-11 cells.
If the sole IgG secretory product of Bec-11 cells was an assymetic­
ally glycosylated molecules, the y-chain bands resolved by SDS-PAGE 
would be expected to be of similar, if not identical, fluorographic
intensity since the 7S IgG molecule would contain y-chain poly-
35peptides of identical radiochemical specific activity ( S-methionine) 
which would have different AMWs due to glycosylation differences. 
Visual inspection of profiles of y^-polypeptide isolated frcm lysates 
or supernates of control cultures of Bec-11 cells (e.g. figure 2,3.) 
indicate that this is not the case. In both lysates and culture 
supernates, the 52K y-chain species predominates over the 55K y-chain 
form. This argues against the notion that assembled Bec-11 IgG is 
assymétrieally glycosylated prior to secretion.
The similarities of relative intensities of the 55K band 
to the 52K band in lysates and supernatants of control Bec-11 cultures 
(i.e. the intensity of the 52K band is always greater than that of the 
55K band) is inconsistent with the hypothesis that the 55K band is 
in a precursor-product relationship with the 52K y-chain band or 
vice-versa. Indeed, the finding of the 55K y-chain in the culture 
supernate is a strong arguement against this hypothesis.
In an attempt to directly demonstrate two distinct 7S 
IgG forms in culture supernates of normal Bec-11 cells, immuno­
precipitated Bec-11 IgG was analysed on a 6% gel under non-reducing 
conditions (figure 3.4.).
FIGURE 2.4.
Secretion of Discrete 7S Molecules from Bec-11 Cells
Pulse-chase radiolabelling and immunoprécipitation of IgG 
from lysates and supernates of control and tunicamycin-treated Bec- 
11 cells was performed identically to the method described in figure
2.3.
Washed immunoprecipitates were dissolved in 25 yl of 
non-reducing SDS-PAGE loading buffer, boiled for two minutes, and 
electrophoresed on a 5% (w/v) acrylamide slab gel (Methods, 13,).
The pattern of radioactive components in the gel was visualised by fluor- 
graphy (Methods, 17.6.).
Key :-
IC - Intracellular
EC - Extracellular
Con - IgG isolated from lysates or supernates of
control cultures.
Tun - IgG isolated from lysates or supernates of
tunicamycin-treated cultures.
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The SDS-PAGE profiles of IgG specifically immunoprecipitated 
from supernates of control and tunicamycin-treated Bec-11 cultures 
each have a major component in the region of the gel expected to 
correspond to 7S IgG. The difference in AMW between IgGs from 
control and tunicamycin-treated culture supernates is small at this 
gel percentage but is nonetheless visible in the profiles. In 
addition to the major IgG component, several minor bands of lower 
AMW are evident in the profile of IgG derived from supernates of 
tunicamycin-treated cultures. This is taken as stronger evidence 
that Bec-11 cells secrete several forms of IS IgG molecules which 
differ not in their polypeptide structure, but in the relative anounts 
of carbohydrate they possess. The observation in the SDS-PAGE profiles 
of unreduced IgG of multiple 7S species argues against assymétrie gly­
cosylation as the principal explanation for the finding of two secret­
ory y-chain polypeptides upon analysis of secreted IgG under reducing 
conditions. However, it is possible that assymetrically glycosylated 
IgG accounts for some of the heterogeneity of the SDS-PAGE profiles 
observed for unreduced IgG secreted from Bec-11 cells. The data are 
most consistent with the proposal that Bec-11' cells secrete 7S IgG 
molecules which are symetrically glycosylated (i.e. containing two 
55k or two 52K y-chains) and also molecules which are assymetrically 
glycosylated.
2.4. EVIDENCE FOR AN HYDROPHOBIC SEQUENCE PRESENT ONLY ON
MEMBRANE GAMMA CHAIN
Preliminary evidence that the membrane form of Bec-11
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y-chain possessed hydrophobic sequences not found in the secretory 
y-chain polypeptide came from studies with the lipophilic nitrene, 
hexanyol-diiodo-NAP-tyramine, Lysates of unlabelled Bec-11 cells 
were prepared in triton X-IOQ and treated with 25 yCi of radioactive 
nitrene in the presence of strong light: after photolysis, the
lysate was made to 3D-TKM by addition of concentrated deoxycholate and 
SDS. Analysis by SDS-PAGE was then performed.
Figure Z.5. compares the results of labelling whole, viable 
cells by lactoperoxidase-catalysed iodination or by use of the photo­
activated nitrene, with the labelling of a cell lysate with hexanyol- 
dioodo-NAP-tyramine. The profiles shown in tracks A, B and C are 
those of total proteins precipitated by acetone; attempts to immuno- 
precipitate IgG labelled with the nitrene have so far been unsuccess­
ful. However, several factors indicate that y is labelled by them
nitrene:
a) a band of AMW 64K is evident in the SDS-PAGE profile 
of lysate material radiolabelled by hexanyl-diiodo- 
NAP-tyramine;
b) this band is of identical electrophoretic mobility to 
the biosynthetically labelled 64K y^ species (track 
D), and;
c) no 55K or 52K species are evident in the profiles of 
nitrene-labelled material, nor is there evidence of 
labelled k - light chain.
These preliminary data tentatively suggest that the 54K 
y species found in control Bec-11 cells possesses hydrophobic areas 
of amino acid sequence not found in the secretory form of the y-chain.
FIGURE 2.5
Labelling of Membrane Gamma Chain using a Radiolabelled Lipophilic 
Nitrene
7
Aliquots of 10 Bec-11 cells were harvested from log phase 
cultures of 95% viability, washed twice with 25 ml aliquots of ice- 
cold RPMl-1540 and once with 25 ml of ice-cold PBS-I. The cells 
were then resuspended in 50 yl of PBS-I and radiolabelled by either:
a) lactoperoxidase-catalysed radioiodination using 1 mCi
131
of I (Methods, 8.2.), or;
b) treatment with radioiodinated ^^^l-hexanoyl-diiodo-
NAP tyramine in the presence of light.
Radiolabelled cells were washed extensively and cell lysates 
prepared in 3D-TKM (Methods, 9,).
7
A lysate of 10 Bec-11 cells was also prepared in 1% (w/v) 
triton X-lOO in TKM buffer and the nuclei removed. The lysate was 
then treated with ^^^I-hexanoyl-diiodo-NAP-tyraraine in the presence 
of light. After photolysis, deoxycholic acid and SDS were added to 
the lysate to the concentrations required to yield 3D-TKM lysis 
buffer (Methods, 9.).
Aliquots of lysate were treated with five volumes of acetone, 
centrifuged and the precipitates allowed to air dry prior to dissolution 
in reducing SDS-PAGE loading buffer. The samples were boiled and 
electrophoresed on a 10% (w/v) acrylamide slab gel (Methods, 13.). 
Radioactive components were detected by autoradiography (Methods, 17.5.),
Key :-
A - Membrane proteins labelled by lactoperoxi­
dase-catalysed radioiodination.
B - Membrane proteins labelled by photoactivated
131I-hexanoyl-diiodo-NAP-tyramine.
C - Cell lysate proteins labelled by photo­
activated ^ ^ ^ I - h e x a n o y l - d i o o d o - N A P - t y r  amine.
D - Biosynthetically radiolabelled Bec-11 intra­
cellular IgG (see legend to figure 2.2.).
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Topological considerations and the known precedents for p-chain 
structure lead one to propose that the putative hydrophobic sequence 
would be located at the C-terminus of the membrane y-chain polypeptide.
The data of figure Z.5. can only be regarded as a prelimin­
ary indication of the hydrophobic properties of the polypeptide.
A significant advance towards substantiation of these data will have 
been made when the material, radiolabelled with the nitrene, is 
successfully immunoprecipitated.
2.5. UBIQUITY OF THE SIZE DIFFERENCE BETWEEN MEMBRANE AM)
SECRETORY GAMMA HEAVY CHAIN POLYPEPTIDES
Analysis of the AMWs of non-glycosylated Bec-11 y-chains
demonstrated that the AMW of y was 60K and the AMW of y was 48K..
'm ' s
The difference in AMW between the two y-chain forms, 12,000 daltons, 
is unexpectedly large and it is, therefore, of great importance to 
examine the three most plausible explanations for this observation. 
These possibilities are;
a) the apparently large size of the C-terminal extension 
of membrane heavy chains is a feature of isotypes 
associated with B-memory cells,
b) the phenomenon is peculiar to IgG-producing cells
but is not evident in IgA or IgE producing cells, and;
c) the large C-terminal extension is peculiar to one 
subclass of IgG.
To investigate these possibilities, pulse-chase experi­
ments were performed on control and tunicamycin-treated cultures of
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three IgG producing cell lines, Bec-11, EB4.9, and Maija. IgG 
was isolated frcm lysates and supernates derived from these cultures 
by specific immunoprécipitation and analysed by SDS-PAGE under re­
ducing conditions (figure 2.6.).
Comparison of the pattern of radioactive components on the 
fluorogram of the SDS-PAGE profile of IgG derived from tunicamycin- 
treated Maija cells reveals that the difference in AMW between the
and polypeptides of that cell is of the order of 12,000 daltons; 
that is, identical to the difference between and y^ polypeptides 
of Bec-11 cells. In control Maija cells, it is interesting to note 
that both y^ and y^ species are apparently expressed as a 'doublet'; 
that is, two discrete glycosylated y^ and y^ bands. These are 
apparently derived from single non-glycosylated y^ and y^ polypeptides 
since only one band is resolved in each of the positions predicted for 
non-glycosylated y^ and y^ polypeptides. In the case of y^ the 
fluorographic intensity of the glycosylated bands is very similar and 
this is taken as tentative evidence for assymetric glycosylation of 
y^ polypeptides during intracellular transport of membrane IgG, It 
is noteworthy that Maija cells have a glycosylated K-light chain.
Since sequences do not contain N-glycosylation sites, this suggests 
that the V-region of Maija K-light chains is glycosylated.
Examination of the AMWs of the y and y polypeptides ofm s
EB4.9 cells again suggested an AMW difference of approximately 12,000 
daltons between the two polypeptides. This is in agreement with the 
findings made for the AMW difference between y^ and y___ polypeptides in 
Bec-11 and Maija cells. These data suggest that finding that the
FIGURE 2.6.
Ubiquity of the 12,000 Dalton AMW Difference between Membrane and
Secretory Gamma Chains
2.5 X 10  ^cells were harvested from log phase cultures of
Bec-11, EB4.9 and Maija cell lines and incubated for 3 hours at 37°c
in the presence or absence of 2 yg/ml tunicamycin in conplete medium.
The cells were then washed twice with labelling medium, resuspended
35in 0.1 ml labelling medium supplemented with 250 yCi S-methionine 
and incubated at 37°C for 90 minutes (Methods, 8.3.), Cell lysates 
were prepared in 250 yl 3D-TKM (Methods, 9), Additionally, a pulse- 
chase experiment was performed on EB4.9 cells,
IgG was isolated from lysates and supernates by treating 
aliquots of the samples with 1 yl RAHy and an equivalence of GARIg 
(Methods, 10.2.1.). Washed immunoprecipitates were dissolved in 
25 yl of reducing SDS-PAGE loading buffer, boiled, and analysed on a 
10% (w/v) acrylamide slab gel (Methods, 13.). The SDS-PAGE profiles 
were visualised by fluorography (Methods, 17.6.).
Key :-
IC - Intracellular
EC - Extracellular
Con - IgG isolated from lysates or supernates of
control cultures.
Tun - IgG isolated from lysates or supernates of
tunicamycin-treated cultures,
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large difference in AMW between and y^ polypeptides seems to be 
common to IgG-producing cells. Although the possibility that it is 
a subclass specific phenomenon cannot be ruled out, it is felt un­
likely that all of the cell lines studied expressed the same sub­
class of IgG. The data of section 2.7. demonstrates a difference
of 2000 daltons between a and a polypeptides which refutes them s
hypothesis that a long C-terminal extension on the membrane heavy 
chain is characteristic of the immunoglobulin isotypes expressed on 
the memory B-lymphocytes. The data from murine and chicken IgG
glycoproteins (Oi al, 1980; Lifter ^  al, 1980) also demonstrate 
a large AMW difference between y^ and y^ polypeptides. These pre­
liminary studies, together with the data of figure 2.6. would support 
the notion that a large C-terminal extension is common to all IgG 
subclasses.
The data obtained for EB4.9 IgG also substantiate two other 
findings originally made in Bec-11 cells;
a) non-glycosylated IgG is efficiently secreted, and;
b) the AMW of the y^ polypeptide is approximately 48K: 
this is entirely consistent with the assignments made 
for Bec-11 y-chains in figure 2.1.
2.6. IN VITRO TRANSLATION OF BEC-11 POLY a "^ RNA
To test the hypothesis that the syntheses of y^ and y^ poly­
peptides were directed by independent raRNA molecules, the following 
experiment was performed. Purified poly A RNA from Bec-11 cells was
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used to programme protein synthesis in the rabbit reticulocyte lysate 
cell-free translation system. After synthesis, the translation 
products were treated with RAHy plus GARIg to specifically immuno- 
precipitate in vitro synthesised y-chains. Purified immunoprecipitates 
were reduced and analysed by SDS-PAGE,
Figure 2.7. illustrates that two putative gamma chains were 
precipitated from cell-free translation products and that these were 
of slower electrophoretic mobility than their non-glycosylated counter­
parts synthesised vivo. These molecules are believed to be the 
precursors of y^ and y^ polypeptides.
The data presented in figure 2.7. represent an initial step 
in testing the hypothesis that separate mRNAs encode y^ and y^ poly­
peptides. Given that there are no reports of post-synthetic modi­
fication in the rabbit reticulocyte lysate protein synthesis system, 
the data are consistent with the above hypothesis. Furthermore, the 
small AMW difference between pre-y^and non-glycosylated y^ and the 
equivalent difference for the y^ polypeptides, suggests that the in 
vitro synthesised y-chains possess hydrophobic leader peptides.
The data are, however, defective in two respects. Firstly, 
the AMW difference between pre-y^ and non-glycosylated is greater 
that the equivalent difference between vitro and vivo synthesised 
y^ polypeptides. If y^ and y^ mRNA-species are derived from a single 
gene by splicing of a single nuclear RNA transcript, then both mRNAs 
should contain the same exon for the leader peptide (see Introduction, 
figure 7.), Therefore, the AMW difference between in vivo and in 
vitro synthesised forms of a given y-chain should be identical,
I
Secondly, decisive proof that the two species postulated to represent
FIGURE 2.7.
Synthesis of y-Chains In Vivo .and In Vitro
Polyribosomes were prepared from 5 x 10^ Bec-11 cells 
(Methods, llolo) and poly A RNA was purified frcm this subcellular 
fraction by oligo-dT cellulose chromatography (Methods, llo2«).
The purified mRNA was resuspended in water at a concentration of Img/ 
ml.
In vitro translation was performed by stimulating the rabbit
reticulocyte lysate cell-free system by addition of 1-2 ug of Bec-11
+ 35poly A RNA: 30 yCi of S-methionine were also added. The mixtures
were incubated at 30°C for 90 minutes whereupon the reaction was 
terminated by placing the tubes on ice (Methods, 12,). In vitro 
synthesised y-chains were specifically immunoprecipitated by addition 
of 1 yl of RAHy plus an equivalence of GARIg to the translation pro­
ducts, The immunoprecipitates were washed, reduced and analysed by 
SDS-PAGE (Methods, 13,). The pattern of radioactive components was 
visualised by fluorography (Methods, 17,6,),
Key:-
In Vivo - IgG synthesised by viable cells.
In Vitro - IgG synthesised in reticulocyte lysate
programmed with Bec-11 poly A RNA,
Con - IgG synthesised by control cultures
of Bec-11 cells.
Tun - IgG synthesised by tunicamycin-treated
 ^ cultures of Bec-11 cells,
pre-y - Denotes y-chain containing leader sequenc
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precursor y-chains are indeed gamma chains is lacking: evidence to
support this action could be obtained by 'cold competitor' experi­
ments where unlabelled IgG would be used to inhibit immunoprécipi­
tation of radiolabelled y-chains synthesised ^  vivo or ^  vitro.
Experiments are in progress to substantiate the above data 
Preliminary studies with the Burkitts Lymphona EB.4 show an SDS-PAGE 
profile of dm vitro synthesised, immunoprecipitated y-chains which 
is identical to that of ^  vitro synthesised Bec-11 y-chains (not 
shown). The data of figure 2,7. do, however, provide tentative 
evidence that independent species of mRNA direct the synthesis of ym
and y^ polypeptides.
2,7. IgA BIOSYNTHESIS IN DAKIKI AROSROS-^1 CELLS
1.7.1. Alpha Chain Species in Dakiki Arosros-1 Cells
IgA was isolated from aliquots of lysates of control and 
tunicamycin-treated Dakiki Arosros-1 cells by specific immuno­
précipitation with RAHA and GARIg. The washed precipitates were 
reduced and analysed by SDS-PAGE.
The fluorogram of the above experiment (figure 2.8.) illus­
trates that two a-chain bands were specifically immunoprecipitable 
from lysates of control and tunicamycin-treated cells. The alpha 
chains isolated from lysates of control cells had AMWs of 55K and 53K, 
and these are postulated to be the raonbrane (a^ ) and secretory (a^ ) 
forms of the alpha chain: the AMWs of the corresponding chains
derived from lysates of tunicamycin-treated cells were 52.5K (a^ ) and 
50.5K (a^). The observation of two distinct a-chain species in
FIGURE 2.8.
Distinct Alpha Chain Polypeptides in Arosros-1 Cells
2.5 X 10^ Dakiki Arosros-1 cells were harvested from log 
phase cultures and incubated in complete medium for 3 hours at 37^C 
in the presence or absence of 2 pg/ml tunicamycin. The cells were 
washed twice with labelling medium, resuspended in 0,1 ml of labelling 
medium containing 250 yCi ^^S-methionine, and incubated at 37°C for 
90 minutes (Methods, 8.3.). After incubation, cultures were divided 
into two equal aliquots; a cell lysate was prepared in 250 ]il of 3D- 
TKM buffer frcm one aliquot (Methods, 9.) and a 5-hour chase carried 
out upon the other aliquot (Methods, 8.3.).
IgA was specifically isolated from aliquots of lysate or 
pulse-chase supernate by immunoprécipitation using 1 yl RAHa and an 
equivalence of GARIg (Methods, 10.2.1.). Immunoprecipitates were 
harvested by centrifugation and washed by pelleting through a two- 
step discontinuous sucrose gradient in 3D-TKM (Methods, 10.3.). The 
washed immunoprecipitates were dissolved in 25 yl of reducing SDS- 
PAGE loading buffer, boiled and electrophoresed on a 10% (w/v) 
acrylamide slabe gel (Methods, 13.). SDS-PAGE profiles were visual­
ised by fluorography (Methods, 17.6.).
Key:-
Con - IgA isolated from lysate or supernate of 
control cultures.
TM - IgA isolated from lysate or supernate of 
tunicamycin-treated cultures.
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lysates of tunicamycin-treated Dakiki Arosros-1 cells leads to the 
proposal that these cells are capable of synthesising structurally 
distinct forms of a-chain: one for insertion into the lymphocyte
manbrane and the other for secretion into the extracellular environ­
ment .
2.7.2. Molecular Weight Estimations
The AMW of each a-chain species resolved in figure 2.8. was 
determined with reference to a set of standards of known molecular 
weight (see methods section 13.5.). 10% (w/v) acrylamide gels were
found to give optimum resolution of a-chains. The AMWs are given 
in table 2.2. below.
TABLE 2.2.
AMWs of Dakiki Arosros-1 Alpha Chains
Alpha Chain Apparent Molecular Weight
Membrane + carbohydrate 55K
Membrane - carbohydrate 52.5K
Secretory + carbohydrate 53K
Secretory - carbohydrate 50.5K
These figures are representative values for AMW and are 
not intended as absolute values. As in the equivalent study on 
y-chains (table 2.1.), these values are useful in a comparative 
context only.
The differences in AMW between glycosylated polypeptides 
'may again be accounted for in terms of addition of pre-formed N-linked
— 201-
oligosaccharide moieties. The AMW difference of 2500 daltons between 
the glycosylated and non-glycosylated forms of the membrane a-chain 
polypeptide is consistent with the notion that a single N-linked 
oligosaccharide is added to the non-glycosylated a^ polypeptide during 
its intracellular transport to give the mature a^ polypeptide. A 
similar interpretation may be advanced for the explanation of the 
2500 dalton difference in the AMWs of glycosylated and non-glycosyl­
ated secretory a-chains.
Comparison of the AMWs of the non-glycosylated a^- and a^- 
polypeptides reveals a difference of 2000 daltons. This is taken as
preliminary evidence that the C-terminal structure of a - and a -m s
polypeptides closely resembles that of y^- and y^- polypeptides.
The data also have implications for the genomic structure and organ­
isation of the 3'-end of the C gene: this is discussed in sectiona
2.8. below. The data refute the hypothesis that a large C-terminal 
extension on the membrane polypeptide (i.e. a 12K difference between 
membrane and secretory polypeptides) is a characteristic of memory 
cell isotypes: this phenomenon appears to be unique to y-producing
lymphocytes.
2.8. SIMULTANEOUS BIOSYNTHESIS OF RECEPTOR AND EFFECTOR
IMMUNOGLOBULINS BY SINGLE B-LYMPHOCYTES: A GENERAL
PHENOMENON
The capacity of primary B-lymphocytes to effect simultan­
eous biosynthesis of membrane (receptor) and secretory (effector) 
forms of y-chain istnow established (Bergman and Haimovich, 1979;
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Singer e^ al, 1980; Alt ejt al, 1980; Rogers et al, 1980; Early e^ al, 
1980). The data of this chapter confirm previous preliminary reports 
that B-lymphocytes expressing other isotypes, e.g. IgG (Oi et al,
1980; Lifter et al, 1980; Singer and Williamson, 1980) are also 
capable of the simultaneous synthesis of membrane and secretory 
polypeptide forms of the immunoglobulin isotype to which that cell 
is committed. Thus, lymphocytes expressing IgG and IgA have been 
shown to synthesise distinct heavy chain polypeptides which are 
structurally differentiated for expression on the cell membrane or 
in aquaeous environments (e.g. serum). In the case of IgG bio­
synthesis , the experiments described above suggest that distinct 
mRNA species direct the synthesis of and y^ polypeptides.
In view of the observations made during these investigations 
it is reasonable to propose that the genetic mechanisms which permit 
memory B-lymphocytes to express membrane and secretory heavy chains 
simultaneously is similar, if not identical, to that described for 
IgM producing cells (see introduction, figure 7.). Thus, it is 
hypothesised that after isotype switching has occurred and the V- 
D-J gene joined in close proximity to any selected gene, trans­
cription will occur to yield a large nuclear RNA transcript which will 
contain nucleotide coding sequences for:
a) the leader sequence followed by an intron separating 
it from;
b) the V-D-J unit which will, in turn, be separated by 
an intron from;
c) the gene, each domain exon being separated from 
its neighbours by an intron, and the most 3' C-region
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domain exon being separated from the M-exon(s) by 
an intron.
The primary nuclear RNA transcript will then undergo 
differential RNA splicing to yield two functional mRNA molecules; 
one encoding the membrane form of the heavy chain polypeptide and 
the other mRNA directing the synthesis of the secretory heavy chain 
polypeptide. After undergoing the appropriate cytoplasmic pro­
cessing and being assembled with light chains, the immunoglobulin 
will be expressed either at the cell membrane or in serum depending 
on the structure of the heavy chain contained in any one molecule.
The data also reveal an interesting feature with respect 
to structural differences between membrane and secretory heavy chain 
polypeptides. In agreement with data for mouse (Oi at al, 1980) and 
chicken IgG glycopeptides (Lifter e^ al, 1980) the data herein 
suggest a large AMW difference between and y^ polypeptides. The 
estimates herein suggest the AMW difference to be 12,000 daltons.
This difference is, so far, unique to y-chains; and polypeptides 
differ by only 2000 daltons in terms of AMW, Comparison of these 
AMW differences with the equivalent difference in the u-chain system 
(table 2.3.) permits meaningful speculation upon the structure and 
genomic organisation of human and genes.
-2o4~
TABLE 2.3.
Comparisons of AMW Differences Between Membrane and Secretory 
Heavy Chain Polypeptides
Apparent Molecular Weight^
_____________membrane__________SECRETORY__________DIFFERENCE
y 68,000 65,000 3,000
a 52,500 50,500 2,000
Y 60,000 48,000 12,000
 ^Based on AMW of non-glycosylated heavy chains
From this type of comparative analysis it is suggested that 
the structure and organisation of the 3' end of the Cy gene, particular­
ly the M-exon, is different frcm that of the Cy gene, while the data 
suggest that Cy and Ca genes may be similarly organised.
The amino acid sequences of secretory human y- and a- 
chains are very similar at their C-termini. Most worthy of note is 
the fact that both y- and a- chains possess a 20 amino acid tail­
piece not found of y- or e- heavy chains. Therefore, based on these 
observations at the amino acid sequence level coupled with the 
experimental observations herein it is proposed that the 3' end of 
the human Ca gene will be similar to that of the human Cy gene 
(Rabbitts et al, 1981). That is, the Ca gene will possess:
a) a nucleotide sequence encoding the 20-amino acid 
tail piece contiguous with the 3 '-end of the C^3 
exon (the T-piece).
I
-205.
b) an intra-exon splice site within C^3 conferring the
ability to transcribe through to the end of the C^T
sequence or to splice to the exons ;
c) an M-exon of similar size and sequence to that de­
scribed for the gene separated from the 3' end of
C T by an intron of about 2kb, and; 
a '
d) a small coding sequence (the exon) for the cyto­
plasmic tail of the polypeptide, again similar to 
that found in the Cy gene, and located some 120 base 
pairs 5' to the exon.
The proposed structures of the human Cy, Ca, and Cy genes 
are diagrammed in figure 2 .10.
The large difference in AMW between y^ and y^ polypeptides 
is more difficult to explain. However, it is proposed that the 3' 
structure of the C^3 exon will differ considerably from that of 
either C^4 or C^3 in that it will not possess a large T-piece. Further­
more, the M-exons of the C^ gene may also be different from those of
C and C , and it is predicted that the C M-exons will be larger than y a y
their counterparts in C^ or C^.
The lack of a 20 amino acid T-piece in C^ genes is an
intriguing paradox. At the protein level, the C-terminal sequence
of y myeloma proteins has been shown to be pro-gly (see Kabat e^ al,
1979). However, nucleotide sequence analysis of cloned germ-line 
Cy genes and cloned cDNAs copies of y-chain mRNA of the mouse predict 
lysine codon at the C-terminus of y^^ and y^^ polypeptides 
(Honjo et al, 1979; Yamawaki-Kataoka et al, 1980; Olio et al, 1981) 
followed by a TGA termination codon. Comparing the nucleotide
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sequence at the 3' end of the Cy3 exon and with the equivalent 
sequence of C^4 (figure 2.9,) it is clear that the glycine codon 
followed by the lysine codon generates a concensus RNA splice site 
for the 5'-boundary of an intron (Rogers and Wall, 1980; Wall, 1980). 
This nucleotide sequence arrangement suggests that genes do possess 
an intraexonic RNA splice site to allow simultaneous expression of 
and y ^ polypeptides and also possess a T-piece of two codons (lys- 
stop).
The 2-codon T-piece has functional significance. The 
existence of an RNA splice site at the 3'-end of the C^3 exon confers 
upon the cell the ability to select for expression of or poly­
peptides, or to express both forms simultaneously. Absence of the 
splice site would result in lymphocyte being capable of synthesis of 
y^ polypeptides only. The presence of the intra-exonic RNA splice 
site permits the lymphocyte to express receptor immunoglobulin, and 
hence to become an immunocompetent cell.
The structure of the M exons of the C genes has not yet
y
been described. The data described in this chapter lead to the con­
clusion that the M-exons of will be considerably larger than those 
described for C (Early et al, 1980) and predicted for C . Two majorp —  —  ct
alternative structures and organisations are envisaged for the M-exons 
of (see figure 2.10.).
a) a large M^-exon encoding negatively charged amino
acids and hydrophobic amino acids for localisation on 
the outer membrane face and within the bilayer respect­
ively ; this large exon would be separated by an intron
I
from a second exon (M^), encoding the positively charged 
amino acids of the cytoplasmic level, and;
FIGURE 2.9.
Alternative RNA Splice Sites in Murine C and C Genes
......................   y .....y
The nucleotide sequences of germ line C‘P4 DNA and y - andm
y^-RNA at the alternative RNA splice site are shown: the splice site
is underlined and the exon-intron boundary is denoted by a slash.
Putative alternative RNA splice sites are illustrated in 
the known sequences for murine C^l, C^2a and C^2b genes at the 3'- 
end of their C^3 exons. The concensus RNA splice site for the 5'- 
end of an intron (Rogers and Wall, 1980) is also shown.
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FIGURE 2.9.
Alternative RNA Splice Sites in Murine and Genes
Germ Line C 4 
y
5'
u -mRNA s 5’
u -mRNA m
51
Germ Line
^1
5'
Germ Line
^2a
5:
Germ Line Y 2b 5*
Concensus Site 5 '
T C C A C T G/G T A A A C C C -  3'
5 ' - T C C A C T G A G G G G A A G
' - T C T A C T  G/G T A A A T G A -  3'
T C T C C G G/G T A A A T G A - 3' 
A G/G T A A G T A  -3'
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b) a M^-exon of similar size and composition as the
equivalent exon in , separated by an intron from 
the exon encoding a larger cytoplasmic tail than 
that predicted for y^-polypeptides (Rogers e^ al,
1980).
In alternative a), the M^-exon may be divided into a number 
of smaller exons (represented as broken lines in figure 2.10) or it 
may be a single large exon.
The second genomic structure postulates a large exon which 
would encode a long cytoplasmic extension of the polypeptide.
The function of such a large cytoplasmic tail may be to promote inter­
action of membrane IgG with elements of the lymphocyte cytoskeleton 
(Flanagan and Koch, 1978).
The structures of the M-exons proposed above would conform 
to rules already established for RNA splicing of the primary transcript. 
That is, the RNA splicing sites would obey the 5'-GT...,AG-3’ rule 
(Breathnach et al, 1978; Catterall et al, 1978) and would be positioned 
to promote joining of :
a) the C 3 and M^  exons;
y 1
b) the M^  and M exons, and;
1 c
c) the M^ and M^ exons if necessary.
A termination codon is predicted to be located at the 3'
end of the M^ exon and two sites of poly-A addition ought to be found
within the gene. One poly-A addition site should occur just 3'
to the C 3 exon, and the second should be located 3' to the M exon, y c
It is predicted from the estimates of the AMW difference between y^
and y polypeptides and from the structure of the 3'-end of the C 3 s y
FIGURE 2.10.
Possible Structures of the 3*-end of Human Cy, Ca and Cy Genes
The organisation of coding DNA for each of the Cy, ca, and
cy genes from the exon encoding the last domain to the exon encoding
the cytoplasmic tail is illustrated: two alternative models are
presented for the Cy gene.
It is envisaged that Cy and Ca will have a similar structure
and organisation. A sequence encoding a secretory peptide (the T-
or tail-piece) will be found contiguous with the last constant region
domain exon. It is predicted that an intraexon RNA splice site will
also be found in C 3. The structure of the M-exons of the C gene a a
will be similar to that of Cy and the intron between C^3 and M^ will 
of approximately the same length as that between C^4 and M^.
Data at the protein level suggest a large C-terminal ex­
tension of y^ polypeptides. The two most plausible genetic structures
which could account for these data are illustrated. In the first 
example the M^ exon may represent a limited tandem repeat of M^ which 
may or may not be separated from M^ by an intron. In the second 
example, the M^ exon of C^ is proposed to be similar to those of C^ 
and C , but M^, which is proposed to encode the cytoplasmic tail of 
the y^ polypeptide, is postulated to be extended to give rise to a 
large cytoplasmic protrusion. A large T-piece is not envisaged for 
the Cy gene (see text).
Key: -
T - Nucleotides encoding the 19 amino acid
secretory tail of secretory y- and a-chains.
- First membrane exon, containing coding 
sequences for hydrophobic intramembrane 
amino acids.
M - Second membrane exon, containing thec
coding DNA for the cytoplasmic tail of 
membrane immunoglobulins 
Shaded Triangle - RNA splice site.
bp t - Base pairs.
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Fig. 2.10 Possible Structures of the 3-End of Human Cfi, Ca and Cv Genes
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exon (i.e. the 2-codon T-piece) that the total coding DNA found in the 
and exons irrespective of their organisation will be in the 
range of 250-300 base pairs. That is, the M exons of the genes 
will encode lOO 20 amino acids.
The results of this chapter provide some evidence that cells 
representative of the memory B-lymphocyte population are capable of 
effecting simultaneous biosynthesis of structurally distinct membrane 
and secretory immunoglobulin heavy chain polypeptides. In agreement 
with the precedent established in the murine and human y-chain systems, 
it appears that the messenger RNA species encoding the membrane and 
secretory polypeptides are distinct molecular species generated by 
differential RNA splicing of a large nuclear RNA transcript of a single 
active V^^D^-J^-C^ gene. It is proposed that this pathway is common 
to all types of B-lymphocyte whether primary or memory, and operates 
irrespective of the isotype which the lymphocyte is expressing.
The biochemical differences between and y^ polypeptides 
and between and polypeptides remain to be established. The 
data herein has delineated the two structural forms only on the basis 
of which cellular or extracellular environment a given polypeptide is 
found. The evidence from experiments using lipophilic nitrenes can 
only be regarded as tentative and more conclusive evidence, for 
example, frcm carboxypeptidase digestion of isolated radiolabelled 
polypeptides, is needed before it can be stated unequivocally that 
the structural differences between membrane and secretory y- and a- 
polypeptides are located at the C-termini of these chains.
The studies of the phenotypic product of the and genes
have provided hints As to the genotypic structures of and genes.
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Based on differences in AMW between membrane and secretory polypeptides, 
it is suggested that the gene is structurally homologous to and
possess similar T- and M-exons. The large AMW difference betweeny ^ 
and y^ polypeptides suggests a different organisation of genetic 
elements. is proposed to have a small T-piece (2 codons) and large
M-exon structures. Although the biosynthesis of and polypeptides 
has not been studies (there is no detectable polypeptide in U266BL 
cells), it is felt that the organisation of the gene will prove to 
be similar to that of the gene. IgD remains unique in having a 
genomic structure which conforms to neither the pattern or that 
proposed for (Tucker e^ al, 1980; Maki et al, 1981).
The conclusion drawn from these investigations is that 
memory B-lymphocytes utilise similar genetic strategies to those 
employed by primary B-lymphocytes to allow simultaneous biosynthesis 
of structurally distinct membrane and secretory immunoglobulin heavy 
chain polypeptides.
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2.9, NOTES ADDED'IN PROOF
1. Probing of a Northern blot of Bec-11 poly A RNA with a 
32P-nick-translated y^-cDNA clone reveals two reactive 
species: these are proposed to represent the distinct
mRNAs for and y^ polypeptides (Coupar, Cushley and 
Williamson, unpublished) .
2. The nucleotide sequence of the murine gene has been 
determined and has been shown to have a T-piece, con­
tiguous with 0^3, encoding 20 amino acids, and also to 
possess an intraexonic RNA splice site (Tucker et al, 
1981, in press).
3. In_ vitro translation of poly A RNA derived from a human 
lymphoblastoid cell line synthesising IgA followed by 
specific immunoprécipitation and analysis by SDS-PAGE 
reveals that two distinct a-chains are synthesised in 
vitro (McCune e^ al, 1981) . This is in agreement with 
the findings for translation of Bec-11 mRNA in vitro.
CHAPTER 3
IMMUNOCHEMICAL INVESTIGATION OF THE 
UNIQUE 33,000 DALTON GLYCOPROTEIN (P33) 
FOUND IN ASSOCIATION WITH MEMBRANE 
IMMUNOGLOBULIN M OF THE B-LYMPHOMA 
CELL LINE DAUDI
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3.1. BACKGROUND AND OBJECTIVES
The B-lymphoma cell line Daudi (Klein et al, 1968) exhibits 
several features which represent a departure from the expected pattern 
of expression of membrane antigens by B-lymphocytes. The most notable 
of these features is the failure to express ELA-A,-B or -C alloantigens 
on the cell membrane (Jones e^ al, 1975) despite the fact that Daudi 
cells synthesise the heavy chain of HLA-A, -B and -C alloantigens in 
their cytoplasm (Pleogh et al, 1979). The defect in membrane in­
sertion of these macromolecules has been shown to be due to the 
absence of g microglobulin (Fellous et al, 1977) caused by an ab­
normality on chromosome fifteen which carries the gene for micro­
globulin (Goodfellow al, 1975). The Daudi cell line does express 
the HLA-DR alloantigens (Jones ^  al, 1975) and consequently has 
found much favour as a model system for the investigation of the role 
of HLA-DR alloantigens in activation of human mixed lymphocyte reactions.
The membrane IgM of Daudi cells also displays an unusual 
feature. The unusually high AMW of the Daudi kappa light chain has 
been well documented (Sherr and Uhr, 1971; Kennel, 1974) and it was 
originally proposed that the higher AMW could be accounted for by 
glycosylation of the normal light chain. This anomalous component 
has since been shown to be a distinct molecular species from the 
normal kappa light chain synthesised by Daudi cells (Singer and 
Williamson, 1979).
Many of the biochemical properties of this novel 33,000 
dalton glycoprotein (P33) have been elucidated (Singer and Williamson, 
1979) and there are Striking similarities between P33 and the ot-chain
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of the HLA-DR alloantigens particularly with regard to isoelectric 
point and cysteine content (see table 3.1.), Furthermore, pre­
liminary work leading up to this study suggested that a rabbit anti­
serum raised against Daudi membranes and capable of blocking mixed 
lymphocyte reaction activation (Deane et al, 1978; Van Heyningen et al,
1981) had specificity for P33 suggesting a functional relationship 
between P33 and the HLA-DR alloantigens.
These investigations were designed to study the serological 
reactions in which P33 was involved and to attempt to elucidate its 
immunological identity and therefore explain its apparent role in 
activation of the human mixed lymphocyte reaction (MLR).
3.2. SEROLOGICAL REACTIONS
3.2.1. Reaction of an MLR-Inhibiting Antiserum with P33
Rabbit antibody to Daudi cell membrane components involved in 
MLR activation was prepared as described by Deane e^ a^ (1978). (See 
materials and methods, section 5,6,), MLR activation is a property 
often associated with the HLA-DR alloantigens (Van Rood ejt al, 1976) 
and since the rabbit antibody (serum No.52) has been shown to be 
capable of inhibiting MLR activation (Van Heyningen e^ al, 1981) it 
was reasonable to propose that serum No,52 would recognise and pre­
cipitate the HLA-DR alloantigens.
The following experiment was performed to investigate the 
specificity of serum No.52. Aliquots of radioiodinated cell membrane 
proteins were treated with one of the following antisera plus GARIg;
a) rabbit anti-human u-chain;
b) serum Ao.52, and
c) serum No.52 after absorption with Bjab cells.
FIGURE 3.1.
Serum No.52 is Specific for Daudi P33 
7
10 viable Daudi cells were harvested from log phase
cultures, washed twice with 25 ml aliquots of ice-cold serum-free
RPMl-1640 and once with 25 ml of ice-cold PBS-I, The cells were
radiolabelled by lactoperoxidase-catalysed iodination using 1 mCi 
125I (Methods, 8.2.), washed extensively and lysates prepared in 
3D-TKM (Methods, 9.).
Radioiodinated membrane proteins were then treated with 
I iil of rabbit antisera and an equivalence of GARIg (Methods 10.2.1.) . 
Washed immune precipitates were dissolved in 25 ]il of SDS-PAGE loading 
buffer, boiled, and electrophoresed on a 12.5% (w/v) acrylaraide slab 
gel (Methods, 13.). , The pattern of radioactive components was
visualised by fluorography (Methods, 17.6,).
The precipitating reagents used were:
A - Acetone (total membrane protein fraction).
B - RAHy
C - Serum No,52,
D - Serum No,52 after absorption against Bjab cells,
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The immune precipitates were washed, reduced and analysed by 
SDS-PAGE. The profiles obtained are shown in figure 3.1. An aliquot 
of total cellular proteins is also shown (track A).
Each antiserum precipitated identical components from ali­
quots of radioiodinated Daudi cell membrane proteins (tracks B, C and 
D) , that is y- and ic-chains and P33. The observation that serum No.
52 specifically immunoprecipitates the IgM-P33 complex (track C) and 
not the HLA-DR alloantigens, as was expected, suggests that the anti­
serum recognises one of the component chains of the IgM-P33 complex.
Treatment of aliquots of radioiodinated cell membrane proteins 
of several B-cell lines with serum No.52 and GARIg failed to immuno- 
precipitate any membrane proteins. Bjab cells were the only exception; 
serum No.52 was capable of immunoprecipitating Bjab membrane IgM but 
only to an extremely limited extent (data not shown). P33 is unique
to Daudi (Singer and Williamson, 1979) and is not found on Bjab cells, 
and therefore it is probable that some of the antibody activity of 
serum No.52 is directed against y-chains, K-chains or an interaction 
antigen presented by y- and K-chains in complex. Therefore serum 
No.52 was extensively absorbed against Bjab cells, and the absorbed 
serum used in immunoprécipitation.
Reactivity with Bjab membrane IgM was abolished (not shown), 
but reactivity with the Daudi membrane IgM-P33 complex was unaffected. 
Since anti-y and anti-K antibodies would have been removed by ab­
sorption with Bjab cells, precipitation of the Daudi IgM-P33 complex 
by serum No.52 occurs through recognition of P33; y- and K-chains 
are co-precipitated by virtue of their covalent association with P33. 
Thus, serum No.52 hai specificity for the P33 component of the Daudi 
IgM-P33 complex.
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The above absorption experiments strongly suggest that 
serum No.52 recognises the P33 component of the Daudi IgM-P33 complex. 
However, the experiments do not rule out the possibility that serum 
No.52 recognises idiotypic determinants on the or sequences of 
Daudi membrane IgM. These idiotopes may be a function of the amino 
acid sequence of the protein or may be influenced by carbohydrate 
moieties.
3.2.2. Hypothesis: P33 is Structurally Related to the Alpha Chain
of the HLA-DR Alloantigens
P33 has several features in conmon with the HLA-DR a-chain (see 
table 3.1.). The most striking similarities between P33 and HLA-DRa- 
chain are the identical isoelectric points (pl=5.2) and identical 
cysteine content (3 residues per molecule). This latter finding is 
particularly significant since it rules out the possibility that P33 
is an extended or heavily glycosylated light chain, as proposed by 
Kennel (1974) , since light chains have a minimum requirement for five 
cysteine residues to fulfil their disulphide bonding requirements.
The finding that MLR activation by Daudi cells can be blocked by an anti- 
serum specific for P33 adds support to the notion that P33 has some 
functional relationship to HLA-DR a-chains. Taken together, the bio­
chemical and functional similarities lead to the formulation of the 
hypothesis that P33 represents an abberant expression of the HLA-DR 
a-chain.
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Table 3.1. Biochemical Properties of HLA-DR a-chain and
Daudi P33
1 2 
HLA-DR a P33
Molecular Weight 34 2 33 3
Glycosylation Yes Yes
Isoelectric Point  ^ 5.2 5.2
Cysteine Content 3 3
1. After Springer et al, 1976,
2. After Singer and Williamson, 1979.
3. The isoelectric points given are approximate since
both P33 and HLA-DR a-chains give a multiple band
spectrotype upon isoelectric focusing. The value
given corresponds to the mean isoelectric point.
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3.3. RELATIONSHIP OF P33 TO HLA-A, -B, -C AND DR ALLOANTIGENS.
3.3.1. Serological Investigations.
The first test of the hypothesis stated above (3.2.2.) was 
to treat aliquots of radioiodinated Daudi cell membrane proteins with 
antisera to products of the HLA gene complex, and to compare the 
nature of the isolated products with those precipitated using RAHy 
and serum No.52.
Figure 3.2. demonstrates that RAHy (track A) and serum No.
52 after extensive absorption against Bjab cells (track B) both pre­
cipitate the IgM-P33 complex: HLA-DR alloantigens were never ob­
served in SDS-PAGE profiles of RAHy or serum No.52 immunoprecipitates 
of Daudi cell membrane proteins. Two rabbit antisera to HLA-DR 
alloantigens. No.254 (track C) and No.70 (track D), specifically 
immunoprecipitated components of AMWs 34,000 daltons and 29,000 
daltons; these are the a- and g-chains, respectively, of the HLA-DR 
alloantigens. The characteristic profile of the IgM-P33 complex 
was never observed upon SDS-PAGE analysis of immune precipitates 
generated using the antisera specific for HLA-DR. The electro­
phoretic mobilities of P33 and HLA-DR a-chain are distinct suggesting 
a difference in primary structure. These data, particularly the 
failure of anti-HLA-DR antisera to precipitate the IgM-P33 complex, 
are a strong indication that P33 has no serological or structural 
relationship the the HLA-DR a-chain.
Support for the latter interpretation was obtained from
further serological studies employing monoclonal antibodies covalently
t
bound to sepharose. These studies (data not illustrated) provided
FIGURE 3.2.
P33 is not Recognised■by Antibody to HIA-DR Antigens 
7
10 viable Daudi cells were harvested from log phase 
cultures and prepared for lactoperoxidase catalysed iodination as 
described in the legend to figure 3.1. (Methods, 8.2.). Radio­
iodinated cells were washed extensively prior to preparation of 
lysates in 3D-TKM (Methods, 9.).
Aliquots of radioiodinated membrane proteins were treated 
with 1 yl rabbit antisera plus an equivalence of GARIg (Methods, 10.2.) 
Washed immunoprecipitates were dissolved in 25 yl of reducing SDS- 
PAGE loading buffer and analysed on a 12.5% (w/v) acrylamide slab 
gel (Methods, 13.). After electrophoresis, the gel was processed 
for fluorography (Methods, 17.6.). •
The precipitating rabbit antisera were:
A - RAHy .
B - Serum No. 52 (absorbed against Bjab cells).
C - Serum No.254 (anti-HLA-DR).
D - Serum No. 70 (anti-HLA-A,-B,-C,-DR).
E - Anti-denatured HLA-A,-B,-C.
F - Normal rabbit serum.
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the following information:
a) IgM-P3 3 was not retained on affinity columns of mono­
clonal anti-HLA-DR antibody, and could be immunopre­
cipitated from material eluting in the void volume 
of the column, and
b) HLA-DR antigens were retained by the affinity columns 
and could be subsequently eluted.
Thus, the evidence argues strongly against the hypothesis 
that P33 represents an abberant expression of the HLA-DR a-chain.
It has been reported that certain xenoantisera could detect 
HLA-A, -B and -C antigens on the Daudi cell membrane (Ostberg e^ al, 
1975). Track E of figure 3.2. illustrates that a rabbit antiserum 
to denatured HLA-A, -B, -C antigen heavy chain (Tanigaki et al, 1975) 
failed to precipitate any material from aliquots of radioiodinated 
Daudi cell membrane proteins. Furthermore, no Daudi membrane pro­
teins were retained on an affinity column of monoclonal antibody to 
a determinant common to HLA-A, -B, -C antigens but which was not 
2^ microglobulin (data not shown). This evidence also refutes any 
suspicions that P33 may have been a fragment of the HLA-A, -B, or -C 
antigen chain.
The serological data are therefore inconsistent with the 
hypothesis that P33 is in any way related to.HLA-A, -B, -C or -DR 
antigen chains.
3.3.2. Two-Dimensional Analysis of Tryptic Peptides of P33 and
HLA-DR Antigens.
Tryptic digests of SDS-PAGE purified P33 and HLA-DR antigen 
component chains wefe compared by two-dimensional peptide mapping
FIGURE 3.3.
Two-Dimensional Analysis of a Tryptic Digest of P33
IgM was isolated from aliquots of Daudi radioiodinated 
cell membrane proteins by specific immunoprécipitation using RAHy 
and GARIg. The washed precipitate was reduced and electrophoresed 
on 12.5% (w/v) acrylamide tube gels. The gels were sliced, counted, 
and the slices containing p33 identified. P33 was eluted from the 
gel slices (Methods, 13.6.) and digested with trypsin (Methods, 14.1.)
The digest was dissolved in water and subjected to high 
voltage electrophoresis (Methods, 14.2.) followed by ascending 
chromatography (Methods, 14.3.) on a thin-layer cellulose plate.
After chromatography, the plate was allowed to dry and was then 
autoradiographed.
Upper Plate - P33
Middle Plate - HLA-DR-a
Lower Plate - HLA-DR-g
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(Barber and Crumpton, 1976). I am indebted to Dr. M.J. Crumpton 
for his assistance in carrying out this experiment during a visit 
to his laboratory.
The chromatographic fingerprint obtained is shown in figure
3.3. Comparison of the P33 fingerprint with either of those of the 
HLA-DR alloantigen chain shows no similarity. The major components 
of the P33 fingerprint migrate anodally while those of the HLA-DR 
alloantigens migrate cathodally. These data provide further 
circumstantial evidence that P33 has no structural relationship to 
HLA-DR a-chain. The differences seen are too great to be accounted 
for by the fact that the comparison is made between Daudi P33 and 
Bri-8 HLA-DR alloantigen.
The serological and chemical analyses described above provide 
compelling evidence that P33 is not an HLA-DR alloantigen a-chain.
3.4. ROLE OF N-LINKED OLIGOSACCHARIDES IN EXPRESSION OF DAUDI
MEMBRANE IgM AND IN SEROLOGICAL ACTIVITY OF P33
3.4.1. Membrane Deposition of Daudi Membrane IgM Requires N- 
Glycosylation
Data presented in results chapter 1 illustrate the re­
quirement for N-glycosylation of Daudi IgM for efficient membrane 
deposition of this macromolecular complex (see figure 1.12). In 
the SDS-PAGE profiles of IgM immunoprecipitated from tunicamycin­
treated Daudi cells, only the glycosylated y, k and P33 components 
were resolved. No bands were resolved which could be proposed as 
candidates for non-^lycosylated P33 molecule. These data also
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suggest that the unusual structure of Daudi membrane IgM does not
exempt this molecule from the requirement for N-linked carbohydrate
side chains for efficient membrane deposition of immunoglobulins.
P33, whether glycosylated or not, is probably not involved in the
intracellular events leading to the membrane deposition of Daudi IgM.
3.4.2. Role of Carbohydrate in Serological Activity of P33
The role of oligosaccharide moieties in the serological
activity of Daudi P33 was investigated in the following experiment.
Cultures of Daudi cells, control or tunicamycin-treated, were pulsed 
35with SCOyCi S-methionine for 10 minutes prior to a chase for 1 hour 
in ccmplete medium. Aliquots were removed at frequent intervals, 
lysates prepared, and IgM-P33 macromolecular complexes specifically 
immunoprecipitated using RAHy or serum No.52 and the S. aureus 
immunoabsorbent. The SDS-PAGE profiles are shown in figure 3.4.
Note that in this analysis, the presence of y-chain is taken as being 
indicative of :
a) IgM-P33 complex assembly, and
b) serologically active P33.
Methionine is not readily incorporated into P33 and, there­
fore, it was decided to invoke similar arguements to those advanced 
in results chapter 1 in the analysis of immunoglobulin assembly.
P33 is covalently bound to the IgM molecule (Singer and Williamson,
1979) and serum No.52 has specificity for P33 (see figure 3.1.).
Thus, the presence of a serologically reactive P33 moiety on Daudi
IgM would result in the precipitation of y-chains.
RAHy was capable of immunoprecipitating IgM from the lysates
FIGURE 3.4.
Role of Carbohydrate in Serological Reactivity of P33
10^ Daudi cells were treated with 2 yg/ml tunicamycin at
37°C for 3 hours in complete medium. Cells were washed twice with
labelling medium and resuspended in 0.1 ml of the same medium con- 
35
taining 500 yCi S-methionine: parallel control cultures were
also prepared. Labelling was carried out at 37°C for 7 minutes 
whereupon 1 ml complete medium was added (time 0) and the culture 
reincubated at 37^0. 0,1 ml aliquots were removed at times 0,2,5,
10,20,30,45 and 60 minutes.
Aliquots removed at each time point were added to 100 yl 
ice-cold PBS-azide and washed twice with the same buffer prior to 
preparation of lysates in 100 yl 3D-TKM (Methods, 9.)., Lysates 
were treated with 5 yl of either RAHy or serum No,52 (absorbed on 
Bjab cells) plus 100 yl of 10% (v/v) S.aureus in 3D-TKM and in­
cubated overnight at 4°C. The bacteria were washed three times 
with 3D-TKM and immune complexes eluted by boiling the organisms in 
2% (w/v) SDS. The bacteria were pelleted, and proteins in the 
supemates were precipitated by addition of 5 volumes of acetone.
The precipitates were dissolved in 25 yl of reducing SDS-PAGE sample 
buffer and analysed on a 10% (w/v) acrylamide slab gel (Methods, 13.). 
The gel was processed for fluorography (Methods, 17.6.).
Key :-
Con - Material isolated from lysates of control
cultures.
Tun ,t- Material isolated from lysates of tunicamycin-
treated cultures,
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of control and tunicamycin-treated Daudi cells (figure 3.4. upper 
panel). However, serum No,52 precipitated IgM from lysates of 
control cells only: IgM was never detected in immunoprecipitates
derived from tunicamycin-treated cells (figure 3,4, lower panel).
It is therefore reasonable to conclude that the N-linked oligo­
saccharides of P33 are of critical importance in the serological 
reactivity of that glycoprotein.
However, the level at which the N-linked sugar moieties 
exert their influence is not clear from the above experiment, and 
two explanations of the data are possible. Firstly, one might 
propose that the IgM-P33 complex is assembled but is not serologically 
reactive due to:
a) absence of an exclusively carbohydrate determinant 
recognised by serum No. 52, or
b) failure of expression of a complex 'interaction antigen' 
structurally influenced by oligosaccharide moieties.
A second interpretation is that P33 is not integrated into 
the IgM molecule in the absence of N-linked carbohydrate and the 
IgM complex can not be immunoprecipitated by the P33-specific serum 
No,52.
Preliminary experiments to explore the latter possibility 
suggest that assembly occurs in tunicamyc in-treated Daudi cells, as 
evidenced by the presence of non-glycosylated y-chains in SDS-PAGE 
profiles of immunoprecipitates generated from lysates of such cells 
using RAHk (data not shown). These data favour the hypothesis that 
carbohydrate plays an important role in expression of the serological 
determinant recognised by serum No.52, Clearly, however, more
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decisive experiments are required before this notion can be regarded 
as conclusive.
3.5. SPECULATION ON THE GENETIC ORIGIN AND IMMJNOLOGICAL
SIGNIFICANCE OF P33
3.5.1. Role of the HLA Complex.
Serum No.52 has been demonstrated to have the capacity to 
inhibit MLR reactions in which Daudi cells act as the stimulator 
population (Deane et al, 1978;Van Heyningen et al, 1981). The 
evidence herein is consistent with the hypothesis that serum No.52 
is specific for the P33 component of the Daudi IgM-P33 complex.
The serological studies herein disprove the hypothesis that P33 is 
a fragment or other abberant phenotypic expression of either HLA-A, 
-B, -C or HLA-DR antigens. The immediately obvious conclusion from 
these data is that P33 is not a product of a structural gene located 
in the HLA complex.
An explanation must be found for the inferred ability of 
P33 to activate the MLR. Three possible explanations may be 
tentatively proposed:
a) an artefact of the antiserum;
b) recognition of P33 as antigen X in association with 
self-histocompatibility antigen, and
c) P33 as a glycosidically 'altered self molecule.
The serological data described above (figure 3.1.) suggest 
that serum No.52 recognises P33 and not HLA-DR antigens as assessed 
by immunoprecipitation studies. The possibility that the antibody
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responsible for the MLR-inhibition and that responsible for immuno­
précipitation of the IgM-P33 complex are different, must be considered. 
If this proposal is correct, then a minor population of anti-HLA-DR 
antibodies would exist in serum No.52 which would be non-precipitating, 
either with GARIg (outside the optimum proportions limits of the 
system) or with S.aureus such that any immune complexes 
formed by this minor population would not be detected by the 
immunoprécipitation - SDS-PAGE analysis. The anti-HLA-DR antibodies 
would, however, be capable of inhibiting the MLR. It may be possible 
that the antibody population responsible for MLR inhibition recognises 
a non-HLA-DR, MHZ-encoded MLR activatory molecule . (the elusive HLA-D 
product).
Can the postulated ability of P33 to activate the MLR be 
accounted for in terms of current models of immune recognition by T- 
cells? A simple explanation which may be advanced in answer to 
this question is that in a dual-recognition model (e.g. Doherty 
et al, 1976; Williamson, 1980) P33 could be recognised as nominal 
antigen X which is recognised in association with the histocompati­
bility antigen of Daudi cells, HLA-DRw6 in the case of the MLR.
Thus, simultaneous occupation of the;
a) anti-X receptor (by P33) , and
b) R anti-H receptor (by HLA-DRw6),
would result in amplification of a specific clone of T-lymphocytes, 
giving rise to a detectable MLR. Recognition of P33 as antigen X 
in association with histocompatibility antigen is also compatible 
with one-receptor models.
An exampletof an altered-self model is provided by an
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hypothesis which proposes that the mechanism which results in 
alteration of self antigens is variation in glycosylation of the 
antigen (Parish e^ al, 1981). If such a model were representative 
of in vivo mechanisms, the immunological properties of P33 may be 
accounted for by proposing that P33 is an over-glycosylated K-light 
chain or K-light chain fragment (vide infra) and as such presents 
an altered-self idiotype to the T-lymphocyte in conjunction with 
HLA-DR which results in a proliferative response. Such a model 
is inconsistent with the findings of Black et al, (1981) who found 
that non-glycosylated H-2 class 1 molecules are less efficient 
target molecules for cytotoxic T-lymphocytes than their glycosylated 
counterparts. The Parish model is also inconsistent with findings 
of many groups that viral glycoproteins require N-glycosidically 
linked oligosaccharide groups for membrane localisation (see 
introduction, table 1), and it is known that cytotoxic T-lymphocytes 
require to "see" both antigen and histocompatibility antigen 
(Doherty et al, 1976).
These arguements lead to the conclusion that the role of 
the HLA gene complex in the structure and function of P33 is 
associative rather than integral or primary: that is, P33 is not
a gene product or abberant gene product of the HLA supergene, but 
the possible MLR activatory properties of this molecule would be 
accountable in terms of recognition of P33 in association with 
histocompatibility antigen.
3.5.2. P33 as a Kappa Chain Fragment
In the original observations of Daudi IgM (Sherr and Uhr, 
1971; Kennel, 1974&, it was proposed tha P33 represented a highly
”230“
glycosylated K-light chain. Charge-shift isoelectric focusing 
experiments demonstrated that this was not the case (Singer and 
Williamson, 1979). However, there are data available which suggest 
that P33 has k chain determinants and the possiblity that P33 
represents a heavily glycosylated k chain fragment must therefore 
be considered.
Elution of P33 from SDS-PAGE gel slices followed by 
digestion with the enzyme endoglycosidase HI generated a molecular 
species which was precipitable by anti-K antibody and had an AMW of 
15-16,000 daltons, (R.T. Kubo, personal communication). Treatment 
of cell-free translation products, the synthesis of which had been 
directed by Daudi poly a"*" RNA, with anti-K antibody resulted in 
immunoprécipitation of a 28K species and of an 18K species. The 18K 
species was a minor product visible only upon prolonged fluorographic 
exposure (Singer and Williamson, unpublished observation). It is 
proposed that this 18K species is the primary translation product of 
an abberant k-ihRNA, which loses its leader sequence to generate the 
15-16K species described by Kubo prior to N-glycosylation to yield 
the 33K glycopeptide.
3.5.3, Possible Genetic Origin of Mutant K-nRNA
Unequivocal evidence to demonstrate that P33 is a heavily 
glycosylated fragment of a K-light chain is needed. However, in 
view of the circumstancial evidence to support this hypothesis it 
is relevant to speculate on the arrangement of the K-coding sequences 
involved and the possible molecular lesions which might give rise to 
such an unusual polypeptide. A precedent for an abberant K-chain is 
provided by the plasmacytoma MPC-11 (Kuehl and Scharff, 1974). The
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mutant K-mRNA produced by this cell line contains nucleotide sequences 
coding for the leader sequence and sequences but lacks the correspond­
ing information for and (Seidman and Leder, 1980; Choi et al,
1980). A similar phenomenon in Daudi would explain the observed data 
for the P33 protein.
The P33 molecule must contain three cysteine residues. These 
three residues can be easily obtained by translation only of the 
gene which contains 3 codons for cysteine. This proposal involves 
either:
a) deletion of and exons;
b) failure to transcribe V and J , or
K K
c) failure to correctly process the VJ unit in the 
primary nuclear RNA transcript to yield a functional 
VJ unit in the mRNA.
These caveats are necessary because utilisation of V^ and 
J would require partial use of to obtain a third cysteine, and 
such a model requires that the P33-K gene be a pseudogene; i.e. con­
tains a termination codon located 3' to cysteine codon 134. While 
such a situation is not impossible, the use of the exon and 
failure to use V and J sequences is a more attractive model. A
K K
further piece of circumstantial evidence to support the above notion 
is the lack of methionine in C sequences (see Kabat et al, 1979) . 
Methionine is not incorporated into P33 in biosynthetic labelling 
experiments, but is incorporated in ^  vitro translation of Daudi 
poly a"*" RNA. These observations are again consistent with the 
hypothesis that P33 mRNA contains coding sequences for the leader 
sequence and C but^has no V or J sequences. Translation of such
K K K
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a messenger would give rise to a translation product of AMW 16,000- 
17,000 daltons which after removal of the leader sequence would have 
an AMW of 13,000-14,000 daltons. This is consistent with findings 
at the protein level.
One flaw in the arguement is the lack of N-glycosylation 
sites in sequences (Rabat et al, 1979). However, is rich in
serine (16 residues) and threonine (7 residues) which may be O- 
glycosylated. If 0-glycosylation of P33 occurs, this would account 
for the failure to detect a putative non-glycosylated form of P33 in 
biosynthetic experiments in the presence of tunicamycin.
The molecular mechanism which may give rise to such a 
unique polypeptide is non-productive gene rearrangement. As has 
been described for MPC-11, it is proposed that a non-productive 
V--J^ joining event has occurred which has deleted the sequences 
and their RNA splice site. Therefore, J^-C^ RNA splicing can not 
occur and the only splicing event which the K-nuclear RNA transcript 
can undergo is to splice the leader sequence immediately 5' to C^.
This would give rise to an mRNA containing leader and exons but 
no or coding sequences.
The chemical characterisation and immunological identifi­
cation of P33 remains incomplete. The data presented herein demon­
strate that P33 is not a gene product of the HLA gene complex although 
an antiserum capable of inhibiting the MLR reacts specifically with 
P33. Glycosylation appears to be necessary for the serological 
reactivity of P33. The hypothesis proposed above, that P33 is a 
heavily glycosylated fragment, makes it unclear whether the gly­
cosylation is necessary on P33 or on p-chains. The hypothesis that
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P33 is a product of a K-pseudogene is interesting because, if sub­
stantiated, it will represent the first example of assembly of a 
defective immunoglobulin gene product into a completed and expressed 
immunoglobulin molecule.
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